PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07K 14/47, 14/52, C12N 15/12, 15/19, 15/63, A61K 38/16, 38/19, 48/00

A1

(11) International Publication Number: **WO 99/29728**

(43) International Publication Date: 17 June 1999 (17.06.99)

(21) International Application Number: PCT/US98/26291

(22) International Filing Date: 11 December 1998 (11.12.98)

(30) Priority Data:
60/069,281 11 December 1997 (11.12.97) US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US 60/069,281 (CON)
Filed on 11 December 1997 (11.12.97)

(71) Applicant *(for all designated States except US)*: UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE [US/US]; 4321 Hartwick Road, College Park, MD 20740 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: GALLO, Robert, C. [US/US]; 8513 Thornden Terrace, Bethesda, MD 02817 (US). DEVICO, Anthony, L. [US/US]; 4533 Peacock Avenue, Alexandria, VA 22304 (US). GARZINO-DEMO, Alfredo [IT/US]; 601 North Eutaw Street, Baltimore, MD 21201 (US).

(74) Agent: BARRETT, William, A.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

(57) Abstract

The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania
AM	Armenia
AT	Austria
AU	Australia
AZ	Azerbaijan
BA	Bosnia and Herzegovina
BB	Barbados
BE	Belgium
BF	Burkina Faso
BG	Bulgaria
BJ	Benin
BR	Brazil
BY	Belarus
CA	Canada
CF	Central African Republic
CG	Congo
CH	Switzerland
CI	Côte d'Ivoire
CM	Cameroon
CN	China
CU	Cuba
CZ	Czech Republic
DE	Germany
DK	Denmark
EE	Estonia
ES	Spain
FI	Finland
FR	France
GA	Gabon
GB	United Kingdom
GE	Georgia
GH	Ghana
GN	Guinea
GR	Greece
HU	Hungary
IE	Ireland
IL	Israel
IS	Iceland
IT	Italy
JP	Japan
KE	Kenya
KG	Kyrgyzstan
KP	Democratic People's Republic of Korea
KR	Republic of Korea
KZ	Kazakstan
LC	Saint Lucia
LI	Liechtenstein
LK	Sri Lanka
LR	Liberia
LS	Lesotho
LT	Lithuania
LU	Luxembourg
LV	Latvia
MC	Monaco
MD	Republic of Moldova
MG	Madagascar
MK	The former Yugoslav Republic of Macedonia
ML	Mali
MN	Mongolia
MR	Mauritania
MW	Malawi
MX	Mexico
NE	Niger
NL	Netherlands
NO	Norway
NZ	New Zealand
PL	Poland
PT	Portugal
RO	Romania
RU	Russian Federation
SD	Sudan
SE	Sweden
SG	Singapore
SI	Slovenia
SK	Slovakia
SN	Senegal
SZ	Swaziland
TD	Chad
TG	Togo
TJ	Tajikistan
TM	Turkmenistan
TR	Turkey
TT	Trinidad and Tobago
UA	Ukraine
UG	Uganda
US	United States of America
UZ	Uzbekistan
VN	Viet Nam
YU	Yugoslavia
ZW	Zimbabwe

METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/069,281 filed December 11, 1997.

2. BACKGROUND OF THE INVENTION

The present invention relates to a method to enhance the efficacy of a vaccine by administration of a chemokine, such as macrophage derived chemokine (MDC), in conjunction with the vaccine. The present invention also relates to compositions useful in the method.

2.1. GENERATION OF AN IMMUNE RESPONSE

The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively (*see generally* Coutinho, 1991, Immune System, *Encyclopedia of Human Biology*, Vol. 4, Ed. Dulbecco, Academic Press, Inc.). A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system.

Another T cell subset is capable of developing into antigen-specific cytotoxic effector cells, which can directly kill antigen-positive target cells. On the other hand, the B cell response is primarily carried out by secretory proteins, antibodies, which directly bind and neutralize antigens.

Helper T cells (TH) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of the glycoprotein marker CD4. Although the mechanism by which $CD4^+$ TH function has not been fully elucidated, the existence of functionally distinct subsets within the $CD4^+$ T cell compartment has been reported (Mosmann and Coffman, 1989, *Ann. Rev. Immunol.*

7:145-173). In the mouse, type 1 helper T cells (TH1) produce interleukin-2 (IL-2) and τ-interferon (τ-IFN) upon activation, while type 2 helper T cells (TH2) produce IL-4 and IL-5. Based on the profile of lymphokine production, TH1 appear to be involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas TH2 specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most TH, these cells display cytolytic activity upon direct contact with target cells, rather than through the production of lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. Significant experimental evidence indicates that CTL rather than B cells and their antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. Class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, *Nature* 329:506-512).

Another level of complexity in the interaction between a T cell and an antigenic fragment is that it occurs only if the MHC molecules involved are the same on the APC and the responding T cells. In other words, a T cell specific for a particular antigenic epitope expresses a receptor having low affinity for self MHC

proteins, which when such MHC proteins on APC are occupied by the epitope, engage the T cell in a stronger interaction leading to antigen-specific T cell activation. The phenomenon of a T cell reacting with a processed antigen only when presented by cells expressing a matching MHC is known as MHC-restriction.

The specificity of T cell immune responses for antigens is a function of the unique receptors expressed by these cells. The T cell receptor (TCR) is structurally homologous to an antibody; it is a heterodimer composed of disulfide-linked glycoproteins. Four TCR polypeptide chains known as α, β, τ, and δ have been identified, although the vast majority of functional T cells express the $\alpha\beta$ heterodimeric TCR. Transfer of α and β genes alone into recipient cells was shown to be both necessary and sufficient to confer antigen specificity and MHC-restriction (Dembic et al., 1986, *Nature* 320:232-238). Thus, the $\alpha\beta$ TCR appears to be responsible for recognizing a combination of antigenic fragment and MHC determinants.

The apparent basis of MHC restriction is that $CD4^+$ T cells express $\alpha\beta$ TCR which recognize antigenic fragments physically associated with MHC class II proteins, while the TCR on $CD8^+$ CTL recognize MHC class I-associated fragments. Thus, $CD4^+$ T cells can recognize only a restricted class of APC that are class II^+, whereas $CD8^+$ CTL can interact with virtually any antigen-positive cells, since all cells express class I molecules. $CD4^+$ CTL have been identified, and they are MHC class II restricted, and lyse target cells only if the latter express self-MHC class II determinants associated with specific antigenic fragments. Both CD4 and CD8 molecules also contribute to this interaction by binding to monotypic determinants on the MHC class II and I molecules, respectively.

A second type of TCR composed of $\tau\delta$ heterodimers is expressed by a small percentage of T cells, but the involvement of $\tau\delta$ T cells in antigen-specific recognition is still poorly understood. Some studies have shown that functionally active $\tau\delta$ T cells can be cytolytic in a MHC non-restricted manner.

In summary, the generation of an immune response begins with the sensitization of $CD4^+$ and $CD8^+$ T cell subsets through their interaction with APC that express MHC-class I or class II molecules associated with antigenic fragments. The sensitized or primed $CD4^+$ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized $CD8^+$ T cells increase in numbers in response to lymphokines and are capable of destroying any

cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. For example, in the course of a viral infection, CTL eradicate virally-infected cells, thereby limiting the progression of virus spread and disease development.

2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as antigen presenting cells (APC). Typically, APC include macrophages/monocytes, B cells, and bone marrow derived dendritic cells (DC). APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded products for expression on the cell surface (Goldberg and Rock, 1992, *Nature* 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both $CD4^+$ and $CD8^+$ T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbit et al., 1985, *Nature* 317:359; Townsend et al., 1986, *Cell* 44:959). However, it is believed that, normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the MHC-encoded proteins intracellularly prior to

trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, *Immunol. Rev.* 98:95-114). It was thought that exogenous antigens were taken up by APC, processed and presented by the exogenous pathway to class II restricted $CD4^+$ T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC class I proteins and presentation to $CD8^+$ CTL. However, although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, *Cell* 54:777).

The term "dendritic cells" (DC) refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues (Steinman, 1991, *Ann. Rev. Immunol.* 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their morphology, high levels of surface MHC-class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all function as APC in the same manner. Further, since the vast majority of published reports have utilized DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types. (Inaba et al., 1997, *J. Exp. Med.* 166:182-194; Hengel et al., 1987, *J. Immunol.*, 139:4196-4202; Kaut et al., 1988, *J. Immunol.*, 140:3186-3193; Romani et al., 1989, *J. Exp. Med.* 169:1169-1178; Macatonia et al., 1989, *J. Exp. Med.* 169:1255-1264; Inaba et al., 1990, *J. Exp. Med.* 172:631-6640). For example, despite high levels of MHC-class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) (Witmer-Pock et al., 1987, *J. Exp. Med.* 166:1484-1498; Heufler et al., 1988, *J. Exp. Med.* 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while blood DC do not. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; in part, due to inherent differences between the

human and murine immune systems.

Recently, a few studies have described the isolation of human DC from the peripheral blood, which involves the use of sheep red blood cells and/or fetal calf serum (Young and Steinman, 1990, *J. Exp. Med.* 171:1315-1332; Freudenthal and Steinman, 1990, *Proc. Natl. Acad. Sci. USA* 87:7698-7702; Macatonia et al., 1989 *Immunol.* 67:285-289; Markowicz and Engleman, 1990, *J. Clin. Invest.* 85:955-961). Engleman et al. described a partial purification procedure of DC from human blood, which does not involve the use of sheep red blood cells and/or fetal calf serum, and showed that the partially purified human DC can, in fact, present exogenous antigens to naive T cells (PCT Publication WO 94/02156 dated February 3, 1994 at page 9, lines 5-32).

Recent studies have indicated that DCs are superior APCs as compared to other APCs such as macrophages and monocytes. First, the potent accessory cell function of DCs provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. For example, Engleman et al. demonstrate that human DCs can present both complex protein antigens and small peptides to $CD4^+$ T cells as well as to as $CD8^+$ CTL (PCT Publication WO 94/02156 dated February 3, 1994, Example 7, from page 29, line 10 to page 34, line 16). Engleman et al. also show that the *in vitro* priming effect of DCs does not require the addition of exogenous lymphokines, indicating that DCs produce all of the necessary signals in antigen presentation leading to the activation of T cells (PCT Publication WO 94/02156 dated February 3, 1994, from page 32, line 36 to page 33, line 2). More importantly, DCs can induce a primary $CD4^+$ T cell-mediated proliferative response when similarly prepared monocytes can not induce such a response (PCT Publication WO 94/02156 dated February 3, 1994 at page 31, lines 23-30). Similarly, when DCs and monocytes ware compared for their ability to present antigens for re-activating secondary T cell response, it was observed that DCs were capable of stimulating a stronger response than monocytes (PCT Publication WO 94/02156 dated February 3, 1994 at page 32, lines 12-16).

2.3. CHEMOKINES

Chemokines, or chemoattractant cytokines, are a subgroup of immune factors

that have been shown to mediate chemotactic and other pro-inflammatory phenomena (see, Schall, 1991, *Cytokine* 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, α which have two N-terminal cysteines separated by a single amino acid (CxC) and β which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1α and MIP-1β are members of the β subgroup (reviewed by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633; Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

MCP-1 has been shown to attract monocytes but not neutrophils. MCP-1, MCP-2, and MCP-3 share a pyroglutamate proline NH_2-terminal motif and are structurally closely related to each other and to eotaxin (56% to 71% amino acid sequence identity). MCP-1, MCP-2, and MCP-3 attract monocytes, $CD4^+$ and $CD8^+$ T lymphocytes (Loetscher et al. *FAESB J.* 1994, 8:1055-60), as well as basophil leukocytes. MCP-2, MCP-3, and MCP-4 (but not MCP-1) attracts eosinophil leukocytes. All four MCPs attract activated T lymphocytes, natural killer (NK) cells, and dendritic cells (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

Eotaxin acts on eosinophils and is inactive on neutrophils and monocytes, but has weak-to-moderate chemotactic activity toward IL-2-conditioned T lymphocytes (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705). Due to its preferential, powerful action on eosinophils and its occurrence in different species, eotaxin is considered to be an important chemokine in the pathophysiology of allergic conditions and asthma (See Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

IP10 is a CXC chemokine attracts human monocytes, T lymphocytes, and NK cells, and Mig attracts tumor-infiltrating T lymphocytes. It has been suggested that IP10 and Mig may also be involved in the regulation of lymphocyte recruitment and the formation of the lymphoid infiltrates observed in autoimmune inflammatory lesions, delayed-type hypersensitivity, some viral infections, and certain tumors (Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

SDF-1 (stromal cell–derived factor 1), including SDF-1 and SDF-1ß stimulates the proliferation of B cell progenitors, and attracts mature dendritic cells (Finkel et al. *Immunobiology* 1998, 198:490-500). Synthetic human SDF-1 stimulates monocytes, neutrophils, and peripheral blood lymphocytes, as is indicated by [Ca2+]i changes and chemotaxis. SDF-1 is also a powerful HIV-suppressive factor (See Baggiolini et al.

Annu. Rev. Immunol. 1997, 15:675-705).

The amino terminus of the β chemokines RANTES, MCP-1, and MCP-3 has been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996, *J. Biol. Chem.* 271:10521-10527; Proudfoot et al., 1996 *J. Biol. Chem.* 271:2599-2603). Additionally, α chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, *J. Biol. Chem.* 267:3455-3459).

The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of α and β groups are distinct. While the monomeric structures of the β and α chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (γ) of chemokines (Yoshida et al., 1995, *FEBS Lett.* 360:155-159; and Kelner et al., 1994, *Science* 266:1395-1399).

Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (*See*, reviews by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; and Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among β chemokine receptors include: CCR-1, which binds RANTES and MIP-1α (Neote et al., 1993, *Cell* 72:415-425), CCR-4, which binds RANTES, MIP-1α, and MCP-1 (Power et al., 1995, *J. Biol. Chem.* 270:19495-19500), and CCR-5, which binds RANTES, MIP-1α, and MIP-1β (Alkhatib et al., 1996, *Science* 272:1955-1958 and Dragic et al., 1996, *Nature* 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both α and β chemokines (Horuk et al., 1994, *J. Biol. Chem.* 269:17730-17733; Neote et al., 1994, *Blood* 84:44-52; and Neote et al., 1993, *J. Biol. Chem.* 268:12247-12249). Thus the sequence and

structural homologies evident among chemokines and their receptors allow some overlap in receptor-ligand interactions.

Godiska et al. identified and described the nucleic acid and amino acid sequences of an additional β chemokine designated macrophage derived chemokine (MDC) (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). PCT publication WO 96/40923 further provides materials and methods for the recombinant production of the chemokine, the purified and isolated chemokine protein, and polypeptide analogues thereof. The PCT publication WO 96/40923 does not disclose that the human MDC has chemotactic activity upon DC. While Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604) showed that, in a microchamber migration assay, monocyte-derived DC migrated toward the human MDC, the reference fails to teach that MDC can enhance an immune response to an antigen *in vivo*.

Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237), isolated a stimulated T cell chemotactic protein (STCP-1) from an activated macrophage cDNA library. The nucleotide sequence of the STCP-1 is identical to that of the MDC isolated by Godiska et al. (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). However, unlike the results observed by Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604), Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237) showed that although the STCP-1 acted as a mild chemoattractant for primary activated T lymphocytes and a potent chemoattractant for chronically activated T lymphocytes, the STCP-1 has no chemoattractant activity for monocytes, neutrophils, eosinophils and resting T lymphocytes. Chang et al. further showed that the STCP-1 does not induce $Ca2^{+}$ mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes.

2.4. HIV VACCINES

Human immunodeficiency virus (HIV) induces a persistent and progressive infection leading, in the vast majority of cases, to the development of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983, *Science* 220:868-870; Gallo et al., 1984, *Science* 224:500-503). The HIV envelope surface glycoproteins are

synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane glycoprotein and gp120 is an extracellular glycoprotein which remains non-covalently associated with gp41, possibly in a trimeric or multimeric form (Hammerskjold, M. and Rekosh, D., 1989, *Biochem. Biophys. Acta* 989:269-280). The V3 loop of gp120 is the major determinant of sensitivity to chemokine inhibition of infection or replication (Cocchi et al., 1996, *Nature Medicine* 2:1244-1247; and Oravecz et al., 1996, *J. Immunol.* 157:1329-1332).

Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for neutralizing anti-HIV antibodies present in AIDS patients (Barin et al., 1985, *Science* 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. Several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system (see, for example, Ivanoff et al., U.S. Pat. No. 5,141,867; Saith et al., PCT publication WO 92/22654; Shafferman, A., PCT publication WO 91/09872; Formoso et al., PCT publication WO 90/07119). Therefore, methods to increase the efficacy of vaccines against HIV, especially vaccines using gp120 as the antigen, are needed.

Additionally a novel vaccine technology, designated genetic vaccination, nucleic acid vaccination or DNA vaccination, has been explored to induce immune responses *in vivo*. Injection of cDNA expression cassettes results in *in vivo* expression of the encoded proteins (Dubensky et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:7529-7533; Raz et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4523; Wolff et al., 1990, *Science* 247:1465-1468), with the concomitant development of specific cellular and humoral immune responses directed against the encoded antigen(s) (Wang et al., 1995, *Hum. Gene Ther.* 6:407-418; Ulmer et al., 1993, *Science* 259:1745-1749; Tang et al., 1992, *Nature* 356:152-154; Michel et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; and Lowrie et al., 1994, *Vaccine* 12:1537-1540). Humoral and cellular responses have been induced to HIV-1 and SIV antigens through various applications of this technology in macaques (Wang et al., 1995, *Virology* 221:102-112; Wang et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; and Boyer et al., 1996, *J. Med.*

Primatol. 25:242-250) as well as mice (Wang et al., 1995, *Virology* 221:102-112; Lu et al., 1995, *Virology* 209:147-154; Haynes et al., 1994, *AIDS Res. Hum. Retroviruses* 10 (Suppl. 2):S43-S45; Okuda et al., 1995, *AIDS Res. Hum. Retroviruses* 11:933-943).

Recently, Lekutis et al. (1997, *J. Immunol.* 158:4471-4477), assessed the TH cell response elicited by an HIV-1 gp120 DNA vaccine in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted $CD4^+$ T cell lines from the vaccinated animals. Lekutis et al. showed that the isolated cell lines proliferated in response to APC in the presence of recombinant gp120, as well as to APC expressing HIV encoded env protein. Lekutis et al. further showed that these cell lines responded to env by secreting IFN-Γ and IFN-α without appreciable IL-4 production. These results demonstrate that the animals exhibited a cellular immune response to the DNA vaccine.

Boyer et al. (1997, *Nature Medicine* 3:625-532), inoculated chimpanzees with an HIV-1 DNA vaccine encoding env, rev, and gag/pol, and found that the immunized animals developed specific cellular and humoral immune responses to these proteins. After challenging the immunized animals with a heterologous chimpanzee titered stock of HIV-1 SF2, Boyer et al. further found, using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay, that those animals vaccinated with the DNA vaccine were protected against infection whereas the control animals were not so protected.

Kim et al., (1997 *J. Immunol.* 158:816-826), investigated the role of co-delivery of genes for IL-12 and GM-CSF along with DNA vaccine formulation for HIV-1 antigens env and gag/pol in mice. Kim et al. observed a dramatic increase in specific CTL response from the mice immunized with the HIV-1 DNA vaccine and IL-12. Kim et al. also observed that the co-delivery of IL-12 genes resulted in the reduction of specific antibody response, whereas the codelivery of GM-CSF genes resulted in the enhancement of specific antibody response. Kim et al. further observed that co-delivery of IL-12 gene with a HIV DNA vaccine results in splenomegaly (Kim et al. 1997, *J. Immunol.*, 158:816-826), which has been shown in mice to have toxic effects such as weight reduction or even death (Eng et al., 1995, *J. Exp. Med.* 181:1893; Stevensen et al., 1995, *J. Immunol.* 155:2545; and Orange et al., 1995, *J. Exp. Med.* 181:901).

Notwithstanding the recent developments of the HIV DNA vaccine, there still

exists a need for a method to enhance the efficacy of a vaccine, especially an HIV DNA vaccine. For instance, for efficacious vaccine against HIV-1 one preferably induces both cellular and humoral immune responses to control the infection (Boyer et al., 1997, *Nature Medicine* 3:625-532). The induction of both cellular and humoral immune response by the Berjer et al. method is still quite low because only one of the three immunized chimpanzees developed both cellular and humoral responses. Similarly, although co-delivery of an IL-12 encoding gene with a HIV DNA vaccine, as described in Kim et al. (1997, *J. Immun.* 158:816-826), may have enhanced the cellular immune response, this co-delivery also decreased the humoral response.

Citation of a reference hereinabove shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION. SUMMARY OF THE INVENTION. . SUMMARY OF THE INVENTION

The present invention is based upon the ability of chemokines, such as MDC, Rantes, MIP-1d, MIP-1B, and I-309, to enhance the immune response to an antigen, particularly a vaccine. Accordingly, in a first aspect, the present invention provides a method for enhancing the efficacy of a vaccine, which method comprises administration to a subject of one or more purified chemokines, or biologically active fragments, analogues or derivatives thereof, either concurrently with one or more purified antigens against which an immune response is desired or within a time period either before or after administration of the antigens such that the immune response against the antigens is enhanced.

In a second aspect, the present invention provides a method to enhance the efficacy of a vaccine, which method comprises administration to a subject of a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments, derivatives, analogues, and/or truncation isoforms thereof, and a second purified nucleic acid comprising a nucleotide sequence encoding one or more antigens against which an immune response is desired, such that, the one or more chemokine(s) and the antigen(s) are expressed in a coordinated manner upon introduction into a suitable cell. Alternatively, the nucleotide sequences encoding one or more chemokines, or

fragments, derivatives, and/or analogues thereof, and the antigens against which an immune response is desired are present on the same nucleic acid.

In a preferred embodiment, the invention provides a method to enhance the efficacy of an HIV vaccine.

In yet another aspect, the present invention provides a composition comprising an immunogenic amount of one or more purified antigens, an amount of one or more purified chemokines, or a fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response to the antigen. In another aspect, the present invention provides a composition comprising a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, fragments, derivatives analogues and or truncation isoforms thereof, and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens against which an immune response is desired, such that, the chemokine(s) and the antigen are expressed in a coordinated manner upon introduction into a suitable cell. In a preferred embodiment, the antigen is an HIV antigen. In another preferred embodiment, the chemokine is selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha

chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. DESCRIPTION OF FIGURES

Figures 1A and 1B. The nucleotide and amino acid sequences of MDC. 1A depicts the nucleotide sequence of MDC (SEQ ID NO:1), with the coding region indicated by the appearance of the amino acid sequence in the line below; and 1B depicts the amino acid of MDC (SEQ ID NO:2) from GenBank accession no. U83171 (Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing the efficacy of a vaccine in a subject comprising administering to the subject one or more purified antigens in conjunction with one or more purified chemokines, or more purified fragments, derivatives or analogues and/or truncation isoforms thereof.

While any chemokine may be employed according to the present invention, the chemokine is preferably selected from the following table:

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines	Macrophage-derived chemokine	MDC/STCP-1	u83171; u83239
	Monocyte chemotactic protein 1	MCP-1	x14768
	Monocyte chemotactic protein 2	MCP-2	X99886
	Monocyte chemotactic protein 3	MCP-3	x72308; s57464
	Monocyte chemotactic protein 4	MCP-4	u46767
	activated macrophage specific chemokine 1	AMAC-1	Y13710
	Macrophage inflammatory protein 1 alpha	MIP-1α	AF043339; X03754; D90144

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Macrophage inflammatory protein 1 beta	MIP-1β	j04130; d90145
	Macrophage inflammatory protein 1 gamma	MIP-1γ	
	Macrophage inflammatory protein 1 delta	MIP-1δ	AF031587
	Macrophage inflammatory protein 2 alpha	MIP-2α	AF043340
	Macrophage inflammatory protein 3 alpha	MIP-3α	u77035
	Macrophage inflammatory protein 3 beta	MIP-3β	u77180
	Regulated upon activation, normal T cell expressed and secreted (and its variants)	RANTES	M21211
	I-309		M57502
	EBI1-ligand chemokine	ELC	AB000887
	Pulmonary and activation regulated chemokine	PARC/DC-CK-1/MIP4	AB000221
	Liver and activation-regulated chemokine	LARC	D86955
	Thymus and activation regulated chemokine	TARC	D43767
	Eotaxin (and variants)		D49372; Z69291; Z75669; Z75668
	Human chemokine 1	HCC1; NCC2	Z49270; z49269
	Human chemokine 2	HCC2; NCC3, MIP-5, MIP-1δ	Z70292
	Human chemokine 3	HCC3	Z70293
	IL-10-inducible chemokine	HCC4	U91746
	liver-expressed chemokine.	LEC; HCC4;NCC4	AB007454
	6Ckine		AF001979
	Exodus 1		u64197
	Exodus 2		U88320
	Exodus 3		U88321
	thymus-expressed chemokine	TECK	U86358
	Secondary Lymphoid tissue chemokine	SLC	AB002409

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Lymphocyte and Monocyte chemoattractant; Monotactin	LMC	AF055467
	Activation-induced, chemokine-related molecule	ATAC	x86474
	Myeloid progenitor inhibitory factor-1	MPIF-1; MIP-3 or ckbeta8	u85767
	Myeloid progenitor inhibitory factor-2	MPIF-2	u85768
	Stromal cell-derived factor 1 alpha	SDF-1α; PBSF	L36034
CXC chemokines	Stromal cell-derived factor 1 beta	SDF-1β; PBSF	L36033
	B-cell-attracting chemokine 1	BLC	AJ002211
	HuMIG		x72755 s60728
	H[illegible]4		AF002985
	Interferon-stimulated T-cell alpha chemoattractant	I-TAC	AF030514
	Interleukin-8	IL-8	m17017; y00787
	IP-10		X02530
	platelet factor 4	PF4	M20901
	growth-regulated gene-alpha	GRO-α	J03561
	growth-regulated gene-beta	GRO-β	M36820
	growth-regulated gene-gamma	GRO-γ	M36821
	Neutrophil-activating protein 2	NAP-2; CTAP-3	M54995; M38441
	ENA-78		L37036
	granulocyte chemotactic protein 2	GCP-2	Y08770
C-CHEMOKINES	LYMPHOTACTIN	SCM-1	D63789 D63790
CX3C-CHEMOKINES	Fractalkine/neurotactin		U91835 U84487

The present invention also relates to the use of fragments, analogues and derivatives of the foregoing chemokines, as well as truncation isoforms of such chemokines which are known in the art.

The present invention also relates to therapeutic compositions comprising one or more chemokines, nucleic acids encoding one or more chemokines, derivatives, analogues, and/or truncation isoforms thereof, and nucleic acids encoding the same, that are effective to enhance the immune response of a subject to a vaccine.

In another preferred embodiment of the invention, nucleic acids comprising

nucleotide sequences encoding one or more chemokines or fragments or derivatives, including truncation isoforms, thereof, and encoding one or more antigens against which an immune response is desired, which coding sequences are operatively linked to gene regulatory sequences capable of directing the expression of the one or more chemokines and the one or more antigens upon introduction into a suitable cell, for example, but not limited to, the cell (of a subject), are administered to a subject such that the one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, and one or more antigens, are expressed in the subject.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE

The present invention provides methods for enhancing the efficacy of a vaccine in a subject, which methods comprise administering to a subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject in conjunction with an amount of one or more purified chemokines, or fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response against the antigen. In one aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered to the subject concurrently with (*e.g.*, in the same composition with) the purified antigen or antigens against which an immune response is desired. In another, aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered either before or after the administration of one or more purified antigens against which immunity is desired in the subject, but is administered within such time that the chemokine(s) enhance the immune response to the one or more antigens. For example, but not by way of limitation, the purified chemokine(s) are administered during the time that the subject mounts an immune response against the administered one or more antigens, or, the purified MDC is administered within, for example, but not limited to, 30 minutes, 1 hour, 5 hours, 10 hours, 1 day, 2 days of (preferably, after) administration of the one or more purified antigens against which immunity is desired.

In a preferred embodiment, the present invention provides compositions comprising an immunogenic amount of one or more purified antigens and an amount of purified MDC, or one or more fragments, derivatives or analogues thereof, effective to enhance the immune response to said antigen and, preferably, the composition further comprises a pharmaceutically acceptable carrier.

A preferred chemokine for use in the methods and compositions of the present invention is any MDC protein, fragment or derivative thereof, that is capable of enhancing the efficacy of a vaccine (for example, but not limited to, as determined by the assays described in Section 5.4, infra). In one specific embodiment, the MDC is purified full length MDC, preferably full length MDC having the amino acid sequence of SEQ ID NO: 2 (Figure 1B). In another embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 2-69 of SEQ ID NO: 2 (Figure 1B). In another specific embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 3-69 of SEQ ID NO: 2 (Figure 1B). In still another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine. In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine.

In yet another specific embodiment, the chemokine is a purified derivative of the protein, which derivative has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. In yet another specific

embodiment, the chemokine is a purified derivative of the protein that has only one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. The chemokines useful in the present invention may be derived from any suitable source and obtained by any method known in the art, for example but not limited to the methods described in Section 5.2 infra.

Preferably, the chemokine(s) are of the same species as the subject to which the vaccine is administered. In a preferred embodiment, one or more human chemokines are administered to a human subject, e.g., human MDC is administered to a human subject, alone or in combination with another chemokine.

The present invention also provides a method to enhance the efficacy of a vaccine in a subject, which method comprises administering to a subject a purified first nucleic acid comprising a nucleotide sequence encoding an antigen against which an immune response is desired in a subject and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragment(s), derivative(s) or analogue(s) thereof, where the expression of the encoded antigen(s) and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are under control of one or more appropriate gene regulatory elements (which regulatory elements can be any regulatory element known in the art, for example, but not limited to, those regulatory elements described in Section 5.2 supra), such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are coordinately expressed, *i.e.*, are expressed either at the same time or within an appropriate time period (*i.e.*, sufficient for the chemokine(s) to enhance the immune response against the antigen relative to a corresponding immune response in the absence of the chemokine) and the antigen(s) are expressed in an immunogenic amount and the chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are expressed in an amount sufficient to enhance the immune response against the antigen(s). In a specific embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen are present on separate nucleic acids. In another embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen(s) are present on the same nucleic acid.

The present invention also provides compositions to enhance the

efficacy of a vaccine in a subject, which compositions comprise a purified first nucleic acid comprising a nucleotide sequence encoding one or more antigen(s) and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, wherein the nucleotide sequences encoding the antigens and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens and a purified second set of one or more purified nucleic acids comprising a nucleotide sequence encoding one or more chemokines, or fragments, analogues, derivatives, (including truncation isoforms) thereof, wherein the nucleotide sequence(s) encoding the antigen(s) and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second sets of nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified nucleic acid comprising a first set of one or more nucleotide sequences encoding one or more antigens and a second set of one ore more nucleotide sequence encoding one or more chemokines, or fragments, derivatives, or analogues thereof (including truncation isoforms), wherein the first and second sets of nucleotide sequences are operably linked to one or more gene regulatory elements such that, upon introduction into a suitable cell, the antigen(s) and the chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are

expressed in an amount effective to enhance the immune response against the antigen(s).

Any nucleic acid comprising a nucleotide sequence encoding one or more chemokine proteins, or fragments or derivatives, thereof (including truncation isoforms), that are capable of enhancing the immune response to the antigen (for example, but not limited to, as determined by any of the assays described in Section 5.2., *infra*) can be used in the methods and compositions of the present invention.

In a preferred embodiment, the nucleotide sequence encodes MDC. In another embodiment, the MDC-encoding nucleotide consists of the nucleotide sequence of SEQ ID NO:1 (Figure 1A). In another specific embodiment, the method or composition of the invention uses a nucleic acid encoding an MDC derivative having deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the immune response against an antigen in a subject.

Such compositions of nucleic acids encoding an antigen are often referred to as DNA vaccines.

Such DNA vaccines are produced by any method known in the art for constructing an expression plasmid vector containing the nucleotide sequences of the antigen(s) and/or chemokine(s) to be expressed which vector is suitable for expression of the encoded proteins in the subject or in cells recombinant for the expression vector, which cells are to be provided to the subject. Such expression vectors may contain various promoters, terminators and polyadenylation coding regions to control the expression of the encoded protein.

The DNA vaccine can be administered by any method known in the art for administration of DNA. The DNA vaccine may be delivered either directly, in which case the subject is directly exposed to the DNA vaccine such that the DNA enters and is expressed in cells of the subject, or indirectly, in which case, the DNA vaccine is first introduced into suitable cells by any method known in the art *in vitro*, then the cells containing the DNA vaccine are transplanted into the subject.

In a specific embodiment, the DNA vaccine is directly administered *in vivo*, where it is expressed to produce the encoded antigens and chemokine(s). This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or

other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In a preferred embodiment, the nucleic acid of a DNA vaccine is injected into the muscle of the subject to be immunized.

Another approach is to introduce the nucleic acid of the DNA vaccine into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign nucleic acid into cells (see e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Cells into which a DNA vaccine can be introduced for purposes of immunization encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, *e.g.*, as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

The resulting recombinant cells can be delivered to a subject by various

methods known in the art. In a preferred embodiment, the recombinant cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The cells can also be encapsulated in a suitable vehicle and then implanted in the subject (see, e.g., Dionne et al. PCT Publication WO 92/19195, dated November 12, 1992). The amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.

By way of example, and not by way of limitation a DNA vaccine may be generated as described by Lekutis et al. for an HIV DNA vaccine (1997, *J. Immunol.* 158:4471-4477). Briefly, an expression vector is constructed with the promoter, enhancer and intron A of human cytomegalovirus (CMV) and the termination and polyadenylation sequences of bovine growth hormone in a plasmid backbone. Additionally, the nucleotide sequence for signal sequence of tissue plasminogen activator is either substituted for the signal sequence of the antigen, if the antigen has a signal sequence or is added onto the amino-terminus of the antigen, thereby eliminating the dependence on viral proteins for expression (e.g., in the case of gp120 expression, rev and env proteins are required unless the HIV-1 signal sequence is so substituted). The resulting formulation is then injected intra-muscularly.

Further examples of DNA vaccines are set forth in Boyer et al. (1996, *J. Med. Primatol.*, 25:242-250), which describes the construction of a plasmid encoding the HIV-1 gp160 envelope glycoprotein as well as the *rev-tax* region cloned into pMAMneoBlue vector (Clonetech, Inc., Palo Alto, CA), and a vector encoding the envelope glycoprotein and rev from HIV-1 strain MN under the control of the CMV promoter. Another vector which can be used in the present invention is as described in Boyer et al. (1997, *Nature Medicine* 3:526-532) and contains expression cassettes encoding the envelope and Rev proteins of HIV-1 strain MN, and encoding the Gag/Pol proteins of HIV-1 strain IIIB.

For the practice of the present invention, the nucleotide sequence for the one or more chemokines, or fragments, derivatives, or analogues thereof, can either be incorporated into the same expression vector containing the nucleotide sequence encoding the antigen in such a manner that the chemokine(s) are expressed. Alternatively, the nucleotide sequence encoding the chemokine(s), or fragment(s),

derivative(s) or analogue(s) thereof, can be cloned into a separate expression vector (e.g., as described above for the expression vector containing the sequences coding for antigen) and the expression vector that expresses the antigen(s) mixed with the expression vector that expresses the chemokine(s). The mixture of the two expression vectors can then be administered to the subject.

The methods and compositions of the present invention may be used as a vaccine in a subject in which immunity for the antigen(s) is desired. Such antigens can be any antigen known in the art to be useful in a vaccine formulation. The methods and compositions of the present invention can be used to enhance the efficacy of any vaccine known in the art. The vaccine of the present invention may be used to enhance an immune response to infectious agents and diseased or abnormal cells, such as but not limited to bacteria, parasites, fungi, viruses, tumors and cancers. The compositions of the invention may be used to either treat or prevent a disease or disorder amenable to treatment or prevention by generating an immune response to the antigen provided in the composition. In one preferred embodiment, the antigen(s) are proteins, fragments or derivatives, including truncation isoforms, thereof, encoded by any genes of the HIV genome including the *env, gag, pol, nef, vif, rev,* and *tat* genes. In a more preferred embodiment, the antigen is an HIV-associated gp120 protein.

The methods and compositions of the present invention may be used to elicit a humoral and/or a cell-mediated response against the antigen(s) of the vaccine in a subject. In one specific embodiment, the methods and compositions elicit a humoral response against the administered antigen in a subject. In another specific embodiment, the methods and compositions elicit a cell-mediated response against the administered antigen in a subject. In a preferred embodiment, the methods and compositions elicit both a humoral and a cell-mediated response.

The subjects to which the present invention is applicable may be any mammalian or vertebrate species, which include, but are not limited to, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats, monkeys, rabbits, chimpanzees, and humans. In a preferred embodiment, the subject is a human. The compositions and methods of the invention can be used to either prevent a disease or disorder, or to treat a particular disease or disorder, where an immune response against a particular antigen or antigens is effective to treat or prevent the

disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc, bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by eliciting an immune response against a particular antigen or antigens. In another preferred embodiment, the subject is infected or at risk of being infected with HIV virus.

In another preferred embodiment the invention provides methods and compositions to enhance the efficacy of an HIV vaccine, such a vaccine can be administered to either prevent or treat HIV.

5.2. CHEMOKINE GENES AND PROTEINS

Chemokine proteins and nucleic acids can be obtained by any method known in the art. Chemokine nucleotide and amino acid sequences are available in public databases such as Genbank and are also published in various references known to those of skill in the art. The gene bank accession numbers for the preferred chemokines of the present invention are provided in Table I, in Section 5 above. The ensuing discussion uses MDC by way of example, but applies equally to other chemokines as well.

The MDC nucleotide and amino acid sequences for, *inter alia*, human, are available in the public databases (*e.g.* Genbank accession No. U83171) also published in Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604. The nucleotide sequence and the amino acid sequence for the human MDC are provided in Figures 1A and B (SEQ ID NOS:1 and 2, respectively).

Chemokines used herein include, but are not limited to, chemokines from mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, and human. In one preferred embodiment, the chemokine is of human origin.

Any vertebrate cell potentially can serve as the nucleic acid source for the isolation of chemokine nucleic acids. The nucleic acid sequences encoding the chemokine(s) can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.*, a

DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from cDNA, cDNA is generated from totally cellular RNA or mRNA by methods that are well known in the art. The gene may also be obtained from genomic DNA, where DNA fragments are generated (e.g. using restriction enzymes or by mechanical shearing), some of which will encode the desired gene. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing all or a portion of the chemokine gene may be accomplished in a number of ways.

A preferred method for isolating a chemokine gene is by the polymerase chain reaction (PCR), which can be used to amplify the desired chemokine sequence in a genomic or cDNA library or from genomic DNA or cDNA that has not been incorporated into a library. Oligonucleotide primers which would hybridize to chemokine sequences can be used as primers in PCR.

Additionally, a portion of the chemokine (of any species) gene or its specific RNA, or a fragment thereof, can be purified (or an oligonucleotide synthesized) and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, Science 196:180; Grunstein, M. And Hogness, D., 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. Chemokine nucleic acids can be also identified and isolated by expression cloning using, for example, anti-chemokine antibodies for selection.

Alternatives to obtaining the chemokine DNA by cloning or amplification

include, but are not limited to, chemically synthesizing the gene sequence itself from the known chemokine sequence or making cDNA to the mRNA which encodes the chemokine protein. Other methods are possible and within the scope of the invention. Once a clone has been obtained, its identity can be confirmed by nucleic acid sequencing (by any method well known in the art) and comparison to known chemokine sequences. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699), use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA) or the method described in PCT Publication WO 97/ 15690.

Nucleic acids which are hybridizable to a chemokine nucleic acid, or to a nucleic acid encoding a chemokine derivative can be isolated, by nucleic acid hybridization under conditions of low, high, or moderate stringency (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792). For example, the nucleic acid of SEQ ID No: 1 is hybridizable to an MDC nucleic acid.

Chemokine proteins and derivatives, analogs and fragments of chemokine proteins can be obtained by any method known in the art, including but not limited to recombinant expression methods, purification from natural sources, and chemical synthesis.

For example, chemokines can be obtained by recombinant protein expression techniques. For recombinant expression, the chemokine gene or portion thereof is inserted into an appropriate cloning vector for expression in a particular host cell. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site

desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and chemokine gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated chemokine gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleotide sequence coding for a chemokine protein or a functionally active analog or fragment or other derivative thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native chemokine gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein

coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a chemokine protein or peptide fragment may be regulated by a second nucleic acid sequence so that the chemokine protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a chemokine protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control chemokine expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the β-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region

which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

For example, a vector can be used that comprises a promoter operably linked to an chemokine-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning a chemokine coding sequence into the *Eco*RI restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression of the chemokine protein product from the subclone in the correct reading frame.

Expression vectors containing chemokine gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a chemokine gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted chemokine gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a chemokine gene in the vector. For example, if the chemokine gene is inserted within the marker gene sequence of the vector, recombinants containing the chemokine insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chemokine protein in *in vitro* assay systems, e.g., binding with anti-chemokine antibody or the chemokine's receptor.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host

system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other specific embodiments, the chemokine protein(s), fragment(s), analogue(s), or derivative(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric protein containing all or a portion of the chemokine is joined via a peptide bond to all or a portion of an antigen against which immunity is desired.

Both cDNA and genomic sequences can be cloned and expressed.

The chemokine protein(s) may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column

chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.5). Alternatively, the protein can be synthesized by standard chemical methods known in the art (*e.g.*, see Hunkapiller, M., et al., 1984, Nature 310:105-111). The chemokine-encoding nucleic acid sequence(s) can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem* 253:6551), use of TAB linkers (Pharmacia), mutation-containing PCR primers, *etc.*

The experimentation involved in mutagenesis consists primarily of site-directed mutagenesis followed by phenotypic testing of the altered gene product. Some of the more commonly employed site-directed mutagenesis protocols take advantage of vectors that can provide single stranded as well as double stranded DNA, as needed. Generally, the mutagenesis protocol with such vectors is as follows. A mutagenic primer, *i.e.*, a primer complementary to the sequence to be changed, but consisting of one or a small number of altered, added, or deleted bases, is synthesized. The primer is extended *in vitro* by a DNA polymerase and, after some additional manipulations, the now double-stranded DNA is transfected into bacterial cells. Next, by a variety of methods, the desired mutated DNA is identified, and the desired protein is purified from clones containing the mutated sequence. For longer sequences, additional cloning steps are often required because long inserts (longer than 2 kilobases) are unstable in those vectors. Protocols are known to these skilled in the art and kits for site-directed mutagenesis are widely available from biotechnology supply companies, for example from Amersham Life Science, Inc. (Arlington Heights, IL) and Stratagene Cloning Systems (La Jolla, CA).

In other specific embodiments, the chemokine derivative(s) or analogue(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analogue, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

In addition, chemokine proteins, derivatives (including fragments and chimeric proteins), and analogues can be chemically synthesized. *See*, e.g., Clark-Lewis et al., 1991, *Biochem.* 30:3128-3135 and Merrifield, 1963, *J. Amer. Chem. Soc.* 85:2149-2156. For example, chemokines, derivatives and analogues can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., *see* Creighton, 1983, Proteins, Structures and Molecular Principles, W.H. Freeman and Co., N.Y., pp. 50-60). Chemokines, derivatives and analogues that are proteins can also be synthesized by use of a peptide synthesizer. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; *see* Creighton, 1983, Proteins, Structures and Molecular Principles, W.H. Freeman and Co., N.Y., pp. 34-49).

The chemokine proteins, derivatives, or analogues of the invention may be synthesized in their entirety by the sequential addition of amino acid residues or alternatively as fragment subcomponents which may be combined using techniques well known in the art, such as, for example, fragment condensation (Shin et al., 1992, *Biosci. Biotech. Biochem.* 56:404-408; Nyfeler et al., 1992, Peptides, Proc. 12th Amer. Pep. Soc., Smith and Rivier (eds), Leiden, pp 661-663); and Nokihara et al., 1990, Protein Research Foundation, Yanaihara (ed), Osaka, pp 315-320).

In a less preferred embodiment, chemokine derivatives can be obtained by proteolysis of the protein followed by purification using standard methods such as those described above (e.g., immunoaffinity purification).

In another alternate embodiment, native chemokine proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).

5.3. COMPOSITION FORMULATIONS AND METHODS OF ADMINISTRATION

The composition formulations of the invention comprise an effective immunizing amount of an immunologically active ingredient, i.e., one or more antigens, and an amount of one or more chemokine(s), or fragment(s) or derivative thereof, effective to enhance the immune response against the antigen in a subject, and a pharmaceutically acceptable carrier or excipient. In a specific embodiment, the

chemokines are selected from the group consisting of Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

Pharmaceutically acceptable carriers or excipients are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

In addition, if desired, the vaccine or composition preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine or composition. Suitable adjuvants may include, but are not limited to: mineral gels,

e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine. The effectiveness of an adjuvant may be determined by comparing the induction of antibodies directed against a MDC-containing composition in the presence and in the absence of various adjuvants.

In instances where the recombinant antigen is a hapten, *i.e.*, a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

The chemokine(s), or fragment(s) or derivative(s) thereof, and/or the antigen(s) may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

An effective dose (immunizing amount) is that amount sufficient to produce an immune response to the antigen(s) in the host to which the vaccine preparation is administered. The precise dose of the composition to be employed in the formulation will depend on the route of administration, and the nature of the subject to be

immunized, and should be decided by the practitioner according to standard clinical techniques. Effective doses of the vaccines or compositions of the present invention may also be extrapolated from dose-response curves derived from animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the composition formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized immunologically active ingredient and one or more chemokine polypeptide(s) of the invention are provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Many methods may be used to introduce the composition formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The DNA vaccines of the invention can be administered by any method known in the art for delivery of DNA to subject (for example, as described in Section 5.3 supra)

5.4. DETERMINATION OF COMPOSITION EFFICACY

The activity of one or more chemokines, or a fragment, derivative or analogue thereof, to enhance immune response to an antigen can be determined by monitoring the immune response in test animals following immunization with a composition containing the chemokine(s) and an antigen and comparing the response to that following immunization with the antigen in the absence of the chemokine(s). Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Assays for humoral and cell-mediated immunity are well known in the art.

Methods of introducing the composition may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches well known in the art, such as but not limited to: testing the reactivity of the resultant immune serum to the antigen of the chemokine-containing vaccine, as assayed by known techniques, *e.g.*, immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.

As one example of suitable animal testing, a composition of the present invention may be tested in mice for the ability to enhance an antibody response to an antigen (using for example, but not limited to, the method as described in Section 6, *infra*) and the delayed-type hypersensitivity (DTH) response (also described in Section 6 infra), measured by an increase in footpad swelling after inoculation in the footpad of the test animal, as compared to the measurements in animals administered the antigen in a composition not containing chemokine. For example, as test animals BALB/c mice may be used. The test group each receives an inoculation with fixed amount of antigen and varying amount of one or more chemokines. The control group receives an inoculation of comparable amount of antigen alone.

Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation), and serum is analyzed for antibodies against the antigen using known methods in the art, *e.g.*, using an ELISA. DTH responses to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and/or

an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokine(s) as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing the chemokine(s), indicates that the chemokine(s) enhance the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokines as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing chemokine(s), indicates that the chemokine(s) enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen.

6. EXAMPLE: IMMUNIZATION WITH MDC-CONTAINING COMPOSITION

The following experiment illustrates the evaluation of whether MDC will act as an adjuvant for a protein antigen and enhance the efficacy of a vaccine. However, it will be appreciated that the description applies equally to other chemokines and combinations of chemokines.

6.1. MATERIALS AND METHODS

6.1.1. ANIMALS AND REAGENTS

BALB/c mice are purchased from Harlan-Sprague-Dawley (Indianapolis, IN).

Human MDC (hMDC) was obtained from $CD8^+$ T cell clones immortalized *in vitro* prepared as previously described (Markham et al., 1983 *Int. J. Cancer* 31:413; Markham et al. 1984, *Int. J. Cancer* 33:13). One such immortalized $CD8^+$ T cell clone, F3b Clone 19, was adapted to growth in serum-free medium by the following procedure and used for further studies. F3b Clone 19 cells were grown in complete medium containing rIL-2 (16 ng/ml) at 37?C in a CO_2 incubator. After expanding the culture to 200 ml, the cells were pelleted and resuspended in RPMI medium containing HB101 (Irvine Scientific) supplemented with 16 ng/ml of rIL-2, 1% glutamine and 1% penicillin/streptomycin. The cells were grown to full confluence and the medium harvested by centrifugation at 670 x g for 10 minutes.

Human MDC (hMDC) was purified from F3b Clone 19 as described in Pal et al., 1997, *Science* 278:695-698. Briefly, the cell free culture supernatant from F3b Clone 19 was clarified by high speed centrifugation and fractionated by heparin affinity chromatography, taking advantage of the heparin binding characteristics of chemokines (Witt and Lander, 1994, *Current Biology* 4:394; Proost et al., 1996, *Method: A Companion to Methods in Enzymology* 10:82). Culture supernatant (1200 ml) from F3b Clone 19, grown to high cell density in serum-free medium supplemented with rIL-2 was clarified by high speed centrifugation (100,000 x g for 60 minutes at 4?C) and applied to a 5 ml HiTrap heparin affinity FPLC column (Pharmacia) equilibrated in 10 mM Tris-HCl, pH 7.6 containing 0.1 M NaCl (column buffer). The column was then washed extensively with column buffer and the bound proteins eluted from the column with 10 mM Tris-HCl, pH 7.6 containing 2.0 M NaCl at a flow rate of 0.5 to 1 ml/minute. Virtually all of the HIV suppressive activity effective against primary NSI and SI isolates and HIV-1_{IIIB} was recovered in the column eluate (data not shown). The heparin affinity column eluate was brought to pH 2.0 by addition of trifluoracetic acid (TFA) and subjected to reversed phase HPLC on a PEEK C-18 column (Waters Instruments) equilibrated in H_2O containing 0.1 % TFA. Proteins bound to the column were eluted with a 5 minute linear gradient of aqueous acetonitrile (0 to 35 %) containing 0.1% TFA. After 10 minutes at 35% acetonitrile, the column was further developed with a 60 minute linear gradient of 35-70% aqueous acetonitrile in TFA. The flow rate was maintained at 0.5 to 1 ml/minute. The fractions obtained were then tested for suppressor activity in the acute infectivity assay using HIV-1_{IIIB}. Active fractions were pooled, diluted twofold in H_2O with 0.1 % TFA

and reapplied to the column. The column was then developed with a 30 minute linear aqueous acetonitrile gradient (0-60%) containing 0.1% TFA at a flow rate of 0.5 to 1 ml/minute. The fractions obtained were assayed as above. Active fractions were pooled, diluted with H_2O/0.1 % TFA and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity was cofractionated with the protein.

Suppressive activity against HIV-1_{IIIB} in the absence of cytotoxic effects consistently copurified with a single protein peak that appeared as a homogeneous 8 kDa band when analyzed by SDS-polyacrylamide gel electrophoresis. This protein was not reactive in ELISAs for RANTES, MIP-1α or MIP-1β (R&D Systems).

Recombinant gp120 protein derived from HIV-1 IIIB isolate is purchased from Intracel (Foster City, CA).

6.1.2 IMMUNIZATION OF MICE

The hMDC and the gp120 is resuspended in a total volume of 50 µl of phosphate-buffered saline (PBS). Mice are divided into 5 groups with 3-4 mice in each group. Groups 1-4 are inoculated with 10 µg gp120 and 0.3 µg, 0.1 µg, 0.03 µg, and 0.01 µg of hMDC, respectively. As a control, group 5 is inoculated with 10 µg of gp120 in the absence of hMDC. For primary inoculation, each group of mice is inoculated with 10 µl of the hMDC and gp120 solution via footpad. Two to three weeks after the primary inoculation, each mouse is given the same does of hMDC/gp120 that is used in primary inoculation.

6.1.3 ELISA ASSAY

Serum samples are collected one week after the second inoculation via tail vein bleed. gp120 serum responses are measured using standard gp120 antibody ELISA assays.

6.1.4 DTH ASSAY

The delayed-type hypersensitivity (DTH) response is measured from 1-7 days after the second inoculation. A caliper is to be used to measure footpad swelling.

6.2. RESULTS

Mice inoculated with hMDC/gp120 are expected to have greater serum antibody and DTH responses than mice inoculated with gp120 alone. The improved responses will be reflected in either increased titers of serum antibody responses or increased footpad swelling. A dose response effect is expected - increasing the dose of hMDC used is expected to cause a corresponding improvement in the serum and DHT gp120-specific responses.

7. EXAMPLE: OTHER CHEMOKINES AND COMBINATIONS OF CHEMOKINES

The foregoing experiments can be repeated using other chemokines and combinations of chemokines. For example, the experiments are preferably repeated using one or more chemokines selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine., 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

THE CLAIMS:

1. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject and an amount of one or more chemokines, or purified fragments or derivatives thereof, effective to enhance the efficacy of said vaccine.

2. The method of claim 1, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.

3. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-

regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.

5. The method of claim 1 wherein the fragment(s) or derivative(s) are truncation isoforms.

6. The method of claim 1, wherein the one or more chemokines include MDC comprising the amino acid sequence of SEQ ID NO: 2.

7. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragmentselected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.

8. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2., which derivative has activity to enhance the efficacy of the vaccine.

9. The method of claim 1, wherein the one or more chemokine derivatives has one or more insertions or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.

10. The method of claim 1, including a chemokine derivative having one or more conservative substitutions in sequence relative a wildtype MDC, which derivative has activity to enhance the efficacy of the vaccine.

11. The method of claim 1, wherein the one or more chemokines include a human chemokine.

12. The method of claim 1, wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof is/are administered concurrently with the purified antigen(s).

13. The method of claim 1 wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof, are administered within a time period before or after administration of the purified antigen, which time period permits the purified MDC or purified fragment or derivative thereof MDC to enhance the efficacy of the vaccine.

14. The method of claim 1, wherein the antigen is an HIV antigen.

15. The method of claim 14, wherein the HIV antigen is HIV-associated gp120 protein.

16. The method of claim 1, wherein the subject is a human.

17. The method of claim 1, wherein the subject is infected or at risk of being infected with HIV virus.

18. The method of claim 1, wherein the vaccine elicits a humoral response against the antigen in the subject.

19. The method of claim 1, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.

20. The method of claim 1, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.

21. The method of claim 1, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

22. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject a first amount of a first set of one or more purified nucleotide sequences encoding one or more antigens against which an immune response is desired in the subject and a second second set of one or more purified nucleic acids, each comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner upon introduction into a suitable cell, said first amount is immunogenic and said second amount is effective in enhancing the efficacy of the vaccine.

23. The method of claim 22, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.

24. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine

1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

25. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.

26. The method of claim 22 wherein the fragment(s) or derivative(s) are truncation isoforms.

27. The method of claim 22, wherein the nucleotide sequence encoding one or more chemokines comprises the nucleotide sequence of SEQ ID NO:1.

28. The method of claim 22, wherein one or more of the chemokine derivative(s) have deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the efficacy of the vaccine.

29. The method of claim 22, wherein the vaccine elicits a humoral response against the antigen in the subject.

30. The method of claim 22, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.

31. The method of claim 22, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.

32. The method of claim 22, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

33. A composition comprising: an immunogenic amount of one or more purified antigens and an amount of one or more purified chemokines, or purified

fragments or derivatives thereof, effective to enhance the immune response to said antigen(s); and a pharmaceutically acceptable carrier.

34. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.

35. The composition of claim 33, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.

36. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating

protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

37. The composition of claim 33, wherein the fragment(s) or derivative(s) are truncation isoforms.

38. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragmentselected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.

39. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragmentselected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2, which derivative has activity to enhance the efficacy of the vaccine.

40. The composition of claim 33, wherein the one or more chemokine derivatives has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.

41. The composition of claim 33, wherein the one or more chemokine derivatives has one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.

42. The composition of claim 33, wherein the chemokine is a human chemokine.

43. The composition of claim 33, wherein the antigen is an HIV antigen.

44. The composition of claim 43, wherein the antigen is HIV associated gp120 protein.

45. A composition comprising an amount of a first set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens

and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s), or fragment(s) or derivative(s) thereof, are expressed from said first set of nucleic acid(s) and second set of nucleic acid(s) in a coordinated manner such that upon introduction into a suitable cell, the amount of said first set of nucleic acid(s) is sufficient to express an immunogenic amount of the antigen and the amount of the said second set of nucleic acid(s) is effective in enhancing the efficacy of the vaccine; and a pharmaceutically acceptable carrier.

46. The composition of claim 45, wherein the chemokine is MDC and the nucleic acid encoding the MDC comprises the nucleotide sequence of SEQ ID NO: 1.

47. The composition of claim 45, wherein the chemokine derivative(s) have deletional, insertional or substitutional mutations and/or combinations thereof, and the derivative(s) have activity to enhance the efficacy of the vaccine.

48. The composition of claim 45, further comprising pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

49. A composition comprising a first set of purified nucleotide sequences encoding one or more antigens and a second set of purified nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner such that upon introduction into a suitable cell, the sets produce an amount of said antigen(s) that is immunogenic and an amount of chemokine(s), or fragment(s) or derivative(s) thereof, that is effective in enhancing the efficacy of the vaccine relative to a corresponding vaccine composition without such chemokine(s), fragment(s) or derivative(s) thereof.

50. The composition of claim 49, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine,

Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

51. The method of claim 49, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.

52. The method of claim 49, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.

53. The composition of claim 49, wherein the fragment(s) or derivative(s) are truncation isoforms.

54. The composition of claim 49, wherein the nucleic acid is administered directly to the subject.

55. The composition of claim 49, wherein the nucleic acid is introduced into a suitable host cell and said suitable host cell is introduced into the subject.

```
GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC        52
                     Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val
                     -24             -20                 -15

CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC       100
Leu Val Leu Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr
          -10                 -5                  1

GGC GCC AAC ATG GAA GAC AGC GTC TGC TGC CGT GAT TAC GTC CGT TAC       148
Gly Ala Asn Met Glu Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr
   5                  10                  15

CGT CTG CCC CTG CGC GTG GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC       196
Arg Leu Pro Leu Arg Val Val Lys His Phe Tyr Trp Thr Ser Asp Ser
20                  25                  30                  35

TGC CCG AGG CCT GGC GTG GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC       244
Cys Pro Arg Pro Gly Val Val Leu Leu Thr Phe Arg Asp Lys Glu Ile
               40                  45                  50

TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG       292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu
          55                  60                  65
```

FIG. 1A-1

AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA 348
Ser Gln

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG 408

CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCACTGCC 468

ATCTCCCCCC TGACCCCTCT AACCCATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCT 528

GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCCATGAC TCCCCACTGC CCTAAGCTGA 588

GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCCATCT CTGTCTCCAG 648

CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTTCTCCAA ACCCATACTA 708

CACATCCCAC TTCTGGGTCT TTGCCTGGGA TGTTGCTGAC ACTCAGAAAG TCCCACCACC 768

TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC 828

CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCCTC TTAATAACCC TAGTCACAGT 888

CTCCGCAGAT TCTTGGGATT TGGGGGTTTT CTCCCCCACC TCTCCACTAG TTGGACCAAG 948

FIG. 1A-2

GTTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCCC 1008

TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAAA TCAATAAAAC TAATGTCCCT 1068

CCCCTCTCCC TGCCAAAAGG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT 1128

GGGCCAGCTG GGTCAATGTG AAGCCCCAAA TTTGCCCAGA TTCACCTTTC TTCCCCCACT 1188

CCCTTTTTTT TTTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTCACCCA CGCTGGAGTG 1248

CAATGGTGTG GTCTTGGCTT ATTGAAGCCT CTGCCTCCTG GGTTCAAGTG ATTCTCTTGC 1308

CTCAGCCTCC TGAGTAGCTG GGATTACAGG TTCCTGCTAC CACGCCCAGC TAATTTTTGT 1368

ATTTTTAGTA GAGACGAGGC TTCACCATGT TGGCCAGGCT GGTCTCGAAC TCCTGTCCTC 1428

AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC 1488

CTGGCCTCTT CCCTCTCCCC ACTGCCCCCC CCAACTTTTT TTTTTTTTTT ATGGCAGGGT 1548

CTCACTCTGT CGCCCAGGCT GGAGTGCAGT GGCGTGATCT CGGCTCACTA CAACCTCGAC 1608

CTCCTGGGTT CAAGTGATTC TCCCACCCCA GCCTCCCAAG TAGCTGGGAT TACAGGTGTG 1668

FIG. 1A-3

TGCCACTACG GCTGGCTAAT TTTTGTATTT TTAGTAGAGA CAGGTTTCAC CATATTGGCC	1728
AGGCTGGTCT TGAACTCCTG ACCTCAAGTG ATCCACCTTC CTTGTGCTCC CAAAGTGCTG	1788
AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTTT TTTTCCTAAT AGGAGACTCC	1848
TGTACCTTTC TTCGTTTTAC CTATGTGTCG TGTCTGCTTA CATTTCCTTC TCCCCTCAGG	1908
CTTTTTTTGG GTGGTCCTCC AACCTCCAAT ACCCAGGCCT GGCCTCTTCA GAGTACCCCC	1968
CATTCCACTT TCCCTGCCTC CTTCCTTAAA TAGCTGACAA TCAAATTCAT GCTATGGTGT	2028
GAAAGACTAC CTTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTATTT GAAAACAGAG	2088
TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAATTTT AGGAACTGTG AGAGGGGGAC	2148
AAGGTGAAGC TTTCCTGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC	2208
TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAATTGAG TGAAGGAATC CTGGGTAGAG	2268
ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCTTTC	2328
TGGCTGATTT TTGTAGAGAC GGGGTTTTGC CATGTTACCC AGGCTGGTCT CAAACTCCTG	2388

FIG. 1A-4

```
GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC    2448

TGCGCCTGGC TTCCTCTTCC TCTTGAGAAA TATTCTTTTC ATACAGCAAG TATGGGACAG    2508

CAGTGTCCCA GGTAAAGGAC ATAAATGTTA CAAGTGTCTG GTCCTTTCTG AGGGAGGCTG    2568

GTGCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTC ACTCCCTGAA    2628

CCCAGCCTGA CAAATCACAG TGAGAATGTT CACCTTATAG GCTTGCTGTG GGGCTCAGGT    2688

TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTCATCCA GGGCCTGTGT    2748

CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCTAC    2808

TGCCCATGAA CGGGGCCCTC AAGCGTCCTG GGATCTCCTT CTCCCTCCTG TCCTGTCCTT    2868

GCCCCTCAGG ACTGCTGGAA AATAAATCCT TTAAAATAGT AAAAAAAAAA AAAAA         2923
```

FIG. 1A-5

FIG. 1A-1
FIG. 1A-2
FIG. 1A-3
FIG. 1A-4
FIG. 1A-5

FIG. 1A

```
Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val Leu Val Leu Leu Ala
-24            -20            -15            -10
Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
            -5              1               5
Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
    10              15              20              55
Val Lys His Phe Tyr Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
25              30              35              40
Val Val Leu Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
                45              50              55
Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
            60              65
```

FIG. 1B

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Gallo, Robert C.
DeVico, Anthony L.
Garzino, Alfedo

(ii) TITLE OF THE INVENTION: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING MACROPHAGE DERIVED CHEMOKINE

(iii) NUMBER OF SEQUENCES: 2
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Pennie & Edmonds LLP
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036/2711
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 8769-029
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2923 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 92..298

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC        52
                     Met Ala Arg Leu Gln Thr Ala Leu Val
                     -24             -20                 -15
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC       100
Leu Val Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr
            -10                 -5                  1
GGC GCC AAC ATG GAA GAC AGC GTC TGC CGT GAT TAC GTC CGT TAC       148
Gly Ala Asn Met Glu Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr
     5                  10                  15
CGT CTG CCC CTG CGC GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC       196
Arg Leu Pro Leu Arg Val Lys His Phe Tyr Trp Thr Ser Asp Ser
 20                  25                  30                  35

TGC CCG AGG CCT GGC GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC       244
Cys Pro Arg Pro Gly Val Leu Thr Phe Arg Asp Lys Glu Ile
                 40                  45                  50
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG       292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu
            55                  60                  65
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA       348
Ser Gln
```

```
GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG      408
CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCACTGCC      468
ATCTCCCCCC TGACCCCTCT AACCCATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCT      528
GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCCATGAC TCCCCACTGC CCTAAGCTGA      588
GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCCATCT CTGTCTCCAG      648
CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTTCTCCAA ACCCATACTA      708
CACATCCCAC TTCTGGGTCT TTGCCTGGGA TGTTGCTGAC ACTCAGAAAG TCCCACCACC      768
TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC      828
CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCCTC TTAATAACCC TAGTCACAGT      888
CTCCGCAGAT TCTTGGGATT TGGGGGTTTT CTCCCCCACC TCTCCACTAG TTGGACCAAG      948
GTTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCCC     1008
TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAAA TCAATAAAAC TAATGTCCCT     1068
CCCCTCTCCC TGCCAAAAGG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT     1128
GGGCCAGCTG GGTCAATGTG AAGCCCCAAA TTTGCCCAGA TTCACCTTTC TTCCCCCACT     1188
CCCTTTTTTT TTTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTCACCCA CGCTGGAGTG     1248
CAATGGTGTG GTCTTGGCTT ATTGAAGCCT CTGCCTCCTG GGTTCAAGTG ATTCTCTTGC     1308
CTCAGCCTCC TGAGTAGCTG GGATTACAGG TTCCTGCTAC CACGCCCAGC TAATTTTTGT     1368
ATTTTTAGTA GAGACGAGGC TTCACCATGT TGGCCAGGCT GGTCTCGAAC TCCTGTCCTC     1428
AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC     1488
CTGGCCTCTT CCCTCTCCCC ACTGCCCCCC CCAACTTTTT TTTTTTTTTT ATGGCAGGGT     1548
CTCACTCTGT CGCCCAGGCT GGAGTGCAGT GGCGTGATCT CGGCTCACTA CAACCTCGAC     1608
CTCCTGGGTT CAAGTGATTC TCCCACCCCA GCCTCCCAAG TAGCTGGGAT TACAGGTGTG     1668
TGCCACTACG GCTGGCTAAT TTTTGTATTT TTAGTAGAGA CAGGTTTCAC CATATTGGCC     1728
AGGCTGGTCT TGAACTCCTG ACCTCAAGTG ATCCACCTTC CTTGTGCTCC CAAAGTGCTG     1788
AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTTT TTTTCCTAAT AGGAGACTCC     1848
TGTACCTTTC TTCGTTTTAC CTATGTGTCG TGTCTGCTTA CATTTCCTTC TCCCCTCAGG     1908
CTTTTTTTGG GTGGTCCTCC AACCTCCAAT ACCCAGGCCT GGCCTCTTCA GAGTACCCCC     1968
CATTCCACTT TCCCTGCCTC CTTCCTTAAA TAGCTGACAA TCAAATTCAT GCTATGGTGT     2028
GAAAGACTAC CTTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTATTT GAAAACAGAG     2088
TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAATTTT AGGAACTGTG AGAGGGGGAC     2148
AAGGTGAAGC TTTCCTGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC     2208
TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAATTGAG TGAAGGAATC CTGGGTAGAG     2268
ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCTTTC     2328
TGGCTGATTT TTGTAGAGAC GGGGTTTTGC CATGTTACCC AGGCTGGTCT CAAACTCCTG     2388
GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC     2448
TGCGCCTGGC TTCCTCTTCC TCTTGAGAAA TATTCTTTTC ATACAGCAAG TATGGGACAG     2508
CAGTGTCCCA GGTAAAGGAC ATAAATGTTA CAAGTGTCTG GTCCTTTCTG AGGGAGGCTG     2568
GTGCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTC ACTCCCTGAA     2628
CCCAGCCTGA CAAATCACAG TGAGAATGTT CACCTTATAG GCTTGCTGTG GGGCTCAGGT     2688
TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTCATCCA GGGCCTGTGT     2748
CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCTAC     2808
TGCCCATGAA CGGGGCCCTC AAGCGTCCTG GGATCTCCTT CTCCCTCCTG TCCTGTCCTT     2868
GCCCCTCAGG ACTGCTGGAA AATAAATCCT TTAAAATAGT AAAAAAAAAA AAAAA          2923
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 93 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Ala Arg Leu Gln Thr Ala Leu Val Leu Val Leu Ala
-24             -20                 -15                 -10
Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
            -5                   1                   5
Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
     10                  15                  20
Val Lys His Phe Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
 25                  30                  35                  40
Val Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
                45                  50                  55
Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
            60                  65
```

C-CHEMOKINES
LYMPHOTACTIN (SCM-1) D63789 D63790

CX3C-chemokines
Fractalkine/neurotactin U91835 U84487

```
LOCUS       HSU83171     2923 bp    mRNA            PRI       31-MAY-1997
DEFINITION    Human  macrophage-derived  chemokine  precursor  (MDC)  mRNA,
complete
            cds.
ACCESSION   U83171
NID         g1931580
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;   Mammalia;   Eutheria;   Primates;   Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 2923)
  AUTHORS   Godiska,R., Chantry,D., Raport,C.J., Sozzani,S., Allavena,P.,
            Leviten,D., Mantovani,A. and Gray,P.W.
  TITLE           Human  macrophage-derived  chemokine  (MDC),  a  novel
chemoattractant
            for monocytes, monocyte-derived dendritic cells, and natural
killer
            cells
  JOURNAL   J. Exp. Med. 185 (9), 1595-1604 (1997)
  MEDLINE   97296313
REFERENCE   2  (bases 1 to 2923)
  AUTHORS   Godiska,R. and Gray,P.W.
  TITLE     Direct Submission
  JOURNAL   Submitted (23-DEC-1996) ICOS Corporation, 22021 20th Avenue SE,
            Bothell, WA 98021, USA
FEATURES             Location/Qualifiers
     source          1..2923
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="16"
     gene            20..301
                     /gene="MDC"
     sig_peptide     20..91
                     /gene="MDC"
     CDS             20..301
                     /gene="MDC"
                     /function="chemotactic for dendritic cells and natural
                     killer cells"
                     /codon_start=1
                     /product="macrophage-derived chemokine precursor"
                     /db_xref="PID:g1931581"

/translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR
                     LPLRVVKHFYWTSDSCPRPGVVLLTFRDKEICADPRVPWVKMILNKLSQ"
     mat_peptide     92..298
                     /gene="MDC"
                     /product="macrophage-derived chemokine"
     repeat_region   complement(1194..1805)
                     /rpt_family="ALU"
     repeat_region   complement(2335..2443)
                     /rpt_family="ALU"
BASE COUNT      605 a    861 c    669 g    788 t
ORIGIN
        1 gagacataca ggacagagca tggctcgcct acagactgca ctcctggttg tcctcgtcct
       61 ccttgctgtg gcgcttcaag caactgaggc aggcccctac ggcgccaaca tggaagacag
      121 cgtctgctgc cgtgattacg tccgttaccg tctgcccctg cgcgtggtga aacacttcta
      181 ctggacctca gactcctgcc cgaggcctgg cgtggtgttg ctaaccttca gggataagga
      241 gatctgtgcc gatcccagag tgccctgggt gaagatgatt ctcaataagc tgagccaatg
      301 aagagcctac tctgatgacc gtggccttgg ctcctccagg aaggctcagg agccctacct
      361 ccctgccatt atagctgctc cccgccagaa gcctgtgcca actctctgca ttccctgatc
      421 tccatccctg tggctgtcac ccttggtcac ctccgtgctg tcactgccat ctccccctg
      481 acccctctaa cccatcctct gcctccctcc ctgcagtcag agggtcctgt tcccatcagc
      541 gattcccctg cttaaaccct tccatgactc cccactgccc taagctgagg tcagtctccc
      601 aagcctggca tgtggccctc tggatctggg ttccatctct gtctccagcc tgcccacttc
      661 ccttcatgaa tgttgggttc tagctccctg ttctccaaac ccatactaca catcccactt
      721 ctgggtcttt gcctgggatg ttgctgacac tcagaaagtc ccaccacctg cacatgtgta
      781 gccccaccag ccctccaagg cattgctcgc ccaagcagct ggtaattcca tttcatgtat
      841 tagatgtccc ctggcccctct gtccccctctt aataacccta gtcacagtct ccgcagattc
```

```
     901 ttgggatttg ggggtttttct ccccccacctc tccactagtt ggaccaaggt ttctagctaa
     961 gttactctag tctccaagcc tctagcatag agcactgcag acaggccctg gctcagaatc
    1021 agagcccaga aagtggctgc agacaaaatc aataaaacta atgtccctcc cctctccctg
    1081 ccaaaaggca gttacatatc aatacagaga ctcaaggtca ctagaaatgg gccagctggg
    1141 tcaatgtgaa gccccaaatt tgcccagatt cacctttctt cccccactcc cttttttttt
    1201 ttttttttt tgagatggag tttcgctctt gtcacccacg ctggagtgca atggtgtggt
    1261 cttggcttat tgaagcctct gcctcctggg ttcaagtgat tctcttgcct cagcctcctg
    1321 agtagctggg attacaggtt cctgctacca cgcccagcta atttttgtat ttttagtaga
    1381 gacgaggctt caccatgttg gccaggctgg tctcgaactc ctgtcctcag gtaatccgcc
    1441 cacctcagcc tcccaaagtg ctgggattac aggcgtgagc cacagtgcct ggcctcttcc
    1501 ctctccccac tgccccccccc aacttttttt tttttttat ggcagggtct cactctgtcg
    1561 cccaggctgg agtgcagtgg cgtgatctcg gctcactaca acctcgacct cctgggttca
    1621 agtgattctc ccaccccagc ctcccaagta gctgggatta caggtgtgtg ccactacggc
    1681 tggctaattt ttgtattttt agtagagaca ggtttcacca tattggccag gctggtcttg
    1741 aactcctgac ctcaagtgat ccaccttcct tgtgctccca aagtgctgag attacaggcg
    1801 tgagctatca cacccagcct ccccctttttt ttcctaatag gagactcctg tacctttctt
    1861 cgttttacct atgtgtcgtg tctgcttaca tttccttctc ccctcaggct ttttttgggt
    1921 ggtcctccaa cctccaatac ccaggcctgg cctcttcaga gtaccccccа ttccactttc
    1981 cctgcctcct tccttaaata gctgacaatc aaattcatgc tatggtgtga aagactacct
    2041 ttgacttggt attataagct ggagttatat atgtatttga aaacagagta aatacttaag
    2101 aggccaaata gatgaatgga agaattttag gaactgtgag agggggacaa ggtgaagctt
    2161 tcctggccct gggaggaagc tggctgtggt agcgtagcgc tctctctctc tgtctgtggc
    2221 aggagccaaa gagtagggtg taattgagtg aaggaatcct gggtagagac cattctcagg
    2281 tggttgggcc aggctaaaga ctgggagttg ggtctatcta tgcctttctg gctgattttt
    2341 gtagagacgg ggttttgcca tgttacccag gctggtctca aactcctggg ctcaagcgat
    2401 cctcctggct cagcctccca aagtgctggg attacaggcg tgaatcactg cgcctggctt
    2461 cctcttcctc ttgagaaata ttcttttcat acagcaagta tgggacagca gtgtcccagg
    2521 taaaggacat aaatgttaca agtgtctggt cctttctgag ggaggctggt gccgctctgc
    2581 agggtatttg aacctgtgga attggaggag gccatttcac tccctgaacc cagcctgaca
    2641 aatcacagtg agaatgttca ccttataggc ttgctgtggg gctcaggttg aaagtgtggg
    2701 gagtgacact gcctaggcat ccagctcagt gtcatccagg gcctgtgtcc ctcccgaacc
    2761 cagggtcaac ctgcctgcca caggcactag aaggacgaat ctgcctactg cccatgaacg
    2821 gggccctcaa gcgtcctggg atctccttct ccctcctgtc ctgtccttgc ccctcaggac
    2881 tgctggaaaa taaatccttt aaaatagtaa aaaaaaaaaa aaa
//
LOCUS       HSU83239      932 bp    mRNA            PRI       02-MAY-1997
DEFINITION  Human CC chemokine STCP-1 mRNA, complete cds.
ACCESSION   U83239
NID         g2062424
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 932)
  AUTHORS       Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
  TITLE     Molecular cloning and functional characterization of a novel CC
            chemokine STCP-1 which specifically acts on activated T
lymphocytes
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 932)
  AUTHORS       Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
  TITLE     Direct Submission
  JOURNAL    Submitted (26-DEC-1996) Research Computing, Amgen Institute,
620
            University Ave, Suite 706, Toronto, ON M5G 2C1, Canada
FEATURES             Location/Qualifiers
     source          1..932
                     /organism="Homo sapiens"
                     /note="Amgen EST program"
                     /db_xref="taxon:9606"
     CDS             15..296
                     /codon_start=1
                     /product="CC chemokine STCP-1"
                     /db_xref="PID:g2062425"

/translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR
```

```
                    LPLRVVKHFYWTSDSCPRPGVVLLTFRDKEICADPRVPWVKMILNKLSQ"
BASE COUNT      166 a    330 c    201 g    235 t
ORIGIN
        1 atacaggaca gagcatggct cgcctacaga ctgcactcct ggttgtcctc gtcctccttg
       61 ctgtggcgct tcaagcaact gaggcaggcc cctacggcgc caacatggaa gacagcgtct
      121 gctgccgtga ttacgtccgt taccgtctgc ccctgcgcgt ggtgaaacac ttctactgga
      181 cctcagactc ctgcccgagg cctggcgtgg tgttgctaac cttcagggat aaggagatct
      241 gtgccgatcc cagagtgccc tgggtgaaga tgattctcaa taagctgagc caatgaagag
      301 cctactctga tgaccgtggc cttggctcct ccaggaaggc tcaggagccc tacctccctg
      361 ccattatagc tgctccccgc cagaagcctg tgccaactct ctgcattccc tgatctccat
      421 ccctgtggct gtcacccttg gtcacctccg tgctgtcact gccatctccc ccctgacccc
      481 tctaacccat cctctgcctc cctccctgca gtcagagggt cctgttccca tcagcgattc
      541 ccctgcttaa acccttccat gactccccac tgccctaagc tgaggtcagt ctcccaagcc
      601 tggcatgtgg ccctctggat ctgggttcca tctctgtctc cagcctgccc acttcccttc
      661 atgaatgttg ggttctagct ccctgttctc caaacccata ctacacatcc cacttctggg
      721 tctttgcctg ggatgttgct gacactcaga aagtcccacc acctgcacat gtgtagcccc
      781 accagccctc caaggcattg ctcgcccaag cagctggtaa ttccatttca tgtattagat
      841 gtcccctggc cctctgtccc ctcttaataa ccctagtcac agtctccgca gattcttggg
      901 atttgggggt tttctccccc acctctccac ta
//
LOCUS       HSMCP1         725 bp    RNA             PRI       03-APR-1995
DEFINITION  H.sapiens mRNA for monocyte chemoattractant protein 1 (MCP-1).
ACCESSION   X14768
NID         g34513
KEYWORDS    monocyte chemoattractant protein 1.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 725)
  AUTHORS   Yoshimura,T., Yuhki,N., Moore,S.K., Appella,E., Lerman,M.I. and
            Leonard,E.J.
  TITLE      Human monocyte chemoattractant protein-1 (MCP-1). Full-length
cDNA
            cloning, expression in mitogen-stimulated blood mononuclear
            leukocytes, and sequence similarity to mouse competence gene JE
  JOURNAL   FEBS Lett. 244 (2), 487-493 (1989)
  MEDLINE   89153605
COMMENT     ZAPII.
FEATURES             Location/Qualifiers
     source          1..725
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="glioma cells"
                     /cell_line="U105MG"
                     /clone_lib="lambda"
     sig_peptide     54..122
                     /note="signal peptide (AA -23 to -1)"
     CDS             54..353
                     /codon_start=1
                     /product="monocyte chemoattractant preprotein"
                     /db_xref="PID:g34514"
                     /db_xref="SWISS-PROT:P13500"

/translation="MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKIS

VQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT"
     mat_peptide     123..350
                     /note="MCP-1 (AA 1 - 76)"
     misc_feature    162..170
                     /note="pot. N-linked glycosylation site"
     misc_feature    707..712
                     /note="pot. polyA signal"
     polyA_site      725
                     /note="polyA site"
BASE COUNT      208 a    171 c    126 g    220 t
ORIGIN
        1 ctaacccaga aacatccaat tctcaaactg aagctcgcac tctcgcctcc agcatgaaag
       61 tctctgccgc ccttctgtgc ctgctgctca tagcagccac cttcattccc caagggctcg
      121 ctcagccaga tgcaatcaat gccccagtca cctgctgtta taacttcacc aataggaaga
      181 tctcagtgca gaggctcgcg agctatagaa gaatcaccag cagcaagtgt cccaaagaag
```

```
      241 ctgtgatctt caagaccatt gtggccaagg agatctgtgc tgaccccaag cagaagtggg
      301 ttcaggattc catggaccac ctggacaagc aaacccaaac tccgaagact tgaacactca
      361 ctccacaacc caagaatctg cagctaactt attttccccc agctttcccc agacaccctg
      421 ttttatttta ttataatgaa ttttgtttgt tgatgtgaaa cattatgcct taagtaatgt
      481 taattcttat ttaagttatt gatgttttaa gtttatcttt catggtacta gtgtttttta
      541 gatacagaga cttggggaaa ttgcttttcc tcttgaacca cagttctacc cctgggatgt
      601 tttgagggtc tttgcaagaa tcattaatac aaagaatttt ttttaacatt ccaatgcatt
      661 gctaaaatat tattgtggaa atgaatattt tgtaactatt acaccaaata aatatatttt
      721 tgtac
//
LOCUS       HSMCP2       2991 bp    DNA             PRI       20-MAR-1997
DEFINITION  H.sapiens MCP-2 gene.
ACCESSION   X99886
NID         g1905800
KEYWORDS    MCP-2 gene; monocyte chemotactic protein 2; SCYA10 gene.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 2991)
  AUTHORS   Van Coillie,E., Fiten,P., Nomiyama,H., Sakaki,Y., Miura,R.,
            Yoshie,O., Van Damme,J. and Opdenakker,G.
  TITLE     The human MCP-2 gene (SCYA8): cloning, sequence analysis,
tissue
            expression, and assignment to the CC chemokine gene contig on
            chromosome 17q11.2
  JOURNAL   Genomics 40 (2), 323-331 (1997)
  MEDLINE   97237052
REFERENCE   2  (bases 1 to 2991)
  AUTHORS   Opdenakker,G.M.M.
  TITLE     Direct Submission
  JOURNAL   Submitted (07-AUG-1996) G.M.M. Opdenakker, Rega Institute for
            Medical Research, Minderbroedersstraat 10, B 3000 Leuven,
BELGIUM
FEATURES             Location/Qualifiers
     source          1..2991
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
                     /map="q11.2"
     repeat_region   209..219
                     /note="DR-A"
                     /rpt_type=DIRECT
     repeat_region   240..248
                     /note="DR-B"
                     /rpt_type=DIRECT
     CAAT_signal     296..300
     repeat_region   310..318
                     /note="IR-A"
                     /rpt_type=INVERTED
     repeat_region   406..415
                     /note="DR-B"
                     /rpt_type=DIRECT
     repeat_region   407..416
                     /note="IR-B"
                     /rpt_type=INVERTED
     repeat_region   425..435
                     /note="DR-A"
                     /rpt_type=DIRECT
     repeat_region   429..437
                     /note="IR-B"
                     /rpt_type=INVERTED
     repeat_region   455..465
                     /note="IR-C"
                     /rpt_type=INVERTED
     TATA_signal     467..472
     repeat_region   492..502
                     /note="IR-C"
                     /rpt_type=INVERTED
     repeat_region   492..500
                     /note="IR-A"
```

```
                     /rpt_type=INVERTED
     exon            534..639
                     /gene="MCP-2 (SCYA10)"
                     /number=1
     gene            534..1969
                     /gene="MCP-2 (SCYA10)"
     CDS             join(534..639,1331..1448,1864..1969)
                     /gene="MCP-2 (SCYA10)"
                     /codon_start=1
                     /product="monocyte chemotactic protein-2"
                     /db_xref="PID:e279930"
                     /db_xref="PID:g1905801"

/translation="MLKLTPLPSKMKVSAALLCLLLMAATFSPQGLAQPDSVSIPITC

CFNVINRKIPIQRLESYTRITNIQCPKEAVIFKTQRGKEVCADPKERWVRDSMKHLDQ
                     IFQNLKP"
     intron          640..1330
                     /gene="MCP-2 (SCYA10)"
                     /number=1
     exon            1331..1448
                     /gene="MCP-2 (SCYA10)"
                     /number=2
     intron          1449..1863
                     /gene="MCP-2 (SCYA10)"
                     /number=2
     exon            1864..1969
                     /gene="MCP-2 (SCYA10)"
                     /number=3
BASE COUNT      799 a    709 c    632 g    851 t
ORIGIN
        1 agattctggg gcattaagac ttagttccag gattctgtca ttctgccaac gttctgtggc
       61 tggggttcta aaggagcttg cctggcttag aactgcaagt gactctagtg tgatggagag
      121 caccagcaaa gccttagggc ccatccctgg cctcctgtta cccacagagg ggtaagcctt
      181 ggctctcttc cactatgacg tcagcttcca ttcttccttt cttatagaca attttccatt
      241 tcaaggaaat cagagccctt aatagttcag tgaggtcact ttgctgagca caatcccata
      301 cccttcagcc tctgctccac agagcctaag caaaagatag aaactcacaa cttccttgtt
      361 ttgttatctg gaaattatcc caggatctgg tgcttactca gcatattcaa ggaaggtctt
      421 acttcattct tccttgattg tgaccatgcc caggctctct gctccctata aaaggcaggc
      481 agagccaccg aggagcagag aggttgagaa caacccagaa accttcacct ctcatgctga
      541 agctcacacc cttgccctcc aagatgaagg tttctgcagc gcttctgtgc ctgctgctca
      601 tggcagccac tttcagccct cagggacttg ctcagccagg taagacctct ccctttttaa
      661 ggggagacca aaagaggaat taagaagagc cattatgtca cagctcatta ggaacaaaac
      721 cagaactaaa ggctcaggtc actgaggctg gttcccttga tctttcctga ccccagtttt
      781 gggaggagac agtggagccg ctacagcaac aaccctccca ttgtttgggg aaataatcca
      841 gaacgaagaa ctgtttctca ctgtgggtgt aaaggacatt tcaggccgta gtggagaggg
      901 agaaactatt gcctgaagct tcaaattttg gttatggttc agtgtacctt ccagaacagt
      961 ggctgtgtaa agaggatgag gacccagagg aatctcagcg tatggcatag gctaactcta
     1021 aagcccatga ggatgaaaga ctgggaagca aggtattgga acttatgttc ccagtgtcag
     1081 aagttttggg ttagtagaca aggactagct tgttactcaa aatgtttcca aacccagtca
     1141 acaatgacgg gccgcagagt tcaatagagg aaagagactc acaggcaaca ttttatctct
     1201 gggatctgga ctaagacact gaacttggga tggtgacttc ttggtcttct ccttccttct
     1261 cttcttttcc ttacaaatgc acacttacgg tgggtcctaa atgtctcatt ctttgcaaaa
     1321 tttctttcag attcagtttc cattccaatc acctgctgct ttaacgtgat caataggaaa
     1381 attcctatcc agaggctgga gagctacaca agaatcacca acatccaatg tcccaaggaa
     1441 gctgtgatgt gagtggacag tgcctggcac ccccattcaa aagttctgat ggacaacata
     1501 gagaagtcaa gattcatgtc catatgagtc ggatgcatat aacttctatc caaaggggcc
     1561 ctctacccca tagagaaact cagtccgtga gaaggagtcc ataactgctc taggattccc
     1621 ttctaggggc ttggtgaaac taacccaata tctgtagcca ggaccctgga gggtttcacc
     1681 tggacagcaa gagcagagct tccttctgga gcttcttcct cccactcttc ccctccctcc
     1741 tctcccgggt ccgggtcctt cacctaagga ccaagggctg atcagtccta gggaccaatg
     1801 gcccacagtc ctgtgcagga tcttcaaagt cttccatcta attgtgccct ctctccccca
     1861 cagcttcaag acccaacggg gcaaggaggt ctgtgctgac cccaaggaga gatgggtcag
     1921 ggattccatg aagcatctgg accaaatatt tcaaaatctg aagccatgag ccttcataca
     1981 tggactgaga gtcagagctt gaagaaaagc ttatttattt tccccaacct cccccaggtg
     2041 cagtgtgaca ttatttttatt ataacatcca caaagagatt atttttaaat aatttaaagc
     2101 ataatatttc ttaaaaagta tttaattata tttaagttgt tgatgtttta actctatctg
     2161 tcatacatcc tagtgaatgt aaaatgcaaa atcctggtga tgtgtttttt gttttgtttt
     2221 tcctgtgagc tcaactaagt tcacggcaaa atgtcattgt tctccctcct acctgtctgt
     2281 agtgttgtgg ggtcctccca tggatcatca aggtgaaaca ctttggtatt ctttggcaat
     2341 cagtgctcct gtaagtcaaa tgtgtgcttt gtactgctgt tgttgaaatt gatgttactg
```

```
     2401 tatataacta tggaattttg aaaaaaaatt tcaaaaagaa aaaaatatat ataatttaac
     2461 actacttagt cttattcttc ttggggtaac atttagctgg gagtgagttt tgggcatcat
     2521 gggtgacagt ttgggcatgg acgggccatt tttcaagaat gtcttctggc tacgctggac
     2581 tcaaccaagg ttctcagaga acttggtggg accaggccag gatgttccag ctctctgact
     2641 ctagtcccta acttcagcag ccctgattcg ctagcctctc ttgtttctct tgtttatata
     2701 ttatccagcc taaggtattt tgttatagct gcccaaaaag actaagataa tctccatcac
     2761 tctaccccca accccaatcc caagaacttg caagcatcca tttaaaggcg tggaaccttct
     2821 tctttttgac agccttttaa ggtcaagatt cccctgtact tagtgagctt agctgaatct
     2881 tcttacaaac atgtgacccg ccatattgag ccatacatac cgagcttatt atttttccag
     2941 cttattggga aaacacgtct aaggcaaaca aatttattgt actgttgaac c
//LOCUS       HSY16645     1368 bp    mRNA            PRI       25-SEP-1998
DEFINITION  Homo sapiens mRNA for monocyte chemotactic protein-2.
ACCESSION   Y16645
NID         g2916795
KEYWORDS    MCP-2 gene; monocyte chemotactic protein 2.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1368)
  AUTHORS   Van Coillie,E.
  TITLE         Functional comparison of two human monocyte chemotactic
protein-2
            isoforms, role of the amino-terminal pyroglutamic acid and
            processing by CD26/dipeptidyl peptidase IV
  JOURNAL   Biochemistry 37, 12672-12680 (1998)
REFERENCE   2  (bases 1 to 1368)
  AUTHORS   Van Coillie,E.
  TITLE     Direct Submission
  JOURNAL     Submitted (23-FEB-1998) E. Van Coillie, Rega Institute for
Medical
            Research, Minderbroedersstraat 10, 3000 Leuven, BELGIUM
COMMENT     Related sequences: X99886, Y10802.
FEATURES             Location/Qualifiers
     source          1..1368
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
                     /tissue_type="testis"
                     /clone_lib="Clontech"
                     /clone="HL1142q"
                     /map="q11.2"
     gene            473..772
                     /gene="MCP-2"
     sig_peptide     473..541
                     /gene="MCP-2"
     CDS             473..772
                     /gene="MCP-2"
                     /codon_start=1
                     /product="monocyte chemotactic protein-2"
                     /db_xref="PID:e1253690"
                     /db_xref="PID:g2916796"

/translation="MKVSAALLCLLLMAATFSPQGLAQPDSVSIPITCCFNVINRKIP

IQRLESYTRITNIQCPKEAVIFKTKRGKEVCADPKERWVRDSMKHLDQIFQNLKP"
     mat_peptide     542..769
                     /gene="MCP-2"
     variation       677
                     /gene="MCP-2"
                     /note="polymorphism, Lys -> Gln"
                     /replace="c"
BASE COUNT      457 a    292 c    243 g    376 t
ORIGIN
        1 atccattgtg ctctaaagtg atggagagca ccagcaaagc cttagggccc atccctggcc
       61 tcctgttacc cacagagggg taggcccttg gctctcttcc actatgacgt cagcttccat
      121 tcttcctttc ttatagacaa ttttccattt caaggaaatc agagccctta atagttcagt
      181 gaggtcactt tgctgagcac aatcccatac ccttcagcct ctgctccaca gagcctaagc
      241 aaaagataga aactcacaac ttccttgttt tgttatctgg aaattatccc aggatctggt
      301 gcttactcag catattcaag gaaggtctta cttcattctt ccttgattgt gaccatgccc
      361 aggctctctg ctccctataa aaggcaggca gagccaccga ggagcagaga ggttgagaac
```

```
      421 aacccagaaa ccttcacctc tcatgctgaa gctcacaccc ttgccctcca agatgaaggt
      481 ttctgcagcg cttctgtgcc tgctgctcat ggcagccact ttcagccctc agggacttgc
      541 tcagccagat tcagtttcca ttccaatcac ctgctgcttt aacgtgatca ataggaaaat
      601 tcctatccag aggctggaga gctacacaag aatcaccaac atccaatgtc ccaaggaagc
      661 tgtgatcttc aagaccaaac ggggcaagga ggtctgtgct gaccccaagg agagatgggt
      721 cagggattcc atgaagcatc tggaccaaat atttcaaaat ctgaagccat gagccttcat
      781 acatggactg agagtcagag cttgaagaaa agcttattta ttttccccaa cctcccccag
      841 gtgcagtgtg acattatttt attataacat ccacaaagag attatttta aataatttaa
      901 agcataatat ttcttaaaaa gtatttaatt atatttaagt tgttgatgtt ttaactctat
      961 ctgtcataca tcctagtgaa tgtaaaatgc aaaatcctgg tgatgtgttt tttgtttttg
     1021 ttttcctgtg agctcaacta agttcacggc aaaatgtcat tgttctccct cctacctgtc
     1081 tgtagtgttg tggggtcctc ccatggatca tcaaggtgaa acactttggt attctttggc
     1141 aatcagtgct cctgtaagtc aaatgtgtgc tttgtactgc tgttgttgaa attgatgtta
     1201 ctgtatataa ctatggaatt ttgaaaaaaa atttcaaaaa gaaaaaaata tatataattt
     1261 aaaactaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
     1321 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa
//LOCUS       HSMCP3A      1085 bp    DNA             PRI       25-JUL-1994
DEFINITION  H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION   X72308 S57464
NID         g313707
KEYWORDS    monocyte chemotactic protein 3.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1085)
  AUTHORS   Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
  TITLE     Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of
            the cDNA and comparison with other chemokines
  JOURNAL   Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
  MEDLINE   93213290
REFERENCE   2  (bases 1 to 1085)
  AUTHORS   Opdenakker,G.M.
  TITLE     Direct Submission
  JOURNAL     Submitted  (27-MAY-1993)  G.M.  Opdenakker,  Rega  Institute,
University
            of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE   3  (bases 1 to 1085)
  AUTHORS   Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
            Speleman,F., Laureys,G. and Van Damme,J.
  TITLE     The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
            assignment to the C-C chemokine gene cluster on chromosome
            17q11.2-q12
  JOURNAL   Genomics 21 (2), 403-408 (1994)
  MEDLINE   94375065
FEATURES             Location/Qualifiers
     source          1..1085
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     gene            299..810
                     /gene="MCP-3"
     CDS             299..628
                     /gene="MCP-3"
                     /codon_start=1
                     /product="monocyte chemotactic protein-3"
                     /db_xref="PID:g313708"
                     /db_xref="SWISS-PROT:P80098"

/translation="MWKPMPSPSNMKASAALLCLLLTAAAFSPQGLAQPVGINTSTTC

CYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWVQDFMKHLDK
                     KTQTPKL"
     sig_peptide     299..397
                     /gene="MCP-3"
     mat_peptide     398..625
                     /gene="MCP-3"
                     /product="monocyte chemotactic protein-3"
     polyA_signal    806..810
                     /gene="MCP-3"
BASE COUNT      314 a    214 c    229 g    328 t
```

```
ORIGIN
        1 ggttttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
       61 ctggggttag tatagcttag ttaaactttc gtttattgct aaaggttaat cactgctgtt
      121 tcccgtgggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
      181 gtcccttttg atcgtggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
      241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
      301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
      361 gctcacagca gctgctttca gccccccaggg gcttgctcag ccagttggga ttaatacttc
      421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
      481 cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaactgga
      541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
      601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
      661 cttgagaaac aaataatttg tataccctgt cctttctcag agtggttctg agattatttt
      721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatggtt tttcttagta
      781 gattttaaaa gttattaata ttttaattta atcttccatg gattttggtg ggttttgaac
      841 ataaagcctt ggatgtatat gtcatctcag tgctgtaaaa actgtgggat gctcctccct
      901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcaaa gatttgcttt
      961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
     1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
     1081 aaaaa
//
LOCUS       HSMCP3A      1085 bp    DNA             PRI       25-JUL-1994
DEFINITION  H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION   X72308 S57464
NID         g313707
KEYWORDS    monocyte chemotactic protein 3.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1085)
  AUTHORS   Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
  TITLE     Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of
            the cDNA and comparison with other chemokines
  JOURNAL   Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
  MEDLINE   93213290
REFERENCE   2  (bases 1 to 1085)
  AUTHORS   Opdenakker,G.M.
  TITLE     Direct Submission
  JOURNAL     Submitted  (27-MAY-1993)  G.M.  Opdenakker,  Rega  Institute,
University
            of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE   3  (bases 1 to 1085)
  AUTHORS   Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
            Speleman,F., Laureys,G. and Van Damme,J.
  TITLE     The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
            assignment to the C-C chemokine gene cluster on chromosome
            17q11.2-q12
  JOURNAL   Genomics 21 (2), 403-408 (1994)
  MEDLINE   94375065
FEATURES             Location/Qualifiers
     source          1..1085
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     gene            299..810
                     /gene="MCP-3"
     CDS             299..628
                     /gene="MCP-3"
                     /codon_start=1
                     /product="monocyte chemotactic protein-3"
                     /db_xref="PID:g313708"
                     /db_xref="SWISS-PROT:P80098"

/translation="MWKPMPSPSNMKASAALLCLLLTAAAFSPQGLAQPVGINTSTTC

CYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWVQDFMKHLDK
                     KTQTPKL"
     sig_peptide     299..397
                     /gene="MCP-3"
     mat_peptide     398..625
```

```
                     /gene="MCP-3"
                     /product="monocyte chemotactic protein-3"
     polyA_signal    806..810
                     /gene="MCP-3"
BASE COUNT      314 a    214 c    229 g    328 t
ORIGIN
        1 ggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
       61 ctggggttag tatagcttag ttaaactttc gtttattgct aaaggttaat cactgctgtt
      121 tcccgtgggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
      181 gtccctttg atcgtggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
      241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
      301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
      361 gctcacagca gctgctttca gcccccaggg gcttgctcag ccagttggga ttaatacttc
      421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
      481 cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaactgga
      541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
      601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
      661 cttgagaaac aaataatttg tataccctgt cctttctcag agtggttctg agattatttt
      721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatggtt tttcttagta
      781 gattttaaaa gttattaata ttttaattta atcttccatg gattttggtg ggttttgaac
      841 ataaagcctt ggatgtatat gtcatctcag tgctgtaaaa actgtgggat gctcctccct
      901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcaaa gatttgcttt
      961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
     1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
     1081 aaaaa
//LOCUS       HSU46767      825 bp    mRNA            PRI       16-DEC-1996
DEFINITION    Human monocyte chemoattractant protein-4 precursor (MCP-4)
mRNA,
            complete cds.
ACCESSION   U46767
NID         g1732122
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 825)
  AUTHORS         Garcia-Zepeda,E.A.,   Combadiere,C.C.,   Rothenberg,M.E.,
Sarafi,M.N.,
            Lavigne,F., Hamid,Q., Murphy,P. and Luster,A.D.
  TITLE     Human monocyte chemoattractant Protein (MCP)-4: A novel CC
            chemokine with activities on monocytes, eosinophils, and
basophils
            induced in allergic and non-allergic inflammation that signals
            through the CC chemokine receptors CCR-2 and 3
  JOURNAL   J. Immunol. 158 (1996) In press
REFERENCE   2  (bases 1 to 825)
  AUTHORS   Garcia-Zepeda,E.A. and Luster,A.D.
  TITLE     Direct Submission
  JOURNAL   Submitted (22-JAN-1996) Eduardo A. Garcia-Zepeda, Infectious
            Disease Unit, Massachusets General Hospital, 149 13th St.,
            Charlestown, MA 02129, USA
FEATURES             Location/Qualifiers
     source          1..825
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /tissue_type="heart"
                     /clone_lib="EG3.16"
     sig_peptide     34..102
                     /gene="MCP-4"
     CDS             34..330
                     /gene="MCP-4"
                     /note="small   cytokine;   intercrine/chemokine;   C-C
subfamily
                     signature; chemoattractant for monocytes, eosinophils"
                     /codon_start=1
                     /product="monocyte      chemoattractant      protein-4
precursor"
                     /db_xref="PID:g1732123"

/translation="MKVSAVLLCLLLMTAAFNPQGLAQPDALNVPSTCCFTFSSKKIS
```

```
LQRLKSYVITTSRCPQKAVIFRTKLGKEICADPKEKWVQNYMKHLGRKAHTLKT"
     gene            34..330
                     /gene="MCP-4"
     mat_peptide     103..327
                     /gene="MCP-4"
BASE COUNT      221 a    175 c    185 g    244 t
ORIGIN
        1 acattgtgaa atctccaact cttaaccttc aacatgaaag tctctgcagt gcttctgtgc
       61 ctgctgctca tgacagcagc tttcaacccc cagggacttg ctcagccaga tgcactcaac
      121 gtcccatcta cttgctgctt cacatttagc agtaagaaga tctccttgca gaggctgaag
      181 agctatgtga tcaccaccag caggtgtccc cagaaggctg tcatcttcag aaccaaactg
      241 ggcaaggaga tctgtgctga cccaaaggag aagtgggtcc agaattatat gaaacacctg
      301 ggccggaaag ctcacaccct gaagacttga actctgctac ccctactgaa atcaagctgg
      361 agtacgtgaa atgacttttc cattctcctc tggcctcctc ttctatgctt tggaatactt
      421 ctaccataat tttcaaatag gatgcattcg gttttgtgat tcaaaatgta ctatgtgtta
      481 agtaatattg gctattattt gacttgttgc tggtttggag tttatttgag tattgctgat
      541 cttttctaaa gcaaggcctt gagcaagtag gttgctgtct ctaagccccc ttcccttcca
      601 ctatgagctg ctggcagtgg gttgtattcg gttcccaggg gttgagagca tgcctgtggg
      661 agtcatggac atgaagggat gctgcaatgt aggaaggaga gctctttgtg aatgtgaggt
      721 tgttgctaaa ttattgttta ttgtggaaag atgaatgcaa tagtaggact gctgacattt
      781 tgcagaaaat acattttatt taaaatctcc taaaaaaaaa aaaaa
//LOCUS       HSAMAC1       803 bp    RNA             PRI       10-AUG-1997
DEFINITION  Homo sapiens mRNA for alternative activated macrophage specific
CC
            chemokine 1.
ACCESSION   Y13710
NID         g2326515
KEYWORDS    AMAC-1 gene; CC-chemokine 1.
SOURCE      human. ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;   Mammalia;   Eutheria;   Primates;   Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 803)
  AUTHORS   Politz,O.
  TITLE     Direct Submission
  JOURNAL   Submitted (10-JUN-1997) Politz O., Dermatology, Free University
            Benjamin Franklin Medical Center, Hindenburgdamm 30; 12200
Berlin
            GERMANY
REFERENCE   2  (bases 1 to 803)
  AUTHORS   Kodelja,V., Mueller,C., Politz,O., Hakiy,N., Orfanos,C.E. and
            Goerdt,S.
  TITLE       Cloning of alternative activated macrophage associated CC
chemokine
            1 (AMAC-1)
  JOURNAL   Unpublished
FEATURES             Location/Qualifiers
     source          1..803
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="macrophage"
     sig_peptide     71..133
                     /gene="amac-1"
     CDS             71..340
                     /gene="amac-1"
                     /note="macrophage specific"
                     /codon_start=1
                     /product="CC-chemokine 1"
                     /db_xref="PID:e321838"
                     /db_xref="PID:g2326516"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKELCCLVYTSWQIPQKFI
                     VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"
     gene            71..340
                     /gene="amac-1"
     mat_peptide     134..337
                     /gene="amac-1"
BASE COUNT      214 a    213 c    160 g    216 t
ORIGIN
```

```
        1 ccggcacgag aggagttgtg agtttccaag ccccagctca ctctgaccac ttctctgcct
       61 gcccagcatc atgaagggcc ttgcagctgc cctccttgtc ctcgtctgca ccatggccct
      121 ctgctcctgt gcacaagttg gtaccaacaa agagctctgc tgcctcgtct atacctcctg
      181 gcagattcca caaaagttca tagttgacta ttctgaaacc agcccccagt gccccaagcc
      241 aggtgtcatc ctcctaacca agagaggccg gcagatctgt gctgacccca ataagaagtg
      301 ggtccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg
      361 gcccagtgaa cttggtgggc ccaggaggga acaggagcct gagccagggc aatggccctg
      421 ccaccctgga ggccacctct tctaagagtc ccatctgcta tgcccagcca cattaactaa
      481 ctttaatctt agtttatgca tcatatttca ttttgaaatt gatttctatt gttgagctgc
      541 attatgaaat tagtattttc tctgacatct catgacattg tctttatcat cctttccccc
      601 ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag
      661 cagacattgt gccatatgta tcaaatgaca aatctttatt gaatggtttt gctcagcacc
      721 acctttaat atattggcag tacttattat ataaaaggta aaccagcatt ctcactgtga
      781 aaaaaaaaaa aaaaaaaaa aaa
//
LOCUS       HUMLD78A     3176 bp    DNA             PRI       17-JAN-1992
DEFINITION  Human LD78 alpha gene.
ACCESSION   D90144
NID         g219905
KEYWORDS    LD78; LD78 alpha; cytokine; inducible gene family; secreted
            peptide.
SOURCE      Human blood lymphocyte DNA, clone Lm LD-3.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;   Mammalia;   Eutheria;   Primates;   Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 3176)
  AUTHORS   Nakao,M., Nomiyama,H. and Shimada,K.
  TITLE     Structures of human genes coding for cytokine LD78 and their
            expression
  JOURNAL   Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
  MEDLINE   90287155
COMMENT       These data kindly submitted in computer readable form by:
Hisayuki
            Nomiyama
            Department of Biochemistry
            Kumamoto University Medical School
            2-2-1 Honjo, Kumamoto 860
            Japan
            Phone:  096-344-2111
            Fax:    096-372-6140.
FEATURES             Location/Qualifiers
     source          1..3176
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     TATA_signal     1041..1045
     exon            1069..1227
                     /number=1
     prim_transcript 1069..2957
                     /note="LD78 alpha mRNA and introns"
     sig_peptide     1155..1220
                     /note="LD78 alpha signal peptide"
     CDS             join(1155..1227,1916..2030,2451..2541)
                     /codon_start=1
                     /product="LD78 alpha precursor"
                     /db_xref="PID:d1014875"
                     /db_xref="PID:g219906"

/translation="MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSYTSRQIPQ
                    NFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA"
     mat_peptide     join(1218..1227,1916..2030,2451..2538)
                     /partial
                     /note="LD78 alpha mature peptide"
     intron          1228..1915
     exon            1916..2030
                     /partial
                     /number=2
     intron          2031..2450
     exon            2451..2957
                     /number=3
```

```
BASE COUNT      833 a    741 c    752 g    850 t
ORIGIN
        1 acccagggac ctatcacaca aatataagaa ctattcattc tttaaggcat gtatttccaa
       61 gcctttgtat ttttttccat gcttagggtt ggcaaggaat atatatatat ttgtacaaat
      121 atatatgtgt atatgtacaa atacatgtat atatagtaca aatatatata tatatttgta
      181 caattcttca gactttgtag aatttgtata atgtcgtatc ttgctttttt taaccactga
      241 tgttataagc atatttatgc cacttcattc attttagaga cttaataata aatgatctag
      301 tggataattt atcattccct gatggagaaa aatttagctt tgtttatttt agagttataa
      361 acgatgctgg gtcaggtatc tttatgtttg aagatggctc catatttggg ttgtttccac
      421 agaactcttt cctagaaatg ctttttctag gttaatggct acagatattt ctaggcacct
      481 gacatattga cacccacctc taaagtattt ttatgatcca caactagcgt ttaacacagc
      541 gccctagtca ctacatgact aataaataga caaatgactg aaacatgacc tcatgctttc
      601 tattcctcca gctttcattc agttctttgc ctctgggagg aggaagggtt gtgcagccct
      661 ccacagcatc agcccatcaa ccctatccct gtggttatag cagctgagga agcagaattg
      721 cagctctgtg ggaaggaatg gggctggaga gttcatgcac agaccagttc ttatgagaag
      781 ggactgacta agaatagcct tgggttgaca tatacccctc ttcacactca caggagaaac
      841 catttcccta tgaaactata acaagtcatg agttgagagc tgagagttag agaatagctc
      901 aaagatgcta ttcttggata tcctgagccc ctgtggtcac cagggaccct gagttgtgca
      961 acttagcatg acagcatcac tacgcttaaa aatttccctc ctcaccccca gattccattt
     1021 ccccatccgc cagggctgcc tataaagagg agagctggtt tcagacttca gaaggacacg
     1081 ggcagcagac agtggtcagt cctttcttgg ctctgctgac actcgagccc acattccgtc
     1141 acctgctcag aatcatgcag gtctccactg ctgcccttgc tgtcctcctc tgcaccatgg
     1201 ctctctgcaa ccagttctct gcatcacgtg agtctgagtt tcgttgtggg tatcaccact
     1261 ctctggccat ggttagacca catcaatctt ttcttgtggc ctaaaagccc ccaagagaaa
     1321 agagaacttc ttaaagggct gccaaacatc ttggtctttc tctttaagac ttttatttct
     1381 atctctagaa ggggtcttag ccccctagtc tccaggtatg agaatctagg caggggcagg
     1441 ggagttacag tccctttcac agatagaaaa acagggttcg aaacgaatca gttagcaaga
     1501 ggcagaatcc agggctgctt actttcccagt ggggtatgtt gttcactctc cagctcactc
     1561 taggtctccc aggagctctg tcccttggat gtcttatgag agatgtccaa ggcttctctt
     1621 gggttggggt atgacttctt gaaccagaca aaattccctg aagagaactg agataagaga
     1681 acagtccgtt caggtatctg gatcacacag agaaacagag aacccactat gaagagtcaa
     1741 ggagaaagaa ggatacagac agaaacaaag agacatttct cagcaaaaat gcccaaatgc
     1801 cttccagtca cttggtctga gcaagcctgc cttcctcaac tgctcgggga tcagaagctg
     1861 cctggccttt tcttctgagc tgtgactcgg gctcattctc ttcctttctc cacagttgct
     1921 gctgacacgc cgaccgcctg ctgcttcagc tacacctccc ggcagattcc acagaatttc
     1981 atagctgact actttgagac gagcagccag tgctccaagc ccggtgtcat gtaagtgcca
     2041 gtcttcctgc tcacctctat ggaggtaggg agggtcaggg ttggggcaga gacaggccag
     2101 aaggctatcc tggaaaggcc cagccttcag gagcctatcg gggatacagg acgcagggct
     2161 ccgaggtgtg acctgacttg gagctggagt gaggcatgtg ttacagagtc aggaagggct
     2221 gccccagccc agaggaaagg gacaggaaga aggaggcagc gggacactct gagggccacc
     2281 cctactgagt cactgagaga agctctctag acagagatag gcaggggcc cctgaaagag
     2341 gagcaagccc tgagctgccc aggacagaga gcagaatggt ggggccatgg tgggcccagg
     2401 attcccctgc tggattcccc agtgcttaac tcttcctccc ttctccacag cttcctaacc
     2461 aagcgaagcc ggcaggtctg tgctgacccc agtgaggagt gggtccagaa atatgtcagc
     2521 gacctggagc tgagtgcctg aggggtccag aagcttcgag gcccagcgac ctcggtgggc
     2581 ccagtgggga ggagcaggag cctgagcctt gggaacatgc gtgtgacctc cacagctacc
     2641 tcttctatgg actggttgtt gccaaacagc cacactgtgg gactcttctt aacttaaatt
     2701 ttaatttatt tatactattt agtttttgta atttattttc gatttcacag tgtgtttgtg
     2761 attgtttgct ctgagagttc ccctgtcccc tccccccttcc ctcacaccgc gtctggtgac
     2821 aaccgagtgg ctgtcatcag cctgtgtagg cagtcatggc accaaagcca ccagactgac
     2881 aaatgtgtat cggatgcttt tgttcagggc tgtgatcggc ctggggaaat aataaagatg
     2941 ctcttttaaa aggtaaacca gtattgagtt tggttttgtt tttctggcaa atcaaaatca
     3001 ctggttaaga ggaatcatag gcaaagatta ggaagaggtg aaatggaggg aaattgggag
     3061 agatggggag ggctaccaca gagttatcca ctttacaacg gagacacagt tctggaacat
     3121 tgaaactacg aatatgttat aactcaaatc ataacatgca tgctctagga gaattc
//
LOCUS       AF043339      225 bp    mRNA            PRI       23-FEB-1998
DEFINITION  Homo sapiens macrophage inflammatory protein 1 alpha (MIP1a)
mRNA,
            partial cds.
ACCESSION   AF043339
NID         g2905627
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 225)
  AUTHORS   Jang,J.S. and Kim,B.E.
  TITLE     Direct Submission
  JOURNAL   Submitted (15-JAN-1998) Protein Engineering, General Institute
```

```
of
            Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
            Sosa-gu, Bucheon 422-231, Korea
COMMENT     forward primer (5'-tgcgcatcacttgctgctgaca-3')
            reverse primer (5'-cttctggacccctcaggcact-3').
FEATURES              Location/Qualifiers
     source           1..225
                      /organism="Homo sapiens"
                      /db_xref="taxon:9606"
                      /cell_type="PHA-treated peripheral blood leukocyte"
     gene             <1..225
                      /gene="MIP1a"
     primer_bind      <1..19
                      /gene="MIP1a"
                      /PCR_conditions="94C-1min,   50C-1min,   72C-3min,   30
cycles;
                      DeltaCycler II from Ericomp"
     CDS              <1..213
                      /gene="MIP1a"
                      /function="CC chemokine"
                      /function="proinflammatory cytokine involved in
                      inflammation"
                      /note="8-10 kDa"
                      /codon_start=1
                      /product="macrophage inflammatory protein 1 alpha"
                      /db_xref="PID:g2905628"

/translation="ASLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLT
                      KRSRQVCADPSEEWVQKYVSDLELSA"
     primer_bind      complement(205..225)
                      /gene="MIP1a"
BASE COUNT       50 a     68 c     62 g     45 t
ORIGIN
        1 gcatcacttg ctgctgacac gccgaccgcc tgctgcttca gctacacctc ccggcagatt
       61 ccacagaatt tcatagctga ctactttgag acgagcagcc agtgctccaa gcccggtgtc
      121 atcttcctaa ccaagcgaag ccggcaggtc tgtgctgacc ccagtgagga gtgggtccag
      181 aaatatgtca gcgacctgga gctgagtgcc tgaggggtcc agaag
//
LOCUS       HUMLD78B     3112 bp    DNA             PRI       17-JAN-1992
DEFINITION  Human LD78 beta gene.
ACCESSION   D90145
NID         g219907
KEYWORDS      LD78; LD78 beta; cytokine; inducible gene family; secreted
peptide.
SOURCE      Human placenta DNA, clone Lm LD-1.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;   Mammalia;   Eutheria;   Primates;   Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 3112)
  AUTHORS   Nakao,M., Nomiyama,H. and Shimada,K.
  TITLE     Structures of human genes coding for cytokine LD78 and their
            expression
  JOURNAL   Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
  MEDLINE   90287155
COMMENT       These data kindly submitted in computer readable form by:
Hisayuki
            Nomiyama
            Department of Biochemistry
            Kumamoto University Medical School
            2-2-1 Honjo, Kumamoto 860
            Japan
            Phone:  096-344-2111
            Fax:    096-372-6140.
FEATURES              Location/Qualifiers
     source           1..3112
                      /organism="Homo sapiens"
                      /db_xref="taxon:9606"
     repeat_unit      498..797
                      /note="Alu repeat"
```

```
     TATA_signal     1078..1082
     prim_transcript 1106..2995
                     /note="LD78 beta mRNA and introns"
     exon            1106..1267
                     /note="LD78 beta precursor, coding region of exon 1"
                     /number=1
     CDS             join(1192..1267,1953..2067,2488..2578)
                     /partial
                     /codon_start=1
                     /product="LD78 beta precursor"
                     /db_xref="PID:d1014876"
                     /db_xref="PID:g219908"

/translation="MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSYTSRQIP
                     QNFIADYFETSSQCSKPSVIFLTKRGRQVCADPSEEWVQKYVSDLELSA"
     sig_peptide     1192..1260
                     /partial
                     /note="LD78 beta signal peptide"
     mat_peptide     join(1258..1267,1953..2067,2488..2575)
                     /partial
                     /note="LD78 beta mature peptide"
     intron          1268..1952
     exon            1953..2067
                     /number=2
     intron          2068..2487
     exon            2488..2955
                     /number=3
BASE COUNT      756 a    775 c    780 g    801 t
ORIGIN
        1 ttagagactt aataataaag gatcttgtgg ataatttatc attccctgat agagaaaaat
       61 ttagctttgc ttattttaga gttataaatg atgctgggtc aggtatcttt atgtttgaag
      121 atggctccat atttgggttg tttccacaga actctttccc agaaatgctt tttctaggtt
      181 aatggctaca catatttcta ggcacctgac atactgacac ccacctctaa agtatttta
      241 tgatccacaa ctagcgttta acacagcgcc ccagtcactc cgagactaat aaatagacaa
      301 atgactgaaa cgtgacctca tgctttctat tcctccagct ttcattgagt tccttcctc
      361 tgggaggact gggggttgtc tagccctcca cagcatcagc ccattgaccc tatccttgtg
      421 gttatagcag ctgaggaagc agaattacag ctctgtggga aggaatgggg ctggagagtt
      481 catgcataga ccaattcttt ttttttttt tttttgagat ggagtttcac ttttgttgcc
      541 caggctggag tgcaatggca tgatctcagc tcaccacagc ccccacctcc tgggttcaag
      601 cgattctcct gccctcagcc tcccgagtag ctgggattac aggcatgtgc caccacgcct
      661 gactactttt gtatttttag tagagatgga gtttctcttt cttggtcagg ttggtctcaa
      721 actcctgacc tcaggtgatc cgcagcctcg gcctcccaaa gtgttgggat tacaggtgtg
      781 agcgaccatg cctggctgca tagaccagtt cttatgagaa gggatcaact aagaatagcc
      841 ttgggttgac acacacccct cttcacactc acaggagaaa ccccatgaag ctagaaccag
      901 tcatgagttg agagctgaga gttagagagt agctcagaga tgctattctt ggatatcctg
      961 agcccctgtg gtcaccaggg accctgagtt gtgcaacact cagcatgaca gcatcactac
     1021 acttaaaaat ttccctcctc acccccagat tccatttccc catccgccag ggctgcctat
     1081 aaagaggaga gatggcttca gacatcagaa ggacgcaggc agcaaagagt agtcagtccc
     1141 ttcttggctc tgctgacact cgagcccaca ttccatcacc tgctcccaat catgcaggtc
     1201 tccactgctg cccttgccgt cctcctctgc accatggctc tctgcaacca ggtcctctct
     1261 gcaccacgtg agtccatgtt gttgttgtgg gtatcaccac tctctggcca tggttagacc
     1321 acatcagtct ttttttgcgg cctgagagcc ccgaagagaa aagaaggaag ttcttaaagc
     1381 gctgccaaac accttggtct ttttcttcac aacttttatt tttatctcta gaaggggtct
     1441 tagccctcct agtctccagg tatgagaatc taggcagggg caggggagtt acagtccctt
     1501 gtacagatag aaaaacaggg ttcaaaacga atcagtttgc aagaggcaga atccagggct
     1561 gcttacttcc cagtggggtc tgttgttcac tctccagctc accctaggtc tcccaggagc
     1621 cctgtccctt ggatgtctta tgagagatgt ccagggcttc tcttgggctg gggtatgact
     1681 tcttgaaccg acaaaattcc atgaagagag ctaagagaac agtccattca ggtatctgga
     1741 tcacatagag aaacagagaa cccactatga agagtcaagg ggaaagagga atatagacag
     1801 aaacaaagag acatttctct gcaaaacccc ccaaatgcct tgcagtcact tggtctgagc
     1861 aagcctgccc tcctcaacca ctcagggatc agaagctgcc tggccttttc ttctgagctg
     1921 tgactcgggc ttattctctc ctttctccgc agttgctgct gacacgccga ccgcctgctg
     1981 cttcagctac acctcccgac agattccaca gaatttcata gctgactact ttgagacgag
     2041 cagccagtgc tccaagccca gtgtcatgta agtgccagtc ttcctgctca cctctaggga
     2101 ggtagggagt gtcagggtgg gggcagaaac aggccagaag gccatcctgg aaaggcccag
     2161 ccttcaggag cctatcgggg atacaggacg cagggcactg aggtgtgacc tgacttgggg
     2221 ctggagtgag gtgggtgtta cagagtcagg aagggctgcc ccaggccaga ggaaaggaac
     2281 aggaagaagg aggcagcagg acactctgag ggcccccttg cctggagtca ctgagagaag
     2341 ctctctagac ggagataggc aggggggccc tgagagagga gcaggccttg agctgcccag
     2401 gacagagagc aggatgtcag gccatggtgg gcccaggatt ccccggctgg attccccagt
     2461 gcttaactct tcctcccttc tccacagctt cctaaccaag agaggccggc aggtctgtgc
```

```
     2521 tgaccccagt gaggagtggg tccagaaata cgtcagtgac ctggagctga gtgcctgagg
     2581 ggtccagaag cttcgaggcc cagcgacctc agtgggccca gtggggagga gcaggagcct
     2641 gagccttggg aacatgcgtg tgacctctac agctacctct tctatggact ggttattgcc
     2701 aaacagccac actgtgggac tcttcttaac ttaaatttta atttatttat actatttagt
     2761 ttttataatt tatttttgat ttcacagtgt gtttgtgatt gtttgctctg agagttcccc
     2821 ctgtcccctc caccttccct cacagtgtgt ctggtgacga ccgagtggct gtcatcggcc
     2881 tgtgtaggca gtcatggcac caaagccacc agactgacaa atgtgtatca gatgcttttg
     2941 ttcagggctg tgatcggcct ggggaaataa taaagatgtt cttttaaacg gtaaaccagt
     3001 attgagtttg gttttgtttt tctggcaaat caaaatcact agttaagagg aatcataggc
     3061 aaagattagg aagaggtgaa atggagggaa actgggagag atggggagcg ct
//
LOCUS       HUMACT2A      696 bp    mRNA            PRI       30-OCT-1994
DEFINITION  Human activation (Act-2) mRNA, complete cds.
ACCESSION   J04130
NID         g178017
KEYWORDS    act2 gene; immune activation gene.
SOURCE      Human (Hut-102B2 library) activated T cells, cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 696)
  AUTHORS       Lipes,M.A.,  Napolitano,M.,  Jeang,K.T.,  Chang,N.T.  and
Leonard,W.J.
  TITLE     Identification, cloning, and characterization of an immune
            activation gene
  JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 85 (24), 9704-9708 (1988)
  MEDLINE   89071764
COMMENT     Draft entry and computer-readable sequence [1] kindly submitted
by
            W.Leonard, 09-JAN-1989.
FEATURES             Location/Qualifiers
     source          1..696
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /map="Unassigned"
     mRNA            <1..696
                     /note="act-2 mRNA"
     sig_peptide     109..177
                     /gene="LAG2"
                     /note="act-2 protein signal peptide"
     gene            109..387
                     /gene="LAG2"
     CDS             109..387
                     /gene="LAG2"
                     /note="act-2 protein precursor"
                     /codon_start=1
                     /db_xref="GDB:G00-127-452"
                     /db_xref="PID:g178018"

/translation="MKLCVTVLSLLMLVAAFCSPALSAPMGSDPPTACCFSYTARKLP
                     RNFVVDYYETSSLCSQPAVVFQTKRSKQVCADPSESWVQEYVYDLELN"
     mat_peptide     178..384
                     /gene="LAG2"
                     /note="act-2 protein"
BASE COUNT      157 a    203 c    139 g    197 t
ORIGIN      Unreported.
        1 ttccccccccc ccccccccc ccccgcccga gcacaggaca cagctgggtt ctgaagcttc
       61 tgagttctgc agcctcacct ctgagaaaac ctcttttcca ccaataccat gaagctctgc
      121 gtgactgtcc tgtctctcct catgctagta gctgccttct gctctccagc gctctcagca
      181 ccaatgggct cagaccctcc caccgcctgc tgcttttctt acaccgcgag gaagcttcct
      241 cgcaactttg tggtagatta ctatgagacc agcagcctct gctcccagcc agctgtggta
      301 ttccaaacca aaagaagcaa gcaagtctgt gctgatccca gtgaatcctg ggtccaggag
      361 tacgtgtatg acctggaact gaactgagct gctcagagac aggaagtctt cagggaaggt
      421 cacctgagcc cggatgcttc tccatgagac acatctcctc catactcagg actcctctcc
      481 gcagttcctg tcccttctct taatttaatc ttttttatgt gccgtgttat tgtattaggt
      541 gtcatttcca ttatttatat tagtttagcc aaaggataag tgtcctatgg ggatggtcca
      601 ctgtcactgt ttctctgctg ttgcaaatac atggataaca catttgattc tgtgtgtttt
      661 ccataataaa actttaaaat aaaatgcaga cagtta
//
LOCUS       AF031587      481 bp    mRNA            PRI       02-JAN-1998
DEFINITION  Homo sapiens MIP-1 delta mRNA, complete cds.
```

```
ACCESSION   AF031587
NID         g2739163
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 481)
  AUTHORS   Wang,W.
  TITLE      Molecular cloning and characterization of a new CC chemokine
MIP-1
            delta
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 481)
  AUTHORS   Wang,W.
  TITLE     Direct Submission
  JOURNAL   Submitted (27-OCT-1997) Immunobiology, DNAX Research Institute,
901
            California Ave, Palo Alto, CA 94304, USA
FEATURES             Location/Qualifiers
     source          1..481
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
     CDS             1..342
                     /note="CC or beta chemokine"
                     /codon_start=1
                     /product="MIP-1 delta"
                     /db_xref="PID:g2739164"

/translation="MKVSVAALSCLMLVAVLGSQAQFINDAETELMMSKLPLENPVVL

NSFHFAADCCTSYISQSIPCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
                     DCMKKLKPYSI"
BASE COUNT      140 a    112 c    100 g    129 t
ORIGIN
        1 atgaaggtct ccgtggctgc cctctcctgc ctcatgcttg ttgctgtcct tggatcccag
       61 gcccagttca taaatgatgc agagacagag ttaatgatgt caaagcttcc actggaaaat
      121 ccagtagttc tgaacagctt tcactttgct gctgactgct gcacctccta catctcacaa
      181 agcatcccgt gttcactcat gaaaagttat tttgaaacga gcagcgagtg ctccaagcca
      241 ggtgtcatat tcctcaccaa gaaggggagg caagtctgtg ccaaacccag tggtccggga
      301 gttcaggatt gcatgaaaaa gctgaagccc tactcaatat aataataaag agacaaaaga
      361 gggcagccac ccacctccaa cacctcctgt gagtttcttg gtctgaaata cttaaaaaat
      421 atatatattg ttgtgtctgg taatgaaagt aatgcatcta ataaagagta ttcaattttt
      481 t
//
LOCUS       AF043340      234 bp    mRNA            PRI       23-FEB-1998
DEFINITION   Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a)
mRNA,
            partial cds.
ACCESSION   AF043340
NID         g2905629
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 234)
  AUTHORS   Jang,J.S. and Kim,B.E.
  TITLE     Direct Submission
  JOURNAL    Submitted (15-JAN-1998) Protein Engineering, General Institute
of
            Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
            Sosa-gu, Bucheon 422-231, Korea
COMMENT     forward primer (5'-tgcgcacccctggccactgaactg-3')
            reverse primer (5'-ccttccttctggtcagttgga-3').
FEATURES             Location/Qualifiers
     source          1..234
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="PHA-treated peripheral blood leukocyte"
```

```
     gene            <1..234
                     /gene="MIP2a"
     primer_bind     <1..21
                     /gene="MIP2a"
                     /PCR_conditions="94C-1min,   50C-1min,   72C-3min,   30
cycles;
                     DeltaCycler II from Ericomp"
     CDS             <1..222
                     /gene="MIP2a"
                     /function="CXC chemokine"
                     /function="proinflammatory cytokine involved in
                     inflammation"
                     /note="8-10 kDa"
                     /codon_start=1
                     /product="macrophage inflammatory protein 2 alpha"
                     /db_xref="PID:g2905630"

/translation="APLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATL
                     KNGQKACLNPASPMVKKIIEKMLKNGKSN"
     primer_bind     complement(214..234)
                     /gene="MIP2a"
BASE COUNT       74 a     70 c     54 g     36 t
ORIGIN
        1 gcacccctgg ccactgaact gcgctgccag tgcttgcaga ccctgcaggg aattcacctc
       61 aagaacatcc aaagtgtgaa ggtgaagtcc cccggacccc actgcgccca aaccgaagtc
      121 atagccacac tcaagaatgg gcagaaagct tgtctcaacc ccgcatcgcc catggttaag
      181 aaaatcatcg aaaagatgct gaaaaatggc aaatccaact gaccagaagg aagg
//
LOCUS       HSU77035      764 bp    mRNA            PRI       23-JAN-1997
DEFINITION  Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA,
            complete cds.
ACCESSION   U77035
NID         g1790924
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 764)
  AUTHORS   Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
            Zlotnik,A.
  TITLE     Identification through bioinformatics of two new macrophage
            proinflammatory human chemokines: MIP-3alpha and MIP-3beta
  JOURNAL   J. Immunol. 158 (3), 1033-1036 (1997)
  MEDLINE   97166046
REFERENCE   2  (bases 1 to 764)
  AUTHORS   Rossi,D.L. and Zlotnik,A.
  TITLE     Direct Submission
  JOURNAL    Submitted (31-OCT-1996) Immunology, DNAX Research Institute,
901
            California Ave., Palo Alto, CA 94304, USA
FEATURES             Location/Qualifiers
     source          1..764
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="elutriated monocytes activated with
                     LPS/IFN-GAMMA"
     gene            1..291
                     /gene="MIP-3a"
     CDS             1..291
                     /gene="MIP-3a"
                     /note="chemokine"
                     /codon_start=1
                     /product="macrophage inflammatory protein 3 alpha"
                     /db_xref="PID:g1790925"

/translation="MCCTKSLLLAALMSVLLLHLCGESEAASNFDCCLGYTDRILHPK
                     FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
BASE COUNT     235 a    121 c    146 g    260 t      2 others
ORIGIN
        1 atgtgctgta ccaagagttt gctcctggct gctttgatgt cagtgctgct actccacctc
```

```
       61 tgcggcgaat cagaagcagc aagcaacttt gactgctgtc ttggatacac agaccgtatt
      121 cttcatccta aatttattgt gggcttcaca cggcagctgg ccaatgaagg ctgtgacatc
      181 aatgctatca tctttcacac aaagaaaaag ttgtctgtgt gcgcaaatcc aaaacagact
      241 tgggtgaaat atattgtgcg tctcctcagt aaaaaagtca agaacatgta aaaactgtgg
      301 cttttctgga atggaattgg acatagccca agaacagaaa gaaccttgct ggggttggag
      361 gtttcacttg cacatcatgg agggtttagt gcttatctaa tttgtgcctc actggacttg
      421 tccaattaat gaagttgatt catattgcat catagtttgc tttgtttaag catcacatta
      481 aagttaaact gtatttttatg ttatttatag ctgtaggttt tctgtgttta gctatttaat
      541 actaattttc cataagctat tttggtttag tgcaaagtat aaaattatat ttgggggga
      601 ataagattat atggactttt ttgcaagcaa caagctattt tttaaaamma actatttaac
      661 attcttttgt ttatattgtt ttgtctccta aattgttgta attgcattat aaaataagaa
      721 aaatattaat aagacaaata ttgaaaataa agaaacaaaa agtt
//
LOCUS       HSU77180      545 bp    mRNA            PRI       23-JAN-1997
DEFINITION  Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA,
            complete cds.
ACCESSION   U77180
NID         g1791002
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 545)
  AUTHORS   Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
            Zlotnik,A.
  TITLE     Identification through bioinformatics of two new macrophage
            proinflammatory human chemokines: MIP-3alpha and MIP-3beta
  JOURNAL   J. Immunol. 158 (3), 1033-1036 (1997)
  MEDLINE   97166046
REFERENCE   2  (bases 1 to 545)
  AUTHORS   Vicari,A. and Zlotnik,A.
  TITLE     Direct Submission
  JOURNAL    Submitted (01-NOV-1996) Immunology, DNAX Research Institute,
901
            California Ave, Palo Alto, CA 94304, USA
FEATURES             Location/Qualifiers
     source          1..545
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="macrophages activated with LPS or IFNg"
                     /chromosome="9"
     gene            1..297
                     /gene="MIP-3beta"
     CDS             1..297
                     /gene="MIP-3beta"
                     /function="chemokine"
                     /codon_start=1
                     /product="macrophage inflammatory protein 3 beta"
                     /db_xref="PID:g1791003"

/translation="MALLLALSLLVLWTSPAPTLSGTNDAEDCCLSVTQKPIPGYIVR

NFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"
BASE COUNT      125 a    160 c    153 g    107 t
ORIGIN
        1 atggccctgc tactggccct cagcctgctg gttctctgga cttccccagc cccaactctg
       61 agtggcacca atgatgctga agactgctgc ctgtctgtga cccagaaacc catccctggg
      121 tacatcgtga ggaacttcca ctaccttctc atcaaggatg gctgcagggt gcctgctgta
      181 gtgttcacca cactgagggg ccgccagctc tgtgcacccc cagaccagcc ctgggtagaa
      241 cgcatcatcc agagactgca gaggacctca gccaagatga agcgccgcag cagttaacct
      301 atgaccgtgc agagggagcc cggagtccga gtcaagcatt gtgaattatt acctaacctg
      361 gggaaccgag gaccagaagg aaggaccagg cttccagctc ctctgcacca gacctgacca
      421 gccaggacag ggcctggggt gtgtgtgagt gtgagtgtga gcgagagggt gagtgtggtc
      481 tagagtaaag ctgctccacc cccagattgc aatgctacca ataaagccgc ctggtgttta
      541 caact
//
LOCUS       HUMTCSM      1160 bp    mRNA            PRI       15-JUN-1989
DEFINITION  Human T cell-specific protein (RANTES) mRNA, complete cds.
ACCESSION   M21121
NID         g339420
```

```
KEYWORDS    Alu repeat; T-cell-specific protein.
SOURCE      Human peripheral blood (T lymphocyte) cell line AH2, cDNA to
mRNA,
            clone 228.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1160)
  AUTHORS       Schall,T.J.,  Jongstra,J.,  Dyer,B.J.,  Jorgensen,J.,
Clayberger,C.,
            Davis,M.M. and Krensky,A.M.
  TITLE     A human T cell-specific molecule is a member of a new gene
family
  JOURNAL   J. Immunol. 141, 1018-1025 (1988)
  MEDLINE   88285659
COMMENT     Draft entry and computer-readable sequence for [1] kindly
provided
            by A.M.Krensky, 24-OCT-1988.
FEATURES             Location/Qualifiers
     source          1..1160
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     CDS             27..302
                     /note="T cell-specific protein precursor"
                     /codon_start=1
                     /db_xref="PID:g339421"

/translation="MKVSAARLAVILIATALCAPASASPYSSDTTPCCFAYIARPLPR
                     AHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS"
     sig_peptide     27..95
                     /note="T cell-specific protein signal peptide"
     mat_peptide     96..299
                     /note="T cell-specific protein"
     repeat_region   450..950
                     /note="Alu-related repeats"
BASE COUNT      298 a    332 c    295 g    235 t
ORIGIN      276 bp upstream of RsaI site.
        1 cctccgacag cctctccaca ggtaccatga aggtctccgc ggcacgcctc gctgtcatcc
       61 tcattgctac tgccctctgc gctcctgcat ctgcctcccc atattcctcg gacaccacac
      121 cctgctgctt tgcctacatt gcccgcccac tgccccgtgc ccacatcaag gagtatttct
      181 acaccagtgg caagtgctcc aacccagcag tcgtctttgt cacccgaaag aaccgccaag
      241 tgtgtgccaa cccagagaag aaatgggttc gggagtacat caactctttg gagatgagct
      301 aggatggaga gtccttgaac ctgaacttac acaaatttgc ctgtttctgc ttgctcttgt
      361 cctagcttgg gaggcttccc ctcactatcc taccccaccc gctccttgaa gggcccagat
      421 tctgaccacg acgagcagca gttacaaaaa ccttccccag gctggacgtg gtggctcagc
      481 cttgtaatcc cagcactttg ggaggccaag gtgggtggat cacttgaggt caggagttcg
      541 agacagcctg gccaacatga tgaaacccca tgtgtactaa aaatacaaaa aattagccgg
      601 gcgtggtagc gggcgcctgt agtcccagct actcgggagg ctgaggcagg agaatggcgt
      661 gaacccggga gcggagcttg cagtgagccg agatcgcgcc actgcactcc agcctgggcg
      721 acagagcgag actccgtctc aaaaaaaaaa aaaaaaaaaa aaaaaataca aaaattagcc
      781 gcgtggtggc ccacgcctgt aatcccagct actcgggagg ctaaggcagg aaaattgttt
      841 gaacccagga ggtggaggct gcagtgagct gagattgtgc cacttcactc cagcctgggt
      901 gacaaagtga gactccgtca caacaacaac aacaaaaagc ttccccaact aaagcctaga
      961 agagcttctg aggcgctgct ttgtcaaaag gaagtctcta ggttctgagc tctggctttg
     1021 ccttggcttt gcaagggctc tgtgacaagg aaggaagtca gcatgcctct agaggcaagg
     1081 aagggaggaa cactgcactc ttaagcttcc gccgtctcaa cccctcacag gagcttactg
     1141 gcaaacatga aaaatcgggg
//
LOCUS       HUMTLI309     520 bp    mRNA            PRI       14-JAN-1995
DEFINITION  Human secreted protein (I-309) mRNA, complete cds.
ACCESSION   M57502
NID         g339728
KEYWORDS    secreted protein.
SOURCE      Human T-cell, cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 520)
  AUTHORS   Miller,M.D., Hata,S., De Waal Malefyt,R. and Krangel,M.S.
  TITLE     A novel polypeptide secreted by activated human T lymphocytes
  JOURNAL   J. Immunol. 143 (9), 2907-2916 (1989)
```

```
  MEDLINE   90038522
FEATURES             Location/Qualifiers
     source          1..520
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="T-cell"
                     /germline
                     /map="17"
     mRNA            <1..520
                     /gene="SCYA1"
                     /note="G00-118-872"
     gene            1..520
                     /gene="SCYA1"
     CDS             51..341
                     /gene="SCYA1"
                     /codon_start=1
                     /db_xref="GDB:G00-118-872"
                     /product="secreted protein I-309"
                     /db_xref="PID:g339729"

/translation="MQIITTALVCLLLAGMWPEDVDSKSMQVPFSRCCFSFAEQEIPL
                     RAILCYRNTSSICSNEGLIFKLKRGKEACALDTVGWVQRHRKMLRHCPSKRK"
BASE COUNT      140 a    137 c    122 g    121 t
ORIGIN
        1 accaggctca tcaaagctgc tccaggaagg cccaagccag accagaagac atgcagatca
       61 tcaccacagc cctggtgtgc ttgctgctag ctgggatgtg gccggaagat gtggacagca
      121 agagcatgca ggtacccttc tccagatgtt gcttctcatt tgcggagcaa gagattcccc
      181 tgagggcaat cctgtgttac agaaatacca gctccatctg ctccaatgag ggcttaatat
      241 tcaagctgaa gagaggcaaa gaggcctgcg ccttggacac agttggatgg gttcagaggc
      301 acagaaaaat gctgaggcac tgcccgtcaa aaagaaaatg agcagatttc tttccattgt
      361 gggctctgga aaccacatgg cttcacctgt ccccgaaact accagcccta caccattcct
      421 tctgccctgc ttttgctagg tcacagagga tctgcttggt cttgataagc tatgttgttg
      481 cactttaaac atttaaatta tacaatcatc aacccccaac
//
LOCUS       AB000887      687 bp    mRNA            PRI       05-JUN-1997
DEFINITION  Human mRNA for EBI1-ligand chemokine, complete cds.
ACCESSION   AB000887
NID         g2189952
KEYWORDS    EBI1-ligand chemokine; ELC.
SOURCE      Homo sapiens fetal tissue_lib:lung cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;   Mammalia;   Eutheria;   Primates;   Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 687)
  AUTHORS       Yoshida,R.,  Imai,T.,  Hieshima,K.,  Kusuda,J.,  Baba,M.,
Kitaura,M.,
            Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.
  TITLE     Direct Submission
  JOURNAL   Submitted (05-FEB-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki  Nomiyama,  Kumamoto  University  Medical  School,
Department
            of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)
REFERENCE   2  (sites)
  AUTHORS       Yoshida,R.,  Imai,T.,  Hieshima,K.,  Kusuda,J.,  Baba,M.,
Kitaura,M.,
            Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.
  TITLE     Molecular cloning of a novel human CC chemokine EBI1-ligand
            chemokine that is a specific functional ligand for EBI1, CCR7
  JOURNAL   J. Biol. Chem. 272 (21), 13803-13809 (1997)
  MEDLINE   97298088
FEATURES             Location/Qualifiers
     source          1..687
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /dev_stage="fetal"
                     /tissue_lib="lung"
     gene            139..435
                     /gene="ELC"
```

```
     CDS             139..435
                     /gene="ELC"
                     /note="CC chemokine"
                     /codon_start=1
                     /product="EBI1-ligand chemokine"
                     /db_xref="PID:d1021215"
                     /db_xref="PID:g2189953"

/translation="MALLLALSLLVLWTSPAPTLSGTNDAEDCCLSVTQKPIPGYIVR

NFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"
     mat_peptide     202..432
                     /gene="ELC"
                     /product="EBI1-ligand chemokine"
     polyA_signal    657..662
BASE COUNT      154 a    223 c    173 g    137 t
ORIGIN
        1 cattcccagc ctcacatcac tcacaccttg catttcaccc ctgcatccca gtcgccctgc
       61 agcctcacac agatcctgca cacacccaga cagctggcgc tcacacattc accgttggcc
      121 tgcctctgtt caccctccat ggccctgcta ctggccctca gcctgctggt tctctggact
      181 tccccagccc caactctgag tggcaccaat gatgctgaag actgctgcct gtctgtgacc
      241 cagaaaccca tccctgggta catcgtgagg aacttccact accttctcat caaggatggc
      301 tgcagggtgc ctgctgtagt gttcaccaca ctgaggggcc gccagctctg tgcaccccca
      361 gaccagccct gggtagaacg catcatccag agactgcaga ggacctcagc caagatgaag
      421 cgccgcagca gttaacctat gaccgtgcag agggagcccg gagtccgagt caagcattgt
      481 gaattattac ctaacctggg gaaccgagga ccagaaggaa ggaccaggct tccagctcct
      541 ctgcaccaga cctgaccagc caggacaggg cctggggtgt gtgtgagtgt gagtgtgagc
      601 gagagggtga gtgtggtcag agtaaagctg ctccaccccc agattgcaat gctaccaata
      661 aagccgcctg gtgtttacaa ctaattg
//
LOCUS       AB000221      760 bp    mRNA            PRI       31-JUL-1997
DEFINITION  Homo sapiens mRNA for CC chemokine, complete cds.
ACCESSION   AB000221
NID         g2289718
KEYWORDS        CC chemokine; PARC; pulmonary and activation-regulated
chemokine.
SOURCE      Homo sapiens lung cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;   Mammalia;   Eutheria;   Primates;   Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 760)
  AUTHORS   Nomiyama,H.
  TITLE     Direct Submission
  JOURNAL   Submitted (04-JAN-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki  Nomiyama,  Kumamoto  University  Medical  School,
Department
            of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE   2  (sites)
  AUTHORS   Hieshima,K., Imai,T., Baba,M., Shoudai,K., Ishizuka,K.,
            Nakagawa,T., Tsuruta,J., Takeya,M., Sakaki,Y., Takatsuki,K.,
            Miura,R., Opdenakker,G., Damme,J., Yoshie,O. and Nomiyama,H.
  TITLE     A novel human CC chemokine PARC that is most homologous to
            macrophage-inflammatory      protein-1alpha/LD78alpha      and
chemotactic
            for T lymphocytes, but not for monocytes
  JOURNAL   J. Immunol. 159 (3), 1140-1149 (1997)
  MEDLINE   97376836
FEATURES            Location/Qualifiers
     source         1..760
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /tissue_type="lung"
     gene           64..333
                    /gene="PARC"
     CDS            64..333
                    /gene="PARC"
                    /note="pulmonary and activation-regulated chemokine"
```

```
                     /codon_start=1
                     /product="CC chemokine"
                     /db_xref="PID:d1022520"
                     /db_xref="PID:g2289719"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKELCCLVYTSWQIPQKFI
                     VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"
BASE COUNT      186 a    208 c    155 g    211 t
ORIGIN
        1 gccaggagtt gtgagtttcc aagccccagc tcactctgac cacttctctg cctgcccagc
       61 atcatgaagg gccttgcagc tgccctcctt gtcctcgtct gcaccatggc cctctgctcc
      121 tgtgcacaag ttggtaccaa caaagagctc tgctgcctcg tctatacctc ctggcagatt
      181 ccacaaaagt tcatagttga ctattctgaa accagccccc agtgccccaa gccaggtgtc
      241 atcctcctaa ccaagagagg ccggcagatc tgtgctgacc ccaataagaa gtgggtccag
      301 aaatacatca gcgacctgaa gctgaatgcc tgaggggcct ggaagctgcg agggcccagt
      361 gaacttggtg ggcccaggag ggaacaggag cctgagccag ggcaatggcc ctgccaccct
      421 ggaggccacc tcttctaaga gtcccatctg ctatgcccag ccacatcaac taactttaat
      481 cttagtttat gcatcatatt tcattttgaa attgatttct attgttgagc tgcattatga
      541 aattagtatt ttctctgaca tctcatgaca ttgtctttat catcctttcc cctttccctt
      601 caactcttcg tacattcaat gcatggatca atcagtgtga ttagctttct cagcagacat
      661 tgtgccatat gtatcaaatg acaaatcttt attgaatggt tttgctcagc accacctttt
      721 aatatattgg cagtacttat tatataaaag gtaaaccagc
//
LOCUS       D86955        799 bp    mRNA            PRI       06-MAR-1997
DEFINITION  Human mRNA for CC chemokine LARC precursor, complete cds.
ACCESSION   D86955
NID         g1871138
KEYWORDS    CC chemokine LARC precursor.
SOURCE      Homo sapiens cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;    Mammalia;    Eutheria;    Primates;    Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (sites)
  AUTHORS   Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
            Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
            Nomiyama,H.
  TITLE     Molecular cloning of a novel human CC chemokine liver and
            activation-regulated chemokine (LARC) expressed in liver.
            Chemotactic activity for lymphocytes and gene localization on
            chromosome 2
  JOURNAL   J. Biol. Chem. 272 (9), 5846-5853 (1997)
  MEDLINE   97190319
REFERENCE   2  (bases 1 to 799)
  AUTHORS   Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
            Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
            Nomiyama,H.
  JOURNAL   Unpublished (1996)
REFERENCE   3  (bases 1 to 799)
  AUTHORS   Nomiyama,H.
  TITLE     Direct Submission
  JOURNAL   Submitted (08-AUG-1996) to the DDBJ/EMBL/GenBank databases.
            Hisayuki  Nomiyama,  Kumamoto  University  Medical  School,
Department
            of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)
FEATURES             Location/Qualifiers
     source          1..799
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="2"
                     /map="q33-37"
     sig_peptide     59..136
                     /gene="LARC"
     CDS             59..349
                     /gene="LARC"
                     /codon_start=1
                     /product="CC chemokine LARC precursor"
                     /db_xref="PID:d1013880"
                     /db_xref="PID:g1871139"
```

```
/translation="MCCTKSLLLAALMSVLLLHLCGESEAASNFDCCLGYTDRILHPK
                    FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
     gene           59..349
                    /gene="LARC"
     mat_peptide    137..346
                    /gene="LARC"
                    /product="CC chemokine LARC"
BASE COUNT      240 a    138 c    153 g    268 t
ORIGIN
        1 cactcccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaaccat
       61 gtgctgtacc aagagtttgc tcctggctgc tttgatgtca gtgctgctac tccacctctg
      121 cggcgaatca gaagcagcaa gcaactttga ctgctgtctt ggatacacag accgtattct
      181 tcatcctaaa tttattgtgg gcttcacacg gcagctggcc aatgaaggct gtgacatcaa
      241 tgctatcatc tttcacacaa agaaaaagtt gtctgtgtgc gcaaatccaa aacagacttg
      301 ggtgaaatat attgtgcgtc tcctcagtaa aaaagtcaag aacatgtaaa aactgtggct
      361 tttctggaat ggaattggac atagcccaag aacagaaaga accttgctgg ggttggaggt
      421 ttcacttgca catcatggag ggtttagtgc ttatctaatt tgtgcctcac tggacttgtc
      481 caattaatga agttgattca tattgcatca tagtttgctt tgtttaagca tcacattaaa
      541 gttaaactgt attttatgtt atttatagct gtaggttttc tgtgtttagc tatttaatac
      601 taattttcca taagctattt tggtttagtg caaagtataa aattatattt gggggggaat
      661 aagattatat ggactttctt gcaagcaaca agctattttt taaaaaaact atttaacatt
      721 cttttgttta tattgttttg tctcctaaat tgttgtaatt gcattataaa ataagaaaaa
      781 cattaataag acaaatatt
//
LOCUS       HUMAR          538 bp    mRNA            PRI       11-SEP-1996
DEFINITION  Human mRNA for chemokine, complete cds.
ACCESSION   D43767
NID         g1536878
KEYWORDS    chemokine, thymus and activation-regulated; chemokine.
SOURCE      Homo sapiens male peripheral blood cDNA to mRNA, clone:D3A.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;    Mammalia;    Eutheria;    Primates;    Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (sites)
  AUTHORS   Imai,T., Yoshida,T., Baba,M., Nishimura,M., Kakizaki,M. and
            Yoshie,O.
  TITLE       Molecular cloning of a novel T cell-directed CC chemokine
expressed
            in thymus by signal sequence trap using Epstein-Barr virus
vector
  JOURNAL   J. Biol. Chem. 271 (35), 21514-21521 (1996)
  MEDLINE   96355526
REFERENCE   2  (bases 1 to 538)
  AUTHORS   Imai,T.
  JOURNAL   Unpublished (1996)
REFERENCE   3  (bases 1 to 538)
  AUTHORS   Imai,T.
  TITLE     Direct Submission
  JOURNAL     Submitted (07-DEC-1994) to the DDBJ/EMBL/GenBank databases.
Toshio
            Imai, Shionogi Institute for Medical Science; 2-5-1 Mishima,
            Settsu, Osaka 566, Japan (Tel:06-382-2612, Fax:06-382-2598)
FEATURES            Location/Qualifiers
     source         1..538
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="D3A"
                    /sex="male"
                    /tissue_type="peripheral blood"
     CDS            53..337
                    /note="thymus and activation regulated"
                    /codon_start=1
                    /product="chemokine"
                    /db_xref="PID:d1008410"
                    /db_xref="PID:g1536879"

/translation="MAPLKMLALVTLLLGASLQHIHAARGTNVGRECCLEYFKGAIPL
                    RKLKTWYQTSEDCSRDAIVFVTVQGRAICSDPNNKRVKNAVKYLQSLERS"
```

```
BASE COUNT      118 a    168 c    149 g    103 t
ORIGIN
        1 ccctgagcag agggacctgc acacagagac tccctcctgg gctcctggca ccatggcccc
       61 actgaagatg ctggccctgg tcaccctcct cctgggggct tctctgcagc acatccacgc
      121 agctcgaggg accaatgtgg gccgggagtg ctgcctggag tacttcaagg gagccattcc
      181 ccttagaaag ctgaagacgt ggtaccagac atctgaggac tgctccaggg atgccatcgt
      241 ttttgtaact gtgcagggca gggccatctg ttcggacccc aacaacaaga gagtgaagaa
      301 tgcagttaaa tacctgcaaa gccttgagag gtcttgaagc ctcctcaccc cagactcctg
      361 actgtctccc gggactacct gggacctcca ccgttggtgt tcaccgcccc caccctgagc
      421 gcctgggtcc aggggaggcc ttccagggac gaagaagagc cacagtgagg gagatcccat
      481 ccccttgtct gaactggagc catgggcaca aagggcccag attaaagtct ttatcctc
//

LOCUS       HUMEOTAXIN    807 bp    mRNA            PRI       25-SEP-1996
DEFINITION  Human mRNA for eotaxin, complete cds.
ACCESSION   D49372
NID         g1552240
KEYWORDS    eotaxin; eosinophil-selective CC chemokine; chemoattractant.
SOURCE      Homo sapiens Small intestine, proximal cDNA to mRNA, clone:141.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;    Mammalia;    Eutheria;    Primates;    Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 807)
  AUTHORS   Kitaura,M., Nakajima,T., Imai,T., Harada,S., Combadiere,C.,
            Tiffany,H.L., Murphy,P.M. and Yoshie,O.
  TITLE     Molecular cloning of human eotaxin, an eosinophil-selective CC
            chemokine, and identification of a specific eosinophil eotaxin
            receptor, CC chemokine receptor 3
  JOURNAL   J. Biol. Chem. 271 (13), 7725-7730 (1996)
  MEDLINE   96205964
REFERENCE   2  (bases 1 to 807)
  AUTHORS   Yoshie,O.
  TITLE     Direct Submission
  JOURNAL     Submitted  (15-FEB-1995)  to  the  DDBJ/EMBL/GenBank  databases.
Osamu
            Yoshie, Shionogi Institute for Medical Science; 2-5-1 Mishima,
            Settsu, Osaka 566, Japan (E-mail:osamu.yoshie@shionogi.co.jp,
            Tel:06-382-2612, Fax:06-382-2598)
COMMENT     On Sep 20, 1996 this sequence version replaced gi:1313900.
FEATURES             Location/Qualifiers
     source          1..807
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="141"
                     /tissue_type="Small intestine, proximal"
     CDS             99..392
                     /codon_start=1
                     /product="eotaxin"
                     /db_xref="PID:d1008966"
                     /db_xref="PID:g1552241"

/translation="MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
                     RLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP"
     misc_signal     548..557
                     /note="mRNA destabilization signal"
     polyA_signal    775..780
     polyA_site      807
BASE COUNT      229 a    198 c    147 g    233 t
ORIGIN
        1 gcatttttc aagttttatg atttatttaa cttgtggaac aaaaataaac cagaaaccac
       61 cacctctcac gccaaagctc acaccttcag cctccaacat gaaggtctcc gcagcacttc
      121 tgtggctgct gctcatagca gctgccttca gcccccaggg gctcgctggg ccagcttctg
      181 tcccaaccac ctgctgcttt aacctggcca ataggaagat acccccttcag cgactagaga
      241 gctacaggag aatcaccagt ggcaaatgtc cccagaaagc tgtgatcttc aagaccaaac
      301 tggccaagga tatctgtgcc gaccccaaga agaagtgggt gcaggattcc atgaagtatc
      361 tggaccaaaa atctccaact ccaaagccat aaataatcac catttttgaa accaaaccag
      421 agcctgagtg ttgcctaatt tgttttccct tcttacaatg cattctgagg taacctcatt
      481 atcagtccaa agggcatggg ttttattata tatatatata ttttttttt aaaaaaaaac
      541 gtattgcatt taatttattg aggctttaaa acttatcctc catgaatatc agttatttt
```

```
      601 aaactgtaaa gctttgtgca gattctttac cccctgggag ccccaattcg atcccctgtc
      661 acgtgtgggc aatgttcccc ctctcctctc ttcctccctg gaatcttgta aaggtcctgg
      721 caaagatgat cagtatgaaa atgtcattgt tcttgtgaac ccaaagtgtg actcattaaa
      781 tggaagtaaa tgttgtttta ggaatac
//
LOCUS       HSCCCHEM      232 bp    RNA            PRI       10-SEP-1996
DEFINITION  H.sapiens mRNA for CC-chemokine.
ACCESSION   Z69291
NID         g1181148
KEYWORDS    CC-chemokine.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 232)
  AUTHORS   Bartels,J.H., Schlueter,C., Richter,E., Christophers,E. and
            Schroeder,J.M.
  TITLE     Cloning of a novel human chemokine homologous to human monocyte
            chemoattractant proteins and rodent eotaxins
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 232)
  AUTHORS   Bartels,J.H.
  TITLE     Direct Submission
  JOURNAL   Submitted (01-FEB-1996) Bartels J. H.,
            Christian-Albrechts-Universitaet            zu            Kiel,
Dermatology/Hautklinik,
            Mol.Biol.Lab.609, Schittenhelmstr. 7, Kiel, Schleswig-Holstein,
            Germany, D-24105
REFERENCE   3  (bases 1 to 232)
  AUTHORS   Bartels,J., Schluter,C., Richter,E., Noso,N., Kulke,R.,
            Christophers,E. and Schroder,J.M.
  TITLE     Human dermal fibroblasts express eotaxin: molecular cloning,
mRNA
            expression, and identification of eotaxin sequence variants
  JOURNAL   Biochem. Biophys. Res. Commun. 225 (3), 1045-1051 (1996)
  MEDLINE   96374440
FEATURES             Location/Qualifiers
     source          1..232
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="clones 4(9512),
                     14(9512),15(9512),10(9601),11(9601)"
                     /tissue_type="foreskin"
                     /cell_type="fibroblast"
                     /sex="Male"
     mRNA            <1..>232
                     /citation=[1]
                     /product="CC-chemokine"
     sig_peptide     56..109
                     /citation=[1]
     CDS             56..>232
                     /function="putative chemoattractant protein"
                     /note="sequence homology to human MCP-1, MCP-2 and
MCP-3
                     and to rodent eotaxins"
                     /citation=[1]
                     /codon_start=1
                     /product="CC-chemokine, preprotein"
                     /db_xref="PID:e221070"
                     /db_xref="PID:g1181149"
                     /db_xref="SWISS-PROT:P50877"

/translation="MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
                     RLESYRRITSGKCPQ"
     mat_peptide     110..>232
                     /citation=[1]
                     /function="putative chemoattractant protein"
                     /product="CC-chemokine"
BASE COUNT       55 a     82 c     50 g     42 t      3 others
ORIGIN
        1 accaaaccag aaaccwccam ytctcacgcc aaagctcaca ccttcagcct ccaacatgaa
```

```
       61 ggtctccgca gcgcttctgt ggctgctgct catagcggct gccttcagcc cccaggggct
      121 cgctgggcca gcttctgtcc caaccacctg ctgctttaac ctggccaata ggaagatacc
      181 ccttcagcga ctagagagct acaggagaat caccagtggc aaatgtcccc ag
//
LOCUS       HSHCC1GEN    4037 bp    DNA             PRI       01-OCT-1995
DEFINITION  H.sapiens gene for chemokine HCC-1.
ACCESSION   Z49269
NID         g1004266
KEYWORDS    chemokine.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 4037)
  AUTHORS     Pardigol,A., Maegert,H.J., Cieslak,A., Hill,O., Schulz-
Knappe,P.
            and Forssmann,W.G.
  TITLE     Nucleotide Sequence of the Gene for the Human Chemokine HCC-1
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 4037)
  AUTHORS   Pardigol,A.
  TITLE     Direct Submission
  JOURNAL    Submitted (18-MAY-1995) Andreas Pardigol, Molecular Biology,
Lower
            Saxony Institute for Peptide Research, Feodor-Lynen-Strasse 31,
            Hannover, Lower Saxon, 30625, Germany
FEATURES             Location/Qualifiers
     source          1..4037
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="ph3b7"
                     /dev_stage="adult"
                     /tissue_type="placenta"
                     /clone_lib="lambda FIX II, Cat.Nr. 946203, Stratagene"
                     /sex="male"
     TATA_signal     727..733
                     /note="putative, determined by consensus rules."
     5'UTR           764..833
                     /note="first base determined by means of consensus
rules"
     exon            764..912
                     /note="first base determined by means of consensus
rules;
                     base 780 is the first base of cDNA (Z49270)"
                     /number=1
     CDS             join(834..912,3021..3135,3585..3672)
                     /codon_start=1
                     /product="chemokine HCC-1"
                     /db_xref="PID:g1004267"

/translation="MKISVAAIPFFLLITIALGTKTESSSRGPYHPSECCFTYTTYKI
                     PRQRIMDYYETNSQCSKPGIVFITKRGHSVCTNPSDKWVQDYIKDMKEN"
     intron          913..3020
                     /number=1
     exon            3021..3135
                     /number=2
     intron          3136..3584
                     /number=2
     exon            3585..3817
                     /number=3
     3'UTR           3673..3817
BASE COUNT     1023 a   1048 c   1004 g    962 t
ORIGIN
        1 gagctccgtt gggagtccca tgtttcttta tggcataatg ggtgagaaca cagacttgga
       61 agccaaacca cctgaatttg aaccccagtt ccatttacca actgtcaaaa gcttaggctt
      121 tgattctaag cctgtttcct caactgctgt tctaaagatt aaataggcta atattcataa
      181 ggcaactggg acagtggctt gtgtgtatag caaccattat ataagtgaat tatctactga
      241 gcaccacagc acttcttcac tccatggtgt ggtgaccaga atggagatga gacagagaac
      301 tgcaggttct gcttcgagtt taagttagga tttcccttga ccaatgagac ctgacttgga
      361 ggagtcctgg cctcattcca ttaccccaaa caccctctag tctctagatg aacagatcct
      421 gaatgtccag gccccacgtg gcctgttcta aggcctgaga tggaattgga tacaggacac
```

```
 481 atccagcctt gagatctttt gctaagtgtg acacagtgcc cccagccctg tgctcatgtt
 541 catgcctagg gaaaggcttc tatcaaaaga gttgaacttc ttcccactgg ggatggaaga
 601 ccatttcctc ccttaaacct tggctctccc tgcttccttc aggccaccaa caacacatgt
 661 gcaggatatg aaattgctga ggcatcactg ctttcctact tcccttccaa gtctcagctc
 721 ccttatttta aaaaatattt ggcctcaatg atcatttctc aacaattcct caccgcagga
 781 gcctctgaag ctcccaccag gccagctctc ctcccacaac agcttcccac agcatgaaga
 841 tctccgtggc tgccattccc ttcttcctcc tcatcaccat cgccctaggg accaagactg
 901 aatcctcctc acgtgagtgc aatgccttgt cttccttcca acctagagcc tgcagggaaa
 961 taagcaggag tgaggttggg gctcagggga agaccaggag cagggactca gaaaggaggg
1021 ctggtatctt cttgaaattg tgtgtatagc aacattatat aaatgaatta tctactgagc
1081 accacagcac ttcaccccat ggtgtggtga gcaggatgga gatgagactt aggactgtag
1141 gttctgctta agagtttaag ttgggatctt ccagccttga ccaatgagac ttgacttggg
1201 agactccagg cttcattcca ctaccccaaa tgccctctag tctccaaata aacagatcct
1261 gaatctccag gcctcacatg gccttgatct cttatcattg ccccccagga ccagtccccc
1321 ctttgccctca aggacatgga gtgagaccag cctgcctctc tactccctca atttctctct
1381 ctttgccgct aagcaaaaga gtggcccacc ccatttgggg tatatttcct cagggagatt
1441 aggagcagtg tcttgagccc ctcaagggca tttttctatt ggcctcctga ggtttgggcc
1501 cagcctgctt ccagcgtcac ctgtgcccag tgagtgcagc attgcttggg tatgggctgg
1561 ggggaaacac gacagtgtgg ggtccatcct aggccccctt ttctcagctg atttcttaga
1621 ataagctgcc tttagagata accaaaacta tttatcactc ttccatttta cctactctcc
1681 ttttcagaaa ctgggggggaa accgaaggtt gttaaaatac agctaaagtt ggtgggtatg
1741 tgcacagttt gacttgccct ctccgatgtc atttgtcagc tcagaggaac aaggtgggag
1801 agtataggag ctctgactgg gtctcaggaa acaggggccc cttatgccgt tctttggatc
1861 gtgaggatgc tgcctggaat ggagctggaa aacaggatga gacccttcca cccagacatc
1921 tggccaccct cagtgacctc tgaggccatt gtgatgcaca tccatgattc tatgaagcag
1981 ggtcacataa catgcacaca cctgatttct ccactccata accacaacat gtgcctgttt
2041 gtacagggct cttggcctac aatgtccttc ctgctacctc tataattcaa gcttggggtg
2101 gctgctgtca ccttgcttct cctataaaag ccatgaaact tctcaatcag aaaatagatg
2161 aaaaaatcac ccaatccagt gatttttaaa acttttaga ccacaaaacc ttttcttcaa
2221 gcaatatctt ccacagaggc ccaatatgta aaacagaaaa aatgggttga gtagggtaca
2281 agacaccact ctcaaatgca gcaaggcctc cacaatagtc cctgaggccc ccagagctca
2341 gtgtaaaaac cactgatgca gtccaagggc ctcatttaca gaggagggaa caggggaaa
2401 gtaaaatggc cacagtacac aggaagcaca ggcaaggtta ggttaggatt tgggtgccct
2461 gactctgtgg cctttgtcct tggggcttgc tgtgggcatc ctgctctctc tgcaggttgt
2521 cggttcaatg gggacatggg cagggtggag cactaggagg ggctgggttt gcattcccaa
2581 atggcatgtc tccaaatccc tattgggatt tcttccaaat attcctccta tttggagcac
2641 ctttcccgaa taaggcatga aggctgcatg atattggcca agtccctagc cttctctgcc
2701 agtcggcccc cagagatggt gtaagaagat ctgagtgtgc tgctcttcaa tcctggagtt
2761 gaaagtcatc caccagtctt tccaagaggg gttgaagaaa aggaggaagg gtgattgatg
2821 atgagggagg agaaaaagaa gagcccagga gtaccatgga gaaggagaag agaagatgag
2881 gaaagcctac tctcccctcc aagttctgag gggctgtctc ctccttcctt ccctcctcca
2941 tgccctcagc ttgcaggagc agccaatggt atggccttta acaaggggcc cctcctcagc
3001 atctgatgct ctctcctcag ggggaccttа ccacccctca gagtgctgct tcacctacac
3061 tacctacaag atcccgcgtc agcggattat ggattactat gagaccaaca gccagtgctc
3121 caagcccgga attgtgtagg tggtacacac acatcacact ggggggagag ggagccagca
3181 gggcctcctg gagggaagca gggagtggtg gtggaatggg gacccccagc gtacctccca
3241 ggtgtgacta catggggaga ggcagctgag gggcaatctg agcgctttct ggctggagcc
3301 tgcaggagcc atggggaaac tgaccccatg gatggggaga tgacagagaa gggagaagaa
3361 ggcaagaggg cacttcctca gggggacaca gagactagat gggtctaggg gtcctaggaa
3421 ccgaagagta tgtctcagag aggagactgg ctctaagctg cctctgtgga agaaaggaaa
3481 agcagtatag gtcaggtggg gaatttagga gggagggaag atgggctgtc tcttccggcc
3541 actgggcccc tcggtttgtg atccttctcc ctcttgctcc acagcttcat caccaaaagg
3601 ggccattccg tctgtaccaa ccccagtgac aagtgggtcc aggactatat caaggacatg
3661 aaggagaact gagtgaccca gaaggggtgg cgaaggcaca gctcagagac ataaagagaa
3721 gatgccaagg ccccctcctc cacccaccgc taactctcag ccccagtcac cctcttggag
3781 cttccctgct ttgaattaaa gaccactcat gctcttccct ggcctcattc ctttctacgg
3841 gatttactca ttggccatgc actgaggaca ccagggtgtg gcaccctcgg catcaagcct
3901 cgctctgcag aagttttggt ggagcctggt acaaaaaata ggtcaggcct gcaatgcagg
3961 tagtgagaag cagaaagtga gaaagaaaag cagtgtaaag accgtctcct cctcagcagc
4021 aacagtagca gaccccg
//
LOCUS       HSCC21        925 bp    mRNA            PRI       30-JUN-1998
DEFINITION  H.sapiens mRNA for chemokine CC-2 and CC-1.
ACCESSION   Z70292
NID         g1296608
KEYWORDS    chemokine CC-1; chemokine CC-2.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 925)
```

```
  AUTHORS    Pardigol,A., Forssmann,U., Zucht,H.D., Loetscher,P.,
             Schulz-Knappe,P., Baggiolini,M., Forssmann,W.G. and Magert,H.J.
  TITLE      HCC-2, a human chemokine: gene structure, expression pattern,
and
             biological activity
  JOURNAL    Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)
  MEDLINE    98263352
REFERENCE    2  (bases 1 to 925)
  AUTHORS    Pardigol,A.
  TITLE      Direct Submission
  JOURNAL      Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
Biology,
             Lower Saxony Institute for Peptide Research, Feodor-Lynen-
Strasse
             31, Hannover, Lower Saxony, 30625, Germany
FEATURES               Location/Qualifiers
     source            1..925
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
                       /dev_stage="adult"
                       /tissue_type="liver"
                       /clone_lib="PCR fragments"
     5'UTR             1..55
     CDS               56..397
                       /note="putative; first coding region of a bicistronic
                       mRNA"
                       /codon_start=1
                       /product="chemokine CC-2"
                       /db_xref="PID:e233855"
                       /db_xref="PID:g1296609"
                       /db_xref="SWISS-PROT:Q16663"

/translation="MKVSVAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL

NSFHFAADCCTSYISQSIPCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
                       DCMKKLKPYSI"
     misc_feature      398..498
                       /note="spacing region between two coding regions of
the
                       bicistronic mRNA"
     CDS               499..780
                       /codon_start=1
                       /evidence=experimental
                       /product="chemokine CC-1"
                       /db_xref="PID:e233856"
                       /db_xref="PID:g1296610"
                       /db_xref="SWISS-PROT:Q16627"

/translation="MKISVAAIPFFLLITIALGTKTESSSRGPYHPSECCFTYTTYKI
                       PRQRIMDYYETNSQCSKPGIVFITKRGHSVCTNPSDKWVQDYIKDMKEN"
     3'UTR             781..925
     polyA_signal      902..908
BASE COUNT      240 a    296 c    199 g    190 t
ORIGIN
        1 ccaggaagca gtgagcccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
       61 ggtctccgtg gctgccctct cctgcctcat gcttgttgct gtccttggat cccaggccca
      121 gttcacaaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
      181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
      241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgctcca agccaggtgt
      301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa cccagtggtc cgggagttca
      361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
      421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc
      481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcatc
      541 accatcgccc tagggaccaa gactgaatcc tcctcacggg gaccttacca cccctcagag
      601 tgctgcttca cctacactac ctacaagatc ccgcgtcagc ggattatgga ttactatgag
      661 accaacagcc agtgctccaa gcccggaatt gtcttcatca ccaaaagggg ccattccgtc
      721 tgtaccaacc ccagtgacaa gtgggtccag gactatatca aggacatgaa ggagaactga
      781 gtgacccaga aggggtggcg aaggcacagc tcagagacat aaagagaaga tgccaaggcc
      841 ccctcctcca cccaccgcta actctcagcc ccagtcaccc tcttggagct tccctgcttt
      901 gaattaaaga ccactcatgc tcttc
//
```

```
LOCUS       HSCC23        973 bp    RNA             PRI       03-MAY-1996
DEFINITION  H.sapiens mRNA for chemokine CC-2 and CC-3.
ACCESSION   Z70293
NID         g1296611
KEYWORDS    Human chemokine CC-2; Human chemokine CC-3.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 973)
  AUTHORS   Pardigol,A., Maegert,H.J., Zucht,HD., Forssmann,W.G. and
            Schulz-Knappe,P.
  TITLE     Transcription of a Human Tandem Gene results in a Mature
            Bicistronic mRNA encoding two Novel CC-Chemokines
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 973)
  AUTHORS   Pardigol,A.
  TITLE     Direct Submission
  JOURNAL     Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
Biology,
            Lower Saxony Institute for Peptide Research, Feodor-Lynen-
Strasse
            31, Hannover, Lower Saxony, 30625, Germany
FEATURES             Location/Qualifiers
     source          1..973
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /dev_stage="adult"
                     /tissue_type="liver"
                     /clone_lib="PCR fragments"
     5'UTR           1..55
     CDS             56..397
                     /note="putative; first coding region of a bicistronic
                     mRNA"
                     /codon_start=1
                     /product="chemokine CC-2"
                     /db_xref="PID:e233857"
                     /db_xref="PID:g1296612"

/translation="MKVSVAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL

NSFHFAADCCTSYISQSIPCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
                     DCMKKLKPYSI"
     misc_feature    398..498
                     /note="spacing region between two coding regions of
the
                     bicistronic mRNA"
     CDS             499..828
                     /note="putative"
                     /codon_start=1
                     /product="chemokine CC-3"
                     /db_xref="PID:e233858"
                     /db_xref="PID:g1296613"

/translation="MKISVAAIPFFLLITIALGTKTESSSQTGGKPKVVKIQLKLVGG

PYHPSECCFTYTTYKIPRQRIMDYYETNSQCSKPGIVFITKRGHSVCTNPSDKWVQDY
                     IKDMKEN"
     3'UTR           829..973
     polyA_signal    950..956
BASE COUNT      257 a    301 c    215 g    200 t
ORIGIN
        1 ccaggaagca gtgagcccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
       61 ggtctccgtg gctgccctct cctgcctcat gcttgttgct gtccttggat cccaggccca
      121 gttcacaaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
      181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
      241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgctcca agccaggtgt
      301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa cccagtggtc cgggagttca
      361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
      421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc
```

```
      481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcatc
      541 accatcgccc tagggaccaa gactgaatcc tcctcacaaa ctgggggaa accgaaggtt
      601 gttaaaatac agctaaagtt ggtgggggga ccttaccacc cctcagagtg ctgcttcacc
      661 tacactacct acaagatccc gcgtcagcgg attatggatt actatgagac caacagccag
      721 tgctccaagc ccggaattgt cttcatcacc aaaaggggcc attccgtctg taccaacccc
      781 agtgacaagt gggtccagga ctatatcaag gacatgaagg agaactgagt gacccagaag
      841 gggtggcgaa ggcacagctc agagacataa agagaagatg ccaaggcccc ctcctccacc
      901 caccgctaac tctcagcccc agtcaccctc ttggagcttc cctgctttga attaaagacc
      961 actcatgctc ttc
//

LOCUS       HSU91746     1430 bp    mRNA            PRI       12-MAR-1998
DEFINITION  Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION   U91746
NID         g2581780
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1430)
  AUTHORS   Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
  TITLE     Identification of a novel human CC chemokine upregulated by IL-
10
  JOURNAL   Blood (1998) In press
REFERENCE   2  (bases 1 to 1430)
  AUTHORS   Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
  TITLE     Direct Submission
  JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901
            California Ave, Palo Alto, CA 94304, USA
FEATURES             Location/Qualifiers
     source          1..1430
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
     gene            1..1430
                     /gene="HCC-4"
     CDS             1..363
                     /gene="HCC-4"
                     /note="CC or beta chemokine family member"
                     /codon_start=1
                     /product="IL-10-inducible chemokine"
                     /db_xref="PID:g2581781"

/translation="MKVSEAALSLLVLILIITSASRSQPKVPEWVNTPSTCCLKYYEK

VLPRRLVVGYRKALNCHLPAIIFVTKRNREVCTNPNDDWVQEYIKDPNLPLLPTRNLS
                    TVKIITAKNGQPQLLNSQ"
BASE COUNT      401 a    351 c    293 g    385 t
ORIGIN
        1 atgaaggtct ccgaggctgc cctgtctctc cttgtcctca tccttatcat tacttcggct
       61 tctcgcagcc agccaaaagt tcctgagtgg gtgaacaccc catccacctg ctgcctgaag
      121 tattatgaga aagtgttgcc aaggagacta gtggtgggat acagaaaggc cctcaactgt
      181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
      241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgctgcc taccaggaac
      301 ttgtccacgg ttaaaattat tacagcaaag aatggtcaac cccagctcct caactcccag
      361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
      421 caggggaagc cttattaggc tgaaactagc cagtcacatt gagagaagca gaacaatgat
      481 caaaataaag gagaagtatt tcgaatattt tctcaatctt aggaggaaat accaaagtta
      541 agggacgtgg gcagaggtac gctcttttat ttttatattt atatttttat ttttttgaga
      601 taggtcttac tctgtcaccc aggctggagt gcagtggtgt gatcttggct cacttgatct
      661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccacccca gcctcccgag
      721 tagctgggac tacaggcttg cgccaccaca cctggctaat ttttgtattt ttggtagaga
      781 cgggattcta ccatgttgcc caggctggtc tcaaactcgt gtgcccaagc aatccacctg
      841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgcac
      901 tcttaatata cagaaaaata tatttcacat ccttctcctg ctctctttca attcctcact
      961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
     1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tcctgtccat
     1081 ctttatggat ttttctggat ctatattttc ttcaattatt ctttcatttt ataatgcaac
```

```
     1141 tttttcatag gaagtccgga tgggaatatt cacattaatc atttttgcag agactttgct
     1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
     1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
     1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
     1381 cttagtccaa aacccaagca tgcaataaat aaaactccct tatttgacaa
//

LOCUS       AB007454     1503 bp    mRNA            PRI       09-APR-1998
DEFINITION  Homo sapiens mRNA for chemokine LEC precursor, complete cds.
ACCESSION   AB007454
NID         g2723285
KEYWORDS    chemokine LEC precursor.
SOURCE      Homo sapiens liver cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (sites)
  AUTHORS   Shoudai,K., Hieshima,K., Fukuda,S., Iio,M., Miura,R., Imai,T.,
            Yoshie,O. and Nomiyama,H.
  TITLE     Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC
  JOURNAL   Biochim. Biophys. Acta 1396 (3), 273-277 (1998)
  MEDLINE   98207719
REFERENCE   2  (bases 1 to 1503)
  AUTHORS   Nomiyama,H.
  TITLE     Direct Submission
  JOURNAL   Submitted (19-SEP-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki  Nomiyama,  Kumamoto  University  Medical  School,
Department
            of  Biochemistry;  Honjo  2-2-1,  Kumamoto,  Kumamoto  860-0811,
Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
FEATURES             Location/Qualifiers
     source          1..1503
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /tissue_type="liver"
     sig_peptide     77..145
     CDS             77..439
                     /codon_start=1
                     /product="chemokine LEC precursor"
                     /db_xref="PID:d1024963"
                     /db_xref="PID:g2723286"

/translation="MKVSEAALSLLVLILIITSASRSQPKVPEWVNTPSTCCLKYYEK

VLPRRLVVGYRKALNCHLPAIIFVTKRNREVCTNPNDDWVQEYIKDPNLPLLPTRNLS
                     TVKIITAKNGQPQLLNSQ"
     mat_peptide     146..436
     polyA_signal    560..565
     polyA_signal    1485..1490
BASE COUNT      417 a    374 c    312 g    400 t
ORIGIN
        1 gttggcaagc ggaccaccag caacagacaa catcttcatt cggctctccc tgaagctgta
       61 ctgcctcgct gagaggatga aggtctccga ggctgccctg tctctccttg tcctcatcct
      121 tatcattact tcggcttctc gcagccagcc aaaagttcct gagtgggtga acaccccatc
      181 cacctgctgc ctgaagtatt atgagaaagt gttgccaagg agactagtgg tgggatacag
      241 aaaggccctc aactgtcacc tgccagcaat catcttcgtc accaagagga accgagaagt
      301 ctgcaccaac cccaatgacg actgggtcca agagtacatc aaggatccca acctaccttt
      361 gctgcctacc aggaacttgt ccacggttaa aattattaca gcaaagaatg gtcaacccca
      421 gctcctcaac tcccagtgat gaccaggctt tagtggaagc ccttgtttac agaagagagg
      481 ggtaaaccta tgaaaacagg ggaagcctta ttaggctgaa actagccagt cacattgaga
      541 gaagcagaac aatgatcaaa ataaaggaga agtatttcga atattttctc aatcttagga
      601 ggaaatacca aagttaaggg acgtgggcag aggtacgctc ttttattttt atatttatat
      661 ttttatttct ttgagatagg gtcttactct gtcacccagg ctggagtgca gtggtgtgat
      721 cttggctcac ttgatcttgg ctcactgtaa cctccacctc ccaggctcaa gtgatcctcc
      781 caccccagcc tcccgagtag ctgggactac aggcttgcgc caccacacct ggctaatttt
      841 tgtatttttg gtagagacgg gattctacca tgttgcccag gctggtctca aactcgtgtg
      901 cccaagcaat ccacctgcct cagccttcca aaagtgctgg gattacaggc gtgagccacc
      961 acatccggcc agtgcactct taatacacag aaaaaatata ttcacatcct tctcctgctc
     1021 tctttcaatt cctcacttca caccagtaca caagccattc taaatactta gccagtttcc
```

```
     1081 agccttccag atgatctttg ccctctgggt cttgacccat taagagcccc atagaactct
     1141 tgatttttcc tgtccatctt tatggatttt tctggatcta tattttcttc aattattctt
     1201 tcattttata atgcaacttt ttcataggaa gtccggatgg gaatattcac attaatcatt
     1261 tttgcagaga ctttgctaga tcctctcata ttttgtcttc ctcagggtgg caggggtaca
     1321 gagatgtcct gattggaaaa aaaaaaaaaa gagagagaga gagaagaaga agaagaagag
     1381 acacaaatct ctacctccca tgttaagctt tgcaggacag ggaaagaaag ggtatgagac
     1441 acggctaggg gtaaactctt agtccaaaac ccaagcatgc aataaataaa actcccttat
     1501 ttg
//

LOCUS       AF001979      800 bp    mRNA            PRI       20-NOV-1997
DEFINITION  Homo sapiens beta chemokine mRNA, complete cds.
ACCESSION   AF001979
NID         g2624924
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 800)
  AUTHORS   Hedrick,J.A. and Zlotnik,A.
  TITLE     Identification and characterization of a novel beta chemokine
            containing six conserved cysteines
  JOURNAL   J. Immunol. 159 (4), 1589-1593 (1997)
  MEDLINE   97400322
REFERENCE   2  (bases 1 to 800)
  AUTHORS   Hedrick,J.A. and Zlotnik,A.
  TITLE     Direct Submission
  JOURNAL   Submitted (01-MAY-1997) Immunobiology, DNAX Research Institute,
901
            California Ave, Palo Alto, CA 94304, USA
FEATURES             Location/Qualifiers
     source          1..800
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     CDS             1..405
                     /note="6Ckine; CC chemokine"
                     /codon_start=1
                     /product="beta chemokine"
                     /db_xref="PID:g2624925"

/translation="MAQSLALSLLILVLAFGIPRTQGSDGGAQDCCLKYSQRKIPAKV

VRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
                     CRKDRGASKTGKKGKGSKGCKRTERSQTPKGP"
BASE COUNT      203 a    248 c    210 g    139 t
ORIGIN
        1 atggctcagt cactggctct gagcctcctt atcctggttc tggcctttgg aatccccagg
       61 acccaaggca gtgatggagg ggctcaggac tgttgcctca agtacagcca aaggaagatt
      121 cccgccaagg ttgtccgcag ctaccggaag caggaaccaa gcttaggctg ctccatccca
      181 gctatcctgt tcttgccccg caagcgctct caggcagagc tatgtgcaga cccaaaggag
      241 ctctgggtgc agcagctgat gcagcatctg gacaagacac catccccaca gaaaccagcc
      301 cagggctgca ggaaggacag gggggcctcc aagactggca agaaaggaaa gggctccaaa
      361 ggctgcaaga ggactgagcg gtcacagacc cctaaagggc catagcccag tgagcagcct
      421 ggagccctgg agaccccacc agcttcacca gcgcttgaag cctgaaccca agatgcaaga
      481 aggaggctat gctcaggggc cctggagcag ccaccccatg ctggccttgc cacactcttt
      541 ctcctgcttt aaccacccca tctgcattcc cagctctacc ctgcatggct gagctgccca
      601 cagcaggcca ggtccagaga gaccgaggag ggagagtctc ccagggagca tgagaggagg
      661 cagcaggact gtcccccttga aggagaatca tcaggaccct ggacctgata cggctcccca
      721 gtacacccca cctcttcctt gtaaatatga tttataccta actgaataaa aagctgttct
      781 gtcttcccac ccaaaaaaaa
//

LOCUS       HSU64197      821 bp    mRNA            PRI       25-JUN-1997
DEFINITION  Homo sapiens chemokine exodus-1 mRNA, complete cds.
ACCESSION   U64197
NID         g1778716
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
```

```
            Vertebrata;    Mammalia;    Eutheria;    Primates;    Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 821)
  AUTHORS   Hromas,R., Gray,P.W., Chantry,D., Godiska,R., Krathwohl,M.,
            Fife,K.,    Bell,G.I.,    Takeda,J.,    Aronica,S.,    Gordon,M.,
Cooper,S.,
            Broxmeyer,H.E. and Klemsz,M.J.
  TITLE     Cloning and characterization of exodus, a novel beta-chemokine
  JOURNAL   Blood 89 (9), 3315-3322 (1997)
  MEDLINE   97275143
REFERENCE   2  (bases 1 to 821)
  AUTHORS   Hromas,R.A.
  TITLE     Direct Submission
  JOURNAL   Submitted (17-JUL-1996) Indiana University Medical Center,
            Medicine, 975 W. Walnut St., Indianapolis, IN 46202, USA
FEATURES             Location/Qualifiers
     source          1..821
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="Exodus-1"
                     /cell_type="islet"
                     /tissue_type="pancreas"
                     /dev_stage="adult"
     CDS             43..330
                     /function="inhibits proliferation of hematopoietic
                     progenitors and HIV"
                     /codon_start=1
                     /product="chemokine exodus-1"
                     /db_xref="PID:g1778717"

/translation="MCCTKSLLLAALMSVLLLHLCGESEASNFDCCLGYTDRILHPKF
                     IVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
     variation       121^122
                     /note="insertion of an extra codon GCA at nt 121,
encoding
                     for an alanine after the alanine at amino acid
position
                     26, represents the allelic difference of the
transcript
                     isolated from macrophages"
BASE COUNT      258 a    134 c    156 g    273 t
ORIGIN
        1 ggtactcaac actgagcaga tctgttcttt gagctaaaaa ccatgtgctg taccaagagt
       61 ttgctcctgg ctgctttgat gtcagtgctg ctactccacc tctgcggcga atcagaagca
      121 agcaactttg actgctgtct tggatacaca gaccgtattc ttcatcctaa atttattgtg
      181 ggcttcacac ggcagctggc caatgaaggc tgtgacatca atgctatcat ctttcacaca
      241 aagaaaaagt tgtctgtgtg cgcaaatcca aaacagactt gggtgaaata tattgtgcgt
      301 ctcctcagta aaaaagtcaa gaacatgtaa aaactgtggc ttttctggaa tggaattgga
      361 catagcccaa gaacagaaag aaccttgctg gggttggagg tttcacttgc acatcatgga
      421 gggtttagtg cttatctaat ttgtgcctca cctggacttg tccaattaat gaagttgatt
      481 catattgcat catagtttgc tttgtttaag catcacatta aagtgaaact gtattttatg
      541 ttatttatag ctgtaggttt tctgtgttta gctatttaat actaattttc cataagctat
      601 tttggtttag tgcaaagtat aaaattatat ttgggggggа ataagattat atggactttc
      661 ttgcaagcaa caagctattt tttaaaaaaa actatttaac attcttttgt ttatattgtt
      721 ttgtctccta aattgttgta atgtcattat aaaataagaa aaatattaat aagacaaata
      781 ttgaaaataa agaaacaaaa agtgcttctg ttaaaaaaaa a
//

LOCUS       HSU88320      828 bp    mRNA            PRI       18-DEC-1997
DEFINITION  Human beta chemokine Exodus-2 mRNA, complete cds.
ACCESSION   U88320
NID         g2196919
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 828)
  AUTHORS       Hromas,R.,  Kim,C.H.,  Klemsz,M.,  Krathwohl,M.,  Fife,K.,
Cooper,S.,
```

```
            Schnizlein-Bick,C. and Broxmeyer,H.E.
  TITLE         Isolation and characterization of Exodus-2, a novel C-C
chemokine
            with a unique 37-amino acid carboxyl-terminal extension
  JOURNAL   J. Immunol. 159 (6), 2554-2558 (1997)
  MEDLINE   97444139
REFERENCE   2  (bases 1 to 828)
  AUTHORS   Hromas,R.A.
  TITLE     Direct Submission
  JOURNAL   Submitted (04-FEB-1997) Medicine, Indiana University Medical
            Center, 975 West Walnut, Indianapolis, IN 46202, USA
FEATURES             Location/Qualifiers
     source          1..828
                     /organism="Homo sapiens"
                     /note="PCR amplified from activated THP-1 cells"
                     /db_xref="taxon:9606"
                     /clone_lib="Soares human placenta cDNA"
                     /cell_line="THP-1"
                     /cell_type="monoblast"
     CDS             15..419
                     /codon_start=1
                     /product="beta chemokine Exodus-2"
                     /db_xref="PID:g2196920"

/translation="MAQSLALSLLILVLAFGIPRTQGSDGGAQDCCLKYSQRKIPAKV

VRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
                    CRKDRGASKTGKKGKGSKGCKRTERSQTPKGP"
BASE COUNT      218 a    255 c    216 g    139 t
ORIGIN
        1 ggcacgaggc agacatggct cagtcactgg ctctgagcct ccttatcctg gttctggcct
       61 ttggcatccc caggacccaa ggcagtgatg gaggggctca ggactgttgc ctcaagtaca
      121 gccaaaggaa gattcccgcc aaggttgtcc gcagctaccg gaagcaggaa ccaagcttag
      181 gctgctccat cccagctatc ctgttcttgc cccgcaagcg ctctcaggca gagctatgtg
      241 cagacccaaa ggagctctgg gtgcagcagc tgatgcagca tctggacaag acaccatccc
      301 cacagaaacc agcccagggc tgcaggaagg acaggggggc ctccaagact ggcaagaaag
      361 gaaagggctc caaaggctgc aagaggactg agcggtcaca gacccctaaa gggccatagc
      421 ccagtgagca gcctggagcc ctggagaccc caccagcctc accagcgctt gaagcctgaa
      481 cccaagatgc aagaaggagg ctatgctcag gggccctgga gcagccaccc catgctggcc
      541 ttgccacact ctttctcctg ctttaaccac cccatctgca ttcccagctc tcaccctgca
      601 tggctgagtc tgcccacagc aggccaggtc cagagagacc gaggagggag agtctcccag
      661 ggagcatgag aggaggcagc aggactgtcc ccttgaagga gaatcatcag gaccctggac
      721 ctgatacggc tccccagtac accccacctc ttccttgtaa atatgattta tacctaactg
      781 aataaaaagc tgttctgtct tcccacccaa aaaaaaaaaa aaaaaaaa
//
LOCUS       HSU88321      502 bp    mRNA            PRI       22-JUN-1998
DEFINITION  Human beta chemokine Exodus-3 mRNA, complete cds.
ACCESSION   U88321
NID         g2196921
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 502)
  AUTHORS   Hromas,R.A., Gray,P., Klemsz,M., Fife,K. and Broxmeyer,H.
  TITLE     DCCL chemokines represent a novel beta chemokine subfamily
  JOURNAL   Unpublished
REFERENCE   2  (bases 1 to 502)
  AUTHORS   Hromas,R.A.
  TITLE     Direct Submission
  JOURNAL   Submitted (04-FEB-1997) Medicine, Indiana University Medical
            Center, 975 West Walnut, Indianapolis, IN 46202, USA
REFERENCE   3  (bases 1 to 502)
  AUTHORS   Hromas,R.A.
  TITLE     Direct Submission
  JOURNAL   Submitted (22-JUN-1998) Medicine, Indiana University Medical
            Center, 975 West Walnut, Indianapolis, IN 46202, USA
  REMARK    Amino acid sequence updated by submitter
FEATURES             Location/Qualifiers
     source          1..502
```

```
                     /organism="Homo sapiens"
                     /note="PCR amplified from THP-1 cells"
                     /db_xref="taxon:9606"
                     /cell_line="THP-1"
                     /cell_type="monoblast"
                     /dev_stage="adult"
     CDS             120..416
                     /note="Mip-3alpha/ELC/CKbeta11"
                     /codon_start=1
                     /product="beta chemokine Exodus-3"
                     /db_xref="PID:g3243080"

/translation="MALLLALSLLVLWTSPAPTLSGTNDAEDCCLSVTQKPIPGYIVR

NFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"
BASE COUNT      113 a    170 c    121 g     98 t
ORIGIN
        1 ctcacacctt gcatttcacc cctgcatccc atgcgccctg cagcctcaca cagatcctgc
       61 acacacccag acagctggcg ctcacacatt caccgttggc ctgcctctgt tcaccctcca
      121 tggccctgct actggccctc agcctgctgg ttctctggac ttccccagcc ccaactctga
      181 gtggcaccaa tgatgctgaa gactgctgcc tgtctgtgac ccagaaaccc atccctgggt
      241 acatcgtgag gaacttccac taccttctca tcaaggatgg ctgcagggtg cctgctgtag
      301 tgttcaccac actgaggggc cgccagctct gtgcaccccc agaccagccc tgggtagaac
      361 gcatcatcca gagactgcag aggacctcag ccaagatgaa gcgccgcagc agttaaccta
      421 tgaccgtgca gagggagccc cgagtccgag tcaagcattg tgaattatta ctaactggga
      481 acgaggacag aaggaaggac ag
//

LOCUS       HSU86358      879 bp    mRNA            PRI       11-SEP-1997
DEFINITION  Human chemokine (TECK) mRNA, complete cds.
ACCESSION   U86358
NID         g2388626
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 879)
  AUTHORS       Vicari,A.P.,  Figueroa,D.J.,  Hedrick,J.A.,  Foster,J.S.,
Singh,K.P.,
            Menon,S., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., Bacon,K.B.
and
            Ziotnik,A.
  TITLE     TECK: a novel cc chemokine specifically expressed by thymic
            dendritic cells and potentially involved in T cell development
  JOURNAL   Immunology 7, 291-301 (1997)
REFERENCE   2  (bases 1 to 879)
  AUTHORS   Vicari,A.P. and Zlotnik,A.
  TITLE     Direct Submission
  JOURNAL    Submitted (21-JAN-1997) Immunology, DNAX Research Institute,
901
            California Ave., Palo Alto, CA 94304, USA
FEATURES             Location/Qualifiers
     source          1..879
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="4"
                     /tissue_type="thymus"
     gene            1..879
                     /gene="TECK"
     CDS             1..453
                     /gene="TECK"
                     /codon_start=1
                     /product="chemokine"
                     /db_xref="PID:g2388627"

/translation="MNLWLLACLVAGFLGAWAPAVHTQGVFEDCCLAYHYPIGWAVLR

RAWTYRIQEVSGSCNLPAAIFYLPKRHRKVCGNPKSREVQRAMKLLDARNKVFAKLHH
                    NMQTFQAGPHAVKKLSSGNSKLSSSKFSNPISSSKRNVSLLISANSGL"
BASE COUNT      191 a    264 c    218 g    206 t
```

```
ORIGIN
        1 atgaacctgt ggctcctggc ctgcctggtg gccggcttcc tgggagcctg ggcccccgct
       61 gtccacaccc aaggtgtctt tgaggactgc tgcctggcct accactaccc cattgggtgg
      121 gctgtgctcc ggcgcgcctg gacttaccgg atccaggagg tgagcgggag ctgcaatctg
      181 cctgctgcga tattctacct ccccaagaga cacaggaagg tgtgtgggaa ccccaaaagc
      241 agggaggtgc agagagccat gaagctcctg gatgctcgaa ataaggtttt tgcaaagctc
      301 caccacaaca tgcagacctt ccaagcaggc cctcatgctg taaagaagtt gagttctgga
      361 aactccaagt tatcatcatc caagtttagc aatcccatca gcagcagcaa gaggaatgtc
      421 tccctcctga tatcagctaa ttcaggactg tgagccggct catttctggg ctccatcggc
      481 acaggagggg ccggatcttt ctccgataaa accgtcgccc tacagaccca gctgtcccca
      541 cgcctctgtc ttttgggtca agtcttaatc cctgcacctg agttggtcct ccctctgcac
      601 ccccaccacc tcctgcccgt ctggcaactg gaaagaagga gttggcctga ttttaacctt
      661 ttgccgctcc ggggaacagc acaatcctgg gcagccagtg gctcttgtag agaaaactta
      721 ggatacctct ctcactttct gtttcttgcc gtccaccccg ggccatgcca gtgtgtcctc
      781 tgggtccccc ccaaaaatct ggtcattcaa ggatcccctc ccaaggctat gcttttctat
      841 aacttttaaa taaaccttgg ggggtgaatg gaataaaaa
//

LOCUS       AB002409      852 bp    mRNA            PRI       15-AUG-1997
DEFINITION  Homo sapiens mRNA for SLC, complete cds.
ACCESSION   AB002409
NID         g2335034
KEYWORDS    SLC; mature ELC.
SOURCE      Homo sapiens cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;   Mammalia;   Eutheria;   Primates;   Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (bases 1 to 852)
  AUTHORS   Nomiyama,H.
  TITLE     Direct Submission
  JOURNAL   Submitted (28-MAR-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki   Nomiyama,   Kumamoto   University   Medical   School,
Department
            of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE   2  (bases 1 to 852)
  AUTHORS      Nagira,M.,  Imai,T.,  Hieshima,K.,  Kusuda,J.,  Ridanpaa,M.,
Takagi,S.,
            Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.
  TITLE     Molecular Cloning of a Novel Human CC Chemokine Secondary
            Lymphoid-Tissue Chemokine (SLC) That is an Efficient
            Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13
  JOURNAL   Unpublished (1997)
FEATURES             Location/Qualifiers
     source          1..852
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     CDS             59..463
                     /codon_start=1
                     /product="SLC"
                     /db_xref="PID:d1022673"
                     /db_xref="PID:g2335035"

/translation="MAQSLALSLLILVLAFGIPRTQGSDGGAQDCCLKYSQRKIPAKV

VRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
                     CRKDRGASKTGKKGKGSKGCKRTERSQTPKGP"
     mat_peptide     <107..460
                     /product="mature ELC"
     polyA_site      823..828
BASE COUNT      205 a    279 c    217 g    151 t
ORIGIN
        1 cttgcagctg cccacctcac cctcagctct ggcctcttac tcaccctcta ccacagacat
       61 ggctcagtca ctggctctga gcctccttat cctggttctg gcctttggca tccccaggac
      121 ccaaggcagt gatggagggg ctcaggactg ttgcctcaag tacagccaaa ggaagattcc
      181 cgccaaggtt gtccgcagct accggaagca ggaaccaagc ttaggctgct ccatcccagc
      241 tatcctgttc ttgccccgca agcgctctca ggcagagcta tgtgcagacc caaaggagct
      301 ctgggtgcag cagctgatgc agcatctgga caagacacca tccccacaga aaccagccca
```

```
      361 gggctgcagg aaggacaggg gggcctccaa gactggcaag aaaggaaagg gctccaaagg
      421 ctgcaagagg actgagcggt cacagacccc taaagggcca tagcccagtg agcagcctgg
      481 agccctggag accccaccag cctcaccaac gcttgaagcc tgaacccaag atgcaagaag
      541 gaggctatgc tcaggggccc tggagcagcc accccatgct ggccttgcca cactctttct
      601 cctgctttaa ccaccccatc tgcattccca gctctaccct gcatggctga gctgcccaca
      661 gcaggccagg tccagagaga ccgaggaggg agagtctccc agggagcatg agaggaggca
      721 gcaggactgt ccccttgaag gagaatcatc aggaccctgg acctgatacg gctccccagt
      781 acaccccacc tcttccttgt aaatatgatt tatacctaac tgaataaaaa gctgttctgt
      841 cttcccaccc gc
//

LOCUS       AF055467     1481 bp    mRNA            PRI       06-AUG-1998
DEFINITION  Homo sapiens monotactin-1 mRNA, complete cds.
ACCESSION   AF055467
NID         g3395775
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1481)
  AUTHORS   Youn,B.S., Zhang,S., Broxmeyer,H.E., Antol,K., Fraser,M.J. Jr.,
            Hangoc,G. and Kwon,B.S.
  TITLE     Isolation and characterization of LMC, a novel lymphocyte and
            monocyte chemoattractant human CC chemokine, with
myelosuppressive
            activity
  JOURNAL   Biochem. Biophys. Res. Commun. 247 (2), 217-222 (1998)
  MEDLINE   98308096
REFERENCE   2  (bases 1 to 1481)
  AUTHORS   Youn,B.S. and Kwon,B.S.
  TITLE     Direct Submission
  JOURNAL   Submitted (24-MAR-1998) Microbiology and Immunology, Indiana
            University, School of Medicine, 605 Barnhill Dr. Medical
Science
            Bldg., Indianapolis, IN 46202, USA
FEATURES             Location/Qualifiers
     source          1..1481
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
     5'UTR           1..34
     CDS             35..397
                     /note="Mtn-1;    LMC;    lymphocyte    and    monocyte
chemoattractant
                     CC chemokine"
                     /codon_start=1
                     /product="monotactin-1"
                     /db_xref="PID:g3395776"

/translation="MKVSEAALSLLVLILIITSASRSQPKVPEWVNTPSTCCLKYYEK

VLPRRLVVGYRKALNCHLPAIIFVTKRNREVCTNPNDDWVQEYIKDPNLPLLPTRNLS
                     TVKIITAKNGQPQLLNSQ"
     3'UTR           398..1481
BASE COUNT      412 a    362 c    302 g    405 t
ORIGIN
        1 gcacgagctg aagctgtact gcctcgctga gaggatgaag gtctccgagg ctgccctgtc
       61 tctccttgtc ctcatcctta tcattacttc ggcttctcgc agccagccaa aagttcctga
      121 gtgggtgaac accccatcca cctgctgcct gaagtattat gagaaagtgt tgccaaggag
      181 actagtggtg ggatacagaa aggccctcaa ctgtcacctg ccagcaatca tcttcgtcac
      241 caagaggaac cgagaagtct gcaccaaccc caatgacgac tgggtccaag agtacatcaa
      301 ggatcccaac ctacctttgc tgcctaccag gaacttgtcc acggttaaaa ttattacagc
      361 aaagaatggt caaccccagc tcctcaactc ccagtgatga ccaagcttta gtggaagccc
      421 ttgtttacag aagagagggg taaactatga aaacagggga agccttatta ggctgaaact
      481 agccagtcac attgagagaa gcagaacaat gatcaaaata aaggagaagt atttcgaata
      541 ttttctcaat cttaggagga aataccaaag ttaagggacg tgggcagagg tacgctcttt
      601 tatttttata tttatatttt tatttttttg agatagggtc ttactctgtc acccaggctg
      661 gagtgcagtg gtgtgatctt ggctcacttg atcttggctc actgtaacct ccacctccca
      721 ggctcaagtg atcctcccac cccaccctcc cgagtagctg ggactacagg cttgcgccac
      781 cacacctggc taatttttgt atttttggta gagacgggat tctaccatgt tgcccaggct
```

```
      841 ggtctcaaac tcgtgtgccc aagcaatcca cctgcctcag ccttccaaaa gtgctgggct
      901 tacaggcgtg agccaccaca tccggccagt ccactcttaa tacacagaaa aatatatttc
      961 acatccttct cctgctctct ttcaattcct cacttcacac cagtacacaa gccattctaa
     1021 atacttagcc agtttccagc cttccagatg atctttgccc tctgggtctt gacccattaa
     1081 gagccccata gaactcttga ttttttcctgt ccatctttat gggatttttc tggatctata
     1141 ttttcttcaa ttattctttc attttataat gcaacttttt cataggaagt ccggtaggga
     1201 atattcacat taatcatttt tgcagagact ttgctagatc ctctcatatt ttgtcttcct
     1261 cagggtggca ggggtacaga agtgcctgat tggttttttt ttttttgag agagagagag
     1321 aagaagaaga agaagagaca caaatctcta cctcccatgt taagctttgc aggacaggga
     1381 aagaaagggt atgagacacg gctagggtaa actcttagtc caaaacccaa gcatgcaata
     1441 aataaaactc ccttatttga caaaaaaaaa aaaaaaaaaa a
//

LOCUS       HSRNAATAC     557 bp    RNA             PRI       06-JUL-1995
DEFINITION  H.sapiens mRNA for ATAC protein.
ACCESSION   X86474
NID         g895846
KEYWORDS    ATAC gene.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 557)
  AUTHORS   Muller,S., Dorner,B., Korthauer,U., Mages,H.W., D'Apuzzo,M.,
            Senger,G. and Kroczek,R.A.
  TITLE        Cloning of ATAC, an activation-induced, chemokine-related
molecule
            exclusively expressed in CD8+ T lymphocytes
  JOURNAL   Eur. J. Immunol. 25 (6), 1744-1748 (1995)
  MEDLINE   95339892
REFERENCE   2  (bases 1 to 557)
  AUTHORS   Kroczek,R.A.
  TITLE     Direct Submission
  JOURNAL   Submitted (20-APR-1995) R.A. Kroczek, Molecular Immunology,
            Robert-Koch-Institute, Nordufer 20, 13353 Berlin, FRG
FEATURES             Location/Qualifiers
     source          1..557
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /tissue_type="peripheral blood"
                     /cell_type="lymphocyte"
                     /chromosome="1"
                     /map="q23"
     gene            25..369
                     /gene="ATAC"
     CDS             25..369
                     /gene="ATAC"
                     /codon_start=1
                     /product="CD8+T cell specific protein"
                     /db_xref="PID:g895847"
                     /db_xref="SWISS-PROT:P47992"

/translation="MRLLILALLGICSLTAYIVEGVGSEVSDKRTCVSLTTQRLPVSR

IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMDRKSNTRNNMIQTKPTGT
                     QQSTNTAVTLTG"
     polyA_signal    469..474
     polyA_signal    534..539
BASE COUNT      157 a    139 c    112 g    149 t
ORIGIN
        1 gcacagctca gcaggacctc agccatgaga cttctcatcc tggccctcct tggcatctgc
       61 tctctcactg catacattgt ggaaggtgta gggagtgaag tctcagataa gaggacctgt
      121 gtgagcctca ctacccagcg actgccggtt agcagaatca agacctacac catcacggaa
      181 ggctccttga gagcagtaat ttttattacc aaacgtggcc taaaagtctg tgctgatcca
      241 caagccacat gggtgagaga cgtggtcagg agcatggaca ggaaatccaa caccagaaat
      301 aacatgatcc agaccaagcc aacaggaacc cagcaatcga ccaatacagc tgtgactctg
      361 actggctagt agtctctggc accctgtccg tctccagcca gccagctcat ttcactttac
      421 acgctcatgg actgagttta tactcgcctt ttatgaaagc actgcatgaa taaaattatt
      481 cctttgtatt tttacttta aatgtcttct gtattcactt atatgttcta attaataaat
      541 tatttattat taagaat
//
```

```
LOCUS       HSU85767      563 bp    mRNA            PRI       01-APR-1997
DEFINITION    Human  myeloid  progenitor  inhibitory  factor-1  MPIF-1  mRNA,
complete
            cds.
ACCESSION   U85767
NID         g1916249
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 563)
  AUTHORS   Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T.,
            Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D.,
            Gentz,R. and Garotta,G.
  TITLE     Molecular and functional characterization of two novel human C-
C
            chemokines as inhibitors of two distinct classes of myeloid
            progenitors
  JOURNAL   J. Exp. Med. (1997) In press
REFERENCE   2  (bases 1 to 563)
  AUTHORS   Li,H. and Patel,V.P.
  TITLE     Direct Submission
  JOURNAL    Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences,
9410
            Keywest Ave., Rockville, MD 20850, USA
FEATURES             Location/Qualifiers
     source          1..563
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     CDS             31..393
                     /note="myeloid progenitor inhibitory factor-1"
                     /codon_start=1
                     /product="MPIF-1"
                     /db_xref="PID:g1916250"

/translation="MKVSVAALSCLMLVTALGSQARVTKDAETEFMMSKLPLENPVLL

DRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQV
                     QVCMRMLKLDTRIKTRKN"
BASE COUNT      164 a    143 c    117 g    139 t
ORIGIN
        1 ctcagccagc cctgcctgcc caccaggagg atgaaggtct ccgtggctgc cctctcctgc
       61 ctcatgcttg ttactgccct tggatcccag gcccgggtca caaaagatgc agagacagag
      121 ttcatgatgt caaagcttcc attggaaaat ccagtacttc tggacagatt ccatgctact
      181 agtgctgact gctgcatctc ctacacccca cgaagcatcc cgtgttcact cctggagagt
      241 tactttgaaa cgaacagcga gtgctccaag ccgggtgtca tcttcctcac caagaagggg
      301 cgacgtttct gtgccaaccc cagtgataag caagttcagg tttgcatgag aatgctgaag
      361 ctggacacac ggatcaagac caggaagaat tgaacttgtc aaggtgaagg gacacaagtt
      421 gccagccacc aactttcttg cctcaactac cttcctgaat tatttttta agaagcattt
      481 attcttgtgt tctggattta gagcaattca tctaataaac agtttctcac ttttaaaaaa
      541 aaaaaaaaaa aaaaaaaaaa aaa
//

LOCUS       HSU85768      360 bp    mRNA            PRI       01-APR-1997
DEFINITION    Human  myeloid  progenitor  inhibitory  factor-1  MPIF-2  mRNA,
complete
            cds.
ACCESSION   U85768
NID         g1916251
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 360)
  AUTHORS   Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T.,
            Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D.,
            Gentz,R. and Garotta,G.
  TITLE     Molecular and functional characterization of two novel human C-
```

```
C
            chemokines as inhibitors of two distinct classes of myeloid
            progenitors
  JOURNAL   J. Exp. Med. (1997) In press
REFERENCE   2  (bases 1 to 360)
  AUTHORS   Li,H. and Patel,V.P.
  TITLE     Direct Submission
  JOURNAL    Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences,
9410
            Keywest Ave., Rockville, MD 20850, USA
FEATURES             Location/Qualifiers
     source          1..360
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     CDS             1..360
                     /note="myeloid progenitor inhibitory factor-2"
                     /codon_start=1
                     /product="MPIF-2"
                     /db_xref="PID:g1916252"

/translation="MAGLMTIVTSLLFLGVCAHHIIPTGSVVIPSPCCMFFVSKRIPE

NRVVSYQLSSRSTCLKGGVIFTTKKGQQFCGDPKQEWVQRYMKNLDAKQKKASPRARA
                     VAVKGPVQRYPGNQTTC"
BASE COUNT       85 a    106 c     96 g     73 t
ORIGIN
        1 atggcaggcc tgatgaccat agtaaccagc cttctgttcc ttggtgtctg tgcccaccac
       61 atcatcccta cgggctctgt ggtcataccc tctccctgct gcatgttctt tgtttccaag
      121 agaattcctg agaaccgagt ggtcagctac cagctgtcca gcaggagcac atgcctcaag
      181 ggaggagtga tcttcaccac caagaagggc cagcagttct gtggcgaccc caagcaggag
      241 tgggtccaga ggtacatgaa gaacctggac gccaagcaga agaaggcttc ccctagggcc
      301 agggcagtgg ctgtcaaggg ccctgtccag agatatcctg gcaaccaaac cacctgctaa
//

LOCUS       HUMSDF1A     1847 bp    mRNA            PRI      26-DEC-1996
DEFINITION  Human pre-B cell stimulating factor homologue (SDF1a) mRNA,
            complete cds.
ACCESSION   L36034
NID         g1220363
KEYWORDS     intercrine; intercrine CXC subfamily; pre-B cell stimulating
factor
            homologue; alpha-chemokine.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1847)
  AUTHORS   Shirozu,M., Nakano,T., Inazawa,J., Tashiro,K., Tada,H.,
            Shinohara,T. and Honjo,T.
  TITLE     Structure and chromosomal localization of the human stromal
            cell-derived factor 1 (SDF1) gene
  JOURNAL   Genomics 28 (3), 495-500 (1995)
  MEDLINE   96039262
FEATURES             Location/Qualifiers
     source          1..1847
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="h5"
                     /cell_line="FLEB14-14"
     sig_peptide     80..142
                     /gene="SDF1a"
     CDS             80..349
                     /codon_start=1
                     /product="pre-B cell stimulating factor homologue"
                     /db_xref="PID:g1220364"

/translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANV
                     KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK"
     gene            80..346
                     /gene="SDF1a"
     mat_peptide     143..346
```

```
                     /gene="SDF1a"
                     /product="pre-B cell stimulating factor homologue"
BASE COUNT       459 a    471 c    417 g    500 t
ORIGIN
        1 tctccgtcag ccgcattgcc cgctcggcgt ccggcccccg acccgtgctc gtccgcccgc
       61 ccgcccgccc gcccgcgcca tgaacgccaa ggtcgtggtc gtgctggtcc tcgtgctgac
      121 cgcgctctgc ctcagcgacg ggaagcccgt cagcctgagc tacagatgcc catgccgatt
      181 cttcgaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
      241 ctgtgcccct cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
      301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagtaag cacaacagcc
      361 aaaaaggact ttccgctaga cccactcgag gaaaactaaa accttgtgag agatgaaagg
      421 gcaaagacgt gggggagggg gccttaacca tgaggaccag gtgtgtgtgt ggggtgggca
      481 cattgatctg ggatcgggcc tgaggtttgc agcatttaga ccctgcattt atagcatacg
      541 gtatgatatt gcagcttata ttcatccatg ccctgtacct gtgcacgttg gaacttttat
      601 tactggggtt tttctaagaa agaaattgta ttatcaacag cattttcaag cagttagttc
      661 cttcatgatc atcacaatca tcatcattct cattctcatt ttttaaatca acgagtactt
      721 caagatctga atttggcttg tttggagcat ctcctctgct cccctgggga gtctgggcac
      781 agtcaggtgg tggcttaaca gggagctgga aaaagtgtcc tttcttcaga cactgaggct
      841 cccgcagcag cgcccctccc aagaggaagg cctctgtggc actcagatac cgactggggc
      901 tggggcgccg ccactgcctt cacctcctct ttcaaacctc agtgattggc tctgtgggct
      961 ccatgtagaa gccactatta ctgggactgt ctcagagacc cctctcccag ctattcctac
     1021 tctctccccg actccgagag catgcttaat cttgcttctg cttctcattt ctgtagcctg
     1081 atcagcgccg caccagccgg gaagagggtg attgctgggg ctcgtgccct gcatccctct
     1141 cctcccaggg cctgccccac agctcgggcc ctctgtgaga tccgtctttg gcctcctcca
     1201 gaatggagct ggccctctcc tggggatgtg taatggtccc cctgcttacc cgcaaaagac
     1261 aagtctttac agaatcaaat gcaattttaa atctgagagc tcgcttgagt gactgggttt
     1321 gtgattgcct ctgaagccta tgtatgccat ggaggcacta acaaactctg aggtttccga
     1381 aatcagaagc gaaaaaatca gtgaataaac catcatcttg ccactacccc ctcctgaagc
     1441 cacagcaggg gttcaggttc caatcagaac tgttggcaag gtgacatttc catgcataga
     1501 tgcgatccac agaaggtcct ggtggtattt gtaacttttt gcaaggcatt tttttatata
     1561 tatttttgtg cacatttttt tttacgattc tttagaaaac aaatgtattt caaaatatat
     1621 ttatagtcga acaagtcata tatatgaatg agagccatat gaatgtcagt agtttatact
     1681 tctctattat ctcaaactac tggcaatttg taaagaaata tatatgatat ataaatgtga
     1741 ttgcagcttt tcaatgttag ccacagtgta ttttttcact tgtactaaaa ttgtatcaaa
     1801 tgtgacatta tatgcactag caataaaatg ctaattgttt catggta
//

LOCUS       HUMSDF1B     3524 bp    mRNA            PRI       26-DEC-1996
DEFINITION  Human pre-B cell stimulating factor homologue (SDF1b) mRNA,
            complete cds.
ACCESSION   L36033
NID         g1220365
KEYWORDS     intercrine; intercrine CXC subfamily; pre-B cell stimulating
factor
            homologue; alpha-chemokine.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 3524)
  AUTHORS   Shirozu,M., Nakano,T., Inazawa,J., Tashiro,K., Tada,H.,
            Shinohara,T. and Honjo,T.
  TITLE     Structure and chromosomal localization of the human stromal
            cell-derived factor 1 (SDF1) gene
  JOURNAL   Genomics 28 (3), 495-500 (1995)
  MEDLINE   96039262
FEATURES             Location/Qualifiers
     source          1..3524
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="h17"
                     /cell_line="FLEB14-14"
     sig_peptide     80..142
                     /gene="SDF1b"
     CDS             80..361
                     /codon_start=1
                     /product="pre-B cell stimulating factor homologue"
                     /db_xref="PID:g1220366"

/translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANV
                     KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRFKM"
```

```
     gene            80..358
                     /gene="SDF1b"
     mat_peptide     143..358
                     /gene="SDF1b"
                     /product="pre-B cell stimulating factor homologue"
BASE COUNT      903 a    886 c    793 g    942 t
ORIGIN
        1 tctccgtcag ccgcattgcc cgctcggcgt ccggcccccg acccgtgctc gtccgcccgc
       61 ccgcccgccc gcccgcgcca tgaacgccaa ggtcgtggtc gtgctggtcc tcgtgctgac
      121 cgcgctctgc ctcagcgacg ggaagcccgt cagcctgagc tacagatgcc catgccgatt
      181 cttcgaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
      241 ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
      301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagaggt tcaagatgtg
      361 agagggtcag acgcctgagg aacccttaca gtaggagccc agctctgaaa ccagtgttag
      421 ggaagggcct gccacagcct cccctgccag ggcagggccc caggcattgc caagggcttt
      481 gttttgcaca ctttgccata ttttcaccat ttgattatgt agcaaaatac atgacattta
      541 ttttcattt agtttgatta ttcagtgtca ctggcgacac gtagcagctt agactaaggc
      601 cattattgta cttgccttat tagagtgtct ttccacggag ccactcctct gactcagggc
      661 tcctgggttt tgtattctct gagctgtgca ggtggggaga ctgggctgag ggagcctggc
      721 cccatggtca gccctagggt ggagagccac caagagggac gcctgggggt gccaggacca
      781 gtcaacctgg gcaaagccta gtgaaggctt ctctctgtgg gatgggatgg tggagggcca
      841 catgggaggc tcacccccct ctccatccac atgggagccg ggtctgcctc ttctgggagg
      901 gcagcagggc taccctgagc tgaggcagca gtgtgaggcc agggcagagt gagacccagc
      961 cctcatcccg agcacctcca catcctccac gttctgctca tcattctctg tctcatccat
     1021 catcatgtgt gtccacgact gtctccatgg ccccgcaaaa ggactctcag gaccaaagct
     1081 ttcatgtaaa ctgtgcacca agcaggaaat gaaaatgtct tgtgttacct gaaaacactg
     1141 tgcacatctg tgtcttgtgt ggaatattgt ccattgtcca atcctatgtt tttgttcaaa
     1201 gccagcgtcc tcctctgtga ccaatgtctt gatgcatgca ctgttccccc tgtgcagccg
     1261 ctgagcgagg agatgctcct tgggcccttt gagtgcagtc ctgatcagag ccgtggtcct
     1321 ttgggggtgaa ctaccttggt tcccccactg atcacaaaaa catggtgggt ccatgggcag
     1381 agcccaaggg aattcggtgt gcaccagggt tgaccccaga ggattgctgc cccatcagtg
     1441 ctccctcaca tgtcagtacc ttcaaactag ggccaagccc agcactgctt gaggaaaaca
     1501 agcattcaca acttgttttt ggtttttaaa acccagtcca caaaataacc aatcctggac
     1561 atgaagattc tttcccaatt cacatctaac ctcatcttct tcaccatttg gcaatgccat
     1621 catctcctgc cttcctcctg ggccctctct gctctgcgtg tcacctgtgc ttcgggccct
     1681 tcccacagga catttctcta agagaacaat gtgctatgtg aagagtaagt caacctgcct
     1741 gacatttgga gtgttccccc cccactgagg gcagtcgata gagctgtatt aagccactta
     1801 aaatgttcac ttttgacaaa ggcaagcact tgtgggtttt tgttttgttt ttcattcagt
     1861 cttacgaata cttttgccct ttgattaaag actccagtta aaaaaaattt taatgaagaa
     1921 agtggaaaac aaggaagtca aagcaaggaa actatgtaac atgtaggaag taggaagtaa
     1981 attatagtga tgtaatcttg aattgtaact gttcgtgaat ttaataatct gtagggtaat
     2041 tagtaacatg tgttaagtat tttcataagt atttcaaatt ggagcttcat ggcagaaggc
     2101 aaacccatca acaaaaattg tcccttaaac aaaaattaaa atcctcaatc cagctatgtt
     2161 atattgaaaa aatagagcct gagggatctt tactagttat aaagatacag aactctttca
     2221 aaacctttg aaattaacct ctcactatac cagtataatt gagttttcag tggggcagtc
     2281 attatccagg taatccaaga tattttaaaa tctgtcacgt agaacttgga tgtacctgcc
     2341 cccaatccat gaaccaagac cattgaattc ttggttgagg aaacaaacat gaccctaaat
     2401 cttgactaca gtcaggaaag gaatcatttc tatttctcct ccatgggaga aaatagataa
     2461 gagtagaaac tgcagggaaa attatttgca taacaattcc tctactaaca atcagctcct
     2521 tcctggagac tgcccagcta aagcaatatg catttaaata cagtcttcca tttgcaaggg
     2581 aaaagtctct tgtaatccga atctcttttt gctttcgaac tgctagtcaa gtgcgtccac
     2641 gagctgttta ctagggatcc ctcatctgtc cctccgggac ctggtgctgc ctctacctga
     2701 cactcccttg ggctccctgt aacctcttca gaggccctcg ctgccagctc tgtatcagga
     2761 cccagaggaa ggggccagag gctcgttgac tggctgtgtg ttgggattga gtctgtgcca
     2821 cgtgtatgtg ctgtggtgtg tccccctctg tccaggcact gagataccag cgaggaggct
     2881 ccagagggca ctctgcttgt tattagagat tacctcctga gaaaaaagct tccgcttgga
     2941 gcagaggggc tgaatagcag aaggttgcac ctcccccaac cttagatgtt ctaagtcttt
     3001 ccattggatc tcattggacc cttccatggt gtgatcgtct gactggtgtt atcaccgtgg
     3061 gctccctgac tgggagttga tcgcctttcc caggtgctac acccttttcc agctggatga
     3121 gaatttgagt gctctgatcc ctctacagag cttccctgac tcattctgaa ggagccccat
     3181 tcctgggaaa tattccctag aaacttccaa atcccctaag cagaccactg ataaaaccat
     3241 gtagaaaatt tgttattttg caacctcgct ggactctcag tctctgagca gtgaatgatt
     3301 cagtgttaaa tgtgatgaat actgtatttt gtattgtttc aagtgcatct cccagataat
     3361 gtgaaaatgg tccaggagaa ggccaattcc tatacgcagc gtgctttaaa aaataaataa
     3421 gaaacaactc tttgagaaac aacaatttct actttgaagt cataccaatg aaaaaatgta
     3481 tatgcactta taattttcct aataaagttc tgtactcaaa tgta
//

LOCUS       HSJ002211     663 bp    mRNA            PRI       11-MAR-1998
DEFINITION  Homo sapiens cDNA for a CXC chemokine.
ACCESSION   AJ002211
```

```
NID          g2832410
KEYWORDS     CXC chemokine.
SOURCE       human.
  ORGANISM   Homo sapiens
             Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
             Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1  (bases 1 to 663)
  AUTHORS        Legler,D.F.,  Loetscher,M.,  Roos,R.S.,  Clark-Lewis,I.,
Baggiolini,M.
             and Moser,B.
  TITLE      B cell-attracting chemokine 1, a human CXC chemokine expressed
in
             lymphoid  tissues,  selectively  attracts  B  lymphocytes  via
BLR1/CXCR5
  JOURNAL    J. Exp. Med. 187 (4), 655-660 (1998)
  MEDLINE    98130629
REFERENCE    2  (bases 1 to 663)
  AUTHORS    Moser,B.
  TITLE      Direct Submission
  JOURNAL    Submitted (05-NOV-1997) Moser B., University of Bern, Theodor
             Kocher Institute, Freiestrasse 1, CH-3012 Bern, SWITZERLAND
FEATURES              Location/Qualifiers
     source           1..663
                      /organism="Homo sapiens"
                      /db_xref="taxon:9606"
                      /cell_type="PBL"
     sig_peptide      35..100
                      /gene="BCA-1"
     CDS              35..364
                      /gene="BCA-1"
                      /codon_start=1
                      /product="CXC chemokine"
                      /db_xref="PID:e1249325"
                      /db_xref="PID:g2832411"

/translation="MKFISTSLLLMLLVSSLSPVQGVLEVYYTSLRCRCVQESSVFIP

RRFIDRIQILPRGNGCPRKEIIVWKKNKSIVCVDPQAEWIQRMMEVLRKRSSSTLPVP
                      VFKRKIP"
     gene             35..364
                      /gene="BCA-1"
     mat_peptide      101..361
                      /gene="BCA-1"
BASE COUNT       176 a    136 c    145 g    198 t      8 others
ORIGIN
        1 cagagctcaa gtctgaactc tacctccaga cagaatgaag ttcatctcga catctctgct
       61 tctcatgctg ctggtcagca gcctctctcc agtccaaggt gttctggagg tctattacac
      121 aagcttgagg tgtagatgtg tccaagagag ctcagtcttt atccctagac gcttcattga
      181 tcgaattcaa atcttgcccc gtgggaatgg ttgtccaaga aaagaaatca tagtctggaa
      241 gaagaacaag tcaattgtgt gtgtggaccc tcaagctgaa tggatacaaa gaatgatgga
      301 agtattgaga aaaagaagtt cttcaactct accagttcca gtgtttaaga gaaagattcc
      361 ctgatgctga tatttccact aagaacacct gcattcttcc cttatccctg ctctgggatt
      421 ttagttttgt gcttagttaa atcttttcca gggagaaaga acttccccat acaaataagg
      481 catgaggact atgtaaaaat aaccttgcag gagctggatg gggggccaaa ctcaagcttc
      541 tttcactcca caggcaccct attntacact tgggggtttt gcnttctttn tttcntcagg
      601 gggggggaaa gtttcttttg gaaantagtt nttccagttn ttaggtatta cagggttntt
      661 ttt
//
LOCUS        HSHUMIG      2545 bp    RNA             PRI       16-NOV-1993
DEFINITION   H.sapiens Humig mRNA.
ACCESSION    X72755 S60728
NID          g311375
KEYWORDS     chemokine; cytokine; Humig gene; secreted protein.
SOURCE       human.
  ORGANISM   Homo sapiens
             Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
             Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1  (bases 1 to 2545)
  AUTHORS    Farber,J.M.
  TITLE      Direct Submission
  JOURNAL    Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
```

```
of
            Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
USA
REFERENCE   2  (bases 1 to 2545)
  AUTHORS   Farber,J.M.
  TITLE     HuMig: a new human member of the chemokine family of cytokines
  JOURNAL   Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
  MEDLINE   93236577
FEATURES             Location/Qualifiers
     source          1..2545
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /germline
                     /dev_stage="child"
                     /tissue_type="leukaemia"
                     /cell_type="monocyte"
                     /cell_line="THP-1"
                     /clone_lib="THP-1/IFN-gamma cDNA"
                     /clone="H-1-3"
     misc_feature    13..19
                     /note="cis-acting element; putative"
     gene            40..417
                     /gene="Humig"
     CDS             40..417
                     /gene="Humig"
                     /codon_start=1
                     /db_xref="PID:g311376"
                     /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSCISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNGVQTCLNPDSADVKELIKKWEKQVSQKKKQKNG
                     KKHQKKKVLKVRKSQRSRQKKTT"
BASE COUNT      755 a    581 c    457 g    752 t
ORIGIN
        1 atccaataca ggagtgactt ggaactccat tctatcacta tgaagaaaag tggtgttctt
       61 ttcctcttgg gcatcatctt gctggttctg attggagtgc aaggaacccc agtagtgaga
      121 aagggtcgct gttcctgcat cagcaccaac caagggacta tccacctaca atccttgaaa
      181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
      241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgattaaa
      301 aagtgggaga aacaggtcag ccaaaagaaa aagcaaaaga atgggaaaaa acatcaaaaa
      361 aagaaagttc tgaaagttcg aaaatctcaa cgttctcgtc aaaagaagac tacataagag
      421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
      481 ttccaaagga ggatggcata taatacaaag gcttattaat ttgactagaa aatttaaaac
      541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
      601 ttgttaaagg ctatgattgt ctttgttctt ctaccaccca ccagttgaat ttcatcatgc
      661 ttaaggccat gattttagca atacccatgt ctacacagat gttcacccaa ccacatccca
      721 ctcacaacag ctgcctggaa gagcagccct aggcttccac gtactgcagc ctccagagag
      781 tatctgaggc acatgtcagc aagtcctaag cctgttagca tgctggtgag ccaagcagtt
      841 tgaaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
      901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggtatcacc
      961 actggagatc accagtgtgt ggctttcaga gcctcctttc tggctttgga agccatgtga
     1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttcccctt tgcttcattc
     1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt cttctctcca gtgcacctgt
     1141 catatgctct gatttatctg agtcaactcc tttctcatct tgtccccaac accccacaga
     1201 agtgctttct tctcccaatt catcctcact cagtccagct tagttcaagt cctgcctctt
     1261 aaataaacct ttttggacac acaaattatc ttaaaactcc tgtttcactt ggttcagtac
     1321 cacatgggtg aacactcaat ggttaactaa ttcttgggtg tttatcctat ctctccaacc
     1381 agattgtcag ctccttgagg gcaagagcca cagtatattt ccctgtttct tccacagtgc
     1441 ctaataatac tgtggaacta ggttttaata atttttaat tgatgttgtt atgggcagga
     1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctggctac tccatgttgg
     1561 ctagcctctg gtaacctctt acttattatc ttcaggacac tcactacagg gaccagggat
     1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgctc agcttctcca acaataagaa
     1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
     1741 aaaatcatat aatcttacaa tgaaaaggac tttatagatc agccagtgac caacctttcc
     1801 ccaaccatac aaaaattcct tttcccgaag gaaaagggct ttctcaataa gcctcagctt
     1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg
     1921 agttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
     1981 tctcccatga agaaagggaa cggtgaagta ctaagcgcta gaggaagcag ccaagtcggt
     2041 tagtggaagc atgattggtg cccagttagc ctctgcagga tgtggaaacc tccttccagg
     2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctatactca
```

```
     2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgctgt ccggtggaga
     2221 tcccacccga acgtcttatc taatcatgaa actccctagt tccttcatgt aacttccctg
     2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
     2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca cacgttataa
     2401 tcatttatca tatatataca tacatgcata cactctcaaa gcaaataatt tttcacttca
     2461 aaacagtatt gacttgtata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
     2521 tatcaataaa tagaccatta atcag
//

LOCUS       HSHUMIG      2545 bp    RNA             PRI       16-NOV-1993
DEFINITION  H.sapiens Humig mRNA.
ACCESSION   X72755 S60728
NID         g311375
KEYWORDS    chemokine; cytokine; Humig gene; secreted protein.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 2545)
  AUTHORS   Farber,J.M.
  TITLE     Direct Submission
  JOURNAL   Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
of
            Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
USA
REFERENCE   2  (bases 1 to 2545)
  AUTHORS   Farber,J.M.
  TITLE     HuMig: a new human member of the chemokine family of cytokines
  JOURNAL   Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
  MEDLINE   93236577
FEATURES             Location/Qualifiers
     source          1..2545
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /germline
                     /dev_stage="child"
                     /tissue_type="leukaemia"
                     /cell_type="monocyte"
                     /cell_line="THP-1"
                     /clone_lib="THP-1/IFN-gamma cDNA"
                     /clone="H-1-3"
     misc_feature    13..19
                     /note="cis-acting element; putative"
     gene            40..417
                     /gene="Humig"
     CDS             40..417
                     /gene="Humig"
                     /codon_start=1
                     /db_xref="PID:g311376"
                     /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSCISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNGVQTCLNPDSADVKELIKKWEKQVSQKKKQKNG
                     KKHQKKKVLKVRKSQRSRQKKTT"
BASE COUNT       755 a    581 c    457 g    752 t
ORIGIN
        1 atccaataca ggagtgactt ggaactccat tctatcacta tgaagaaaag tggtgttctt
       61 ttcctcttgg gcatcatctt gctggttctg attggagtgc aaggaacccc agtagtgaga
      121 aagggtcgct gttcctgcat cagcaccaac caagggacta tccacctaca atccttgaaa
      181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
      241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgattaaa
      301 aagtgggaga aacaggtcag ccaaaagaaa aagcaaaaga atgggaaaaa acatcaaaaa
      361 aagaaagttc tgaaagttcg aaaatctcaa cgttctcgtc aaaagaagac tacataagag
      421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
      481 ttccaaagga ggatggcata taatacaaag gcttattaat ttgactagaa aatttaaaac
      541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
      601 ttgttaaagg ctatgattgt ctttgttctt ctaccaccca ccagttgaat ttcatcatgc
      661 ttaaggccat gattttagca atacccatgt ctacacagat gttcacccaa ccacatccca
      721 ctcacaacag ctgcctggaa gagcagccct aggcttccac gtactgcagc ctccagagag
      781 tatctgaggc acatgtcagc aagtcctaag cctgttagca tgctggtgag ccaagcagtt
```

```
     841 tgaaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
     901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggtatcacc
     961 actggagatc accagtgtgt ggctttcaga gcctcctttc tggctttgga agccatgtga
    1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttcccctt tgcttcattc
    1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt cttctctcca gtgcacctgt
    1141 catatgctct gatttatctg agtcaactcc tttctcatct tgtccccaac accccacaga
    1201 agtgctttct tctcccaatt catcctcact cagtccagct tagttcaagt cctgcctctt
    1261 aaataaacct ttttggacac acaaattatc ttaaaactcc tgtttcactt ggttcagtac
    1321 cacatgggtg aacactcaat ggttaactaa ttcttgggtg tttatcctat ctctccaacc
    1381 agattgtcag ctccttgagg gcaagagcca cagtatattt ccctgtttct tccacagtgc
    1441 ctaataatac tgtggaacta ggttttaata atttttaat tgatgttgtt atgggcagga
    1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctggctac tccatgttgg
    1561 ctagcctctg gtaacctctt acttattatc ttcaggacac tcactacagg gaccagggat
    1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgctc agcttctcca acaataagaa
    1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
    1741 aaaatcatat aatcttacaa tgaaaaggac tttatagatc agccagtgac caacctttc
    1801 ccaaccatac aaaaattcct tttcccgaag gaaaagggct ttctcaataa gcctcagctt
    1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg
    1921 agttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
    1981 tctcccatga agaaagggaa cggtgaagta ctaagcgcta gaggaagcag ccaagtcggt
    2041 tagtggaagc atgattggtg cccagttagc ctctgcagga tgtggaaacc tccttccagg
    2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctatactca
    2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgctgt ccggtggaga
    2221 tcccacccga acgtcttatc taatcatgaa actccctagt tccttcatgt aacttccctg
    2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
    2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca cacgttataa
    2401 tcatttatca tatatataca tacatgcata cactctcaaa gcaaataatt tttcacttca
    2461 aaacagtatt gacttgtata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
    2521 tatcaataaa tagaccatta atcag
//

LOCUS       AF002985      995 bp    mRNA            PRI       01-NOV-1997
DEFINITION  Homo sapiens putative alpha chemokine (H174) mRNA, complete
cds.
ACCESSION   AF002985
NID         g2580585
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 995)
  AUTHORS   Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M.,    Kelleher,K.,    Kriz,R.,    LaVallie,E.R.,
Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
  TITLE       A genetic selection for isolating cDNAs encoding secreted
proteins
  JOURNAL   Gene 198 (1-2), 289-296 (1997)
  MEDLINE   98036061
REFERENCE   2  (bases 1 to 995)
  AUTHORS   Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M.,    Kelleher,K.,    Kriz,R.,    LaVallie,E.R.,
Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
  TITLE     Direct Submission
  JOURNAL   Submitted (07-MAY-1997) Genetics Institute, 87 Cambridge Park
            Drive, Cambridge, MA 02140, USA
FEATURES             Location/Qualifiers
     source          1..995
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="PHA and PMA activated human peripheral
blood
                     mononuclear cells"
     gene            1..995
                     /gene="H174"
     CDS             88..372
                     /gene="H174"
                     /codon_start=1
                     /product="putative alpha chemokine"
```

```
                     /db_xref="PID:g2580586"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVAD
                     IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF"
BASE COUNT      382 a    170 c    194 g    249 t
ORIGIN
        1 gaattcggcc aaagaggcct acttccaaga agagcagcaa agctgaagta gcagcaacag
       61 caccagcagc aacagcaaaa aacaaacatg agtgtgaagg gcatggctat agccttggct
      121 gtgatattgt gtgctacagt tgttcaaggc ttccccatgt tcaaaagagg acgctgtctt
      181 tgcataggcc ctggggtaaa agcagtgaaa gtggcagata ttgagaaagc ctccataatg
      241 tacccaagta acaactgtga caaaatagaa gtgattatta ccctgaaaga aaataaagga
      301 caacgatgcc taaatcccaa atcgaagcaa gcaaggctta taatcaaaaa agttgaaaga
      361 aagaattttt aaaaatatca aaacatatga agtcctggaa aagggcatct gaaaaaccta
      421 gaacaagttt aactgtgact actgaaatga caagaattct acagtaggaa actgagactt
      481 ttctatggtt ttgtgacttt caacttttgt acagttatgt gaaggatgaa aggtgggtga
      541 aaggaccaaa aacagaaata cagtcttcct gaatgaatga caatcagaat tccactgccc
      601 aaaggagtcc aacaattaaa tggatttcta ggaaaagcta ccttaagaaa ggctggttac
      661 catcggagtt tacaaagtgc tttcacgttc ttacttgttg tattatacat tcatgcattt
      721 ctaggctaga gaaccttcta gatttgatgc ttacaactat tctgttgtga ctatgagaac
      781 atttctgtct ctagaagtta tctgtctgta ttgatcttta tgctatatta ctatctgtgg
      841 ttacagtgga gacattgaca ttattactgg agtcaagccc ttataagtca aaagcaccta
      901 tgtgtcgtaa agcattcctc aaacatttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
      961 aaaaaaaaaa aaaaaaaaaa aaaaaaagcg gccgc
//

LOCUS       AF030514     1371 bp    mRNA            PRI       17-JUN-1998
DEFINITION  Homo sapiens interferon stimulated T-cell alpha chemoattractant
            precursor, mRNA, complete cds.
ACCESSION   AF030514
NID         g3219692
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1371)
  AUTHORS       Cole,K.E.,   Strick,C.A.,   Paradis,T.J.,   Ogborne,K.T.;
Loetscher,M.,
            Gladue,R.P.,    Lin,W.,    Boyd,J.G.,    Moser,B.,    Wood,D.E.,
Sahagan,B.G.
            and Neote,K.
  TITLE       Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel
            non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
  JOURNAL   J. Exp. Med. 187 (12), 2009-2021 (1998)
  MEDLINE   98290735
REFERENCE   2  (bases 1 to 1371)
  AUTHORS   Cole,K.E., Strick,C.A. and Sahagan,B.G.
  TITLE     Direct Submission
  JOURNAL     Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern
            Point Road, Groton, CT 06340, USA
FEATURES             Location/Qualifiers
     source          1..1371
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="4"
                     /cell_type="astrocytes"
     sig_peptide     70..132
     CDS             70..354
                     /note="chemokine; I-TAC"
                     /codon_start=1
                     /product="interferon stimulated T-cell alpha
                     chemoattractant precursor"
                     /db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVAD
                     IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF"
     mat_peptide     133..351
                     /evidence=not_experimental
```

```
                     /product="interferon stimulated T-cell alpha
                     chemoattractant"
BASE COUNT       487 a    228 c    244 g    411 t      1 others
ORIGIN
        1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
       61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
      121 gttgttcaag gcttccccat gttcaaaaga ggacgctgtc tttgcatagg ccctggggta
      181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
      241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
      301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
      361 caaaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
      421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
      481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
      541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
      601 aatggatttc taggaaaagc taccttaaga aaggctggtt accatcggag tttacaaagt
      661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
      721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
      781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
      841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
      901 tcaaacattt tttcatgcaa atacacaytt ctttccccaa atatcatgta gcacatcaat
      961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
     1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
     1081 atttcataac caaattagca gcaccggtct taatttgatg tttttcaact tttattcatt
     1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccgttt
     1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctaccaaa
     1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
     1321 tgtctcttag aaaaatacat aatctaatca aaaaaaaaaa aaaaaaaaaa a
//

LOCUS       AF030514     1371 bp    mRNA            PRI       17-JUN-1998
DEFINITION  Homo sapiens interferon stimulated T-cell alpha chemoattractant
            precursor, mRNA, complete cds.
ACCESSION   AF030514
NID         g3219692
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1371)
  AUTHORS       Cole,K.E.,   Strick,C.A.,   Paradis,T.J.,   Ogborne,K.T.,
Loetscher,M.,
            Gladue,R.P.,   Lin,W.,   Boyd,J.G.,   Moser,B.,   Wood,D.E.,
Sahagan,B.G.
            and Neote,K.
  TITLE       Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel
            non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
  JOURNAL   J. Exp. Med. 187 (12), 2009-2021 (1998)
  MEDLINE   98290735
REFERENCE   2  (bases 1 to 1371)
  AUTHORS   Cole,K.E., Strick,C.A. and Sahagan,B.G.
  TITLE     Direct Submission
  JOURNAL     Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern
            Point Road, Groton,.CT 06340, USA
FEATURES             Location/Qualifiers
     source          1..1371
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="4"
                     /cell_type="astrocytes"
     sig_peptide     70..132
     CDS             70..354
                     /note="chemokine; I-TAC"
                     /codon_start=1
                     /product="interferon stimulated T-cell alpha
                     chemoattractant precursor"
                     /db_xref="PID:g3219693"
```

```
/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVAD
                    IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF"
     mat_peptide     133..351
                     /evidence=not_experimental
                     /product="interferon stimulated T-cell alpha
                     chemoattractant"
BASE COUNT      487 a    228 c    244 g    411 t      1 others
ORIGIN
        1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
       61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
      121 gttgttcaag gcttccccat gttcaaaaga ggacgctgtc tttgcatagg ccctggggta
      181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
      241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
      301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
      361 caaaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
      421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
      481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
      541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
      601 aatggatttc taggaaaagc taccttaaga aaggctggtt accatcggag tttacaaagt
      661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
      721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
      781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
      841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
      901 tcaaacattt tttcatgcaa atacacaytt ctttccccaa atatcatgta gcacatcaat
      961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
     1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
     1081 atttcataac caaattagca gcaccggtct taatttgatg tttttcaact tttattcatt
     1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccgttt
     1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctaccaaa
     1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
     1321 tgtctcttag aaaaatacat aatctaatca aaaaaaaaaa aaaaaaaaaa a
//

LOCUS       AF030514     1371 bp    mRNA            PRI       17-JUN-1998
DEFINITION  Homo sapiens interferon stimulated T-cell alpha chemoattractant
            precursor, mRNA, complete cds.
ACCESSION   AF030514
NID         g3219692
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1371)
  AUTHORS         Cole,K.E.,   Strick,C.A.,   Paradis,T.J.,   Ogborne,K.T.,
Loetscher,M.,
            Gladue,R.P.,    Lin,W.,    Boyd,J.G.,    Moser,B.,    Wood,D.E.,
Sahagan,B.G.
            and Neote,K.
  TITLE       Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel
            non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
  JOURNAL   J. Exp. Med. 187 (12), 2009-2021 (1998)
  MEDLINE   98290735
REFERENCE   2  (bases 1 to 1371)
  AUTHORS   Cole,K.E., Strick,C.A. and Sahagan,B.G.
  TITLE     Direct Submission
  JOURNAL     Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern
            Point Road, Groton, CT 06340, USA
FEATURES             Location/Qualifiers
     source          1..1371
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="4"
                     /cell_type="astrocytes"
     sig_peptide     70..132
     CDS             70..354
                     /note="chemokine; I-TAC"
                     /codon_start=1
```

```
                     /product="interferon stimulated T-cell alpha
                     chemoattractant precursor"
                     /db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVAD
                     IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF"
     mat_peptide     133..351
                     /evidence=not_experimental
                     /product="interferon stimulated T-cell alpha
                     chemoattractant"
BASE COUNT      487 a    228 c    244 g    411 t      1 others
ORIGIN
        1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
       61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
      121 gttgttcaag gcttccccat gttcaaaaga ggacgctgtc tttgcatagg ccctggggta
      181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
      241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
      301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
      361 caaaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
      421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
      481 ttcaacttttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
      541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
      601 aatggatttc taggaaaagc taccttaaga aaggctggtt accatcggag tttacaaagt
      661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
      721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
      781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
      841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
      901 tcaaacattt tttcatgcaa atacacaytt ctttccccaa atatcatgta gcacatcaat
      961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
     1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
     1081 atttcataac caaattagca gcaccggtct taatttgatg tttttcaact tttattcatt
     1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccgttt
     1201 gtataaatga tagcaatatc ttggacacat ttgaaatata aaatgttttt gtctaccaaa
     1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
     1321 tgtctcttag aaaaatacat aatctaatca aaaaaaaaaa aaaaaaaaaa a
//

LOCUS       HSMDNCF      1560 bp    RNA             PRI       31-MAR-1995
DEFINITION  Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic
            factor).
ACCESSION   Y00787
NID         g34518
KEYWORDS    cytokine.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1560)
  AUTHORS   Matsushima,K.
  TITLE     Direct Submission
  JOURNAL       Submitted  (03-MAY-1988)  Matsushima  K.,  National  Cancer
Institute,,
            Bldg 560, Rm 31-19, Frederick, MD 21701
REFERENCE   2  (bases 1 to 1560)
  AUTHORS         Matsushima,K.,   Morishita,K.,   Yoshimura,T.,   Lavu,S.,
Kobayashi,Y.,
            Lew,W., Appella,E., Kung,H.F., Leonard,E.J. and Oppenheim,J.J.
  TITLE     Molecular cloning of a human monocyte-derived neutrophil
            chemotactic factor (MDNCF) and the induction of MDNCF mRNA by
            interleukin 1 and tumor necrosis factor
  JOURNAL   J. Exp. Med. 167 (6), 1883-1893 (1988)
  MEDLINE   88258376
COMMENT     for overlapping sequence see M17016 - M17017.
FEATURES             Location/Qualifiers
     source          1..1560
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="monocyte"
                     /clone_lib="lambda gt10"
     sig_peptide     102..182
                     /note="signal peptide (AA -27 to -1)"
```

```
     CDS             102..401
                     /codon_start=1
                     /product="MDNCF precursor (AA -27 to 72)"
                     /db_xref="PID:g34519"
                     /db_xref="SWISS-PROT:P10145"

/translation="MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPF

HPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS"
     mat_peptide     183..398
                     /note="mat. MDNCF (AA 1 - 72)"
BASE COUNT      526 a    247 c    281 g    506 t
ORIGIN
        1 ctccataagg cacaaacttt cagagacagc agagcacaca agcttctagg acaagagcca
       61 ggaagaaacc accggaagga accatctcac tgtgtgtaaa catgacttcc aagctggccg
      121 tggctctctt ggcagccttc ctgatttctg cagctctgtg tgaaggtgca gttttgccaa
      181 ggagtgctaa agaacttaga tgtcagtgca taaagacata ctccaaacct ttccacccca
      241 aatttatcaa agaactgaga gtgattgaga gtggaccaca ctgcgccaac acagaaatta
      301 ttgtaaagct ttctgatgga agagagctct gtctggaccc caaggaaaac tgggtgcaga
      361 gggttgtgga gaagtttttg aagagggctg agaattcata aaaaaattca ttctctgtgg
      421 tatccaagaa tcagtgaaga tgccagtgaa acttcaagca aatctacttc aacacttcat
      481 gtattgtgtg ggtctgttgt agggttgcca gatgcaatac aagattcctg gttaaatttg
      541 aatttcagta aacaatgaat agtttttcat tgtaccatga aatatccaga acatacttat
      601 atgtaaagta ttatttattt gaatctacaa aaaacaacaa ataatttta aatataagga
      661 ttttcctaga tattgcacgg gagaatatac aaatagcaaa attgggccaa gggccaagag
      721 aatatccgaa ctttaatttc aggaattgaa tgggtttgct agaatgtgat atttgaagca
      781 tcacataaaa atgatgggac aataaatttt gccataaagt caaatttagc tggaaatcct
      841 ggatttttt ctgttaaatc tggcaaccct agtctgctag ccaggatcca caagtccttg
      901 ttccactgtg ccttggtttc tcctttattt ctaagtggaa aaagtattag ccaccatctt
      961 acctcacagt gatgttgtga ggacatgtgg aagcacttta agtttttca tcataacata
     1021 aattattttc aagtgtaact tattaaccta tttattattt atgtatttat ttaagcatca
     1081 aatatttgtg caagaatttg gaaaaataga agatgaatca ttgattgaat agttataaag
     1141 atgttatagt aaatttattt tattttagat attaaatgat gttttattag ataaatttca
     1201 atcagggttt ttagattaaa caaacaaaca attgggtacc cagttaaatt ttcatttcag
     1261 atatacaaca aataatttttt tagtataagt acattattgt ttatctgaaa ttttaattga
     1321 actaacaatc ctagtttgat actcccagtc ttgtcattgc cagctgtgtt ggtagtgctg
     1381 tgttgaatta cggaataatg agttagaact attaaaacag ccaaaactcc acagtcaata
     1441 ttagtaattt cttgctggtt gaaacttgtt tattatgtac aaatagattc ttataatatt
     1501 atttaaatga ctgcatttttt aaatacaagg ctttatattt ttaactttaa aaaaaaccgg
//

LOCUS       HSINFGER     1172 bp    RNA             PRI       21-MAR-1995
DEFINITION  Human mRNA for gamma-interferon inducible early response gene
(with
            homology to platelet proteins).
ACCESSION   X02530 M17752
NID         g33917
KEYWORDS    interferon response; signal peptide.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1172)
  AUTHORS   Luster,A.D., Unkeless,J.C. and Ravetch,J.V.
  TITLE     Gamma-interferon transcriptionally regulates an early-response
gene
            containing homology to platelet proteins
  JOURNAL   Nature 315 (6021), 672-676 (1985)
  MEDLINE   85240552
REFERENCE   2  (bases 1 to 1172)
  AUTHORS   Luster,A.D.
  TITLE     Direct Submission
  JOURNAL   Submitted (29-JUL-1986) to the EMBL/GenBank/DDBJ databases
COMMENT     Data kindly reviewed (29-JUL-1986) by Luster A.D.
FEATURES             Location/Qualifiers
     source          1..1172
                     /organism="Homo sapiens"
                     /strain="(U 937 histiocytic lymphoma cell line)"
                     /db_xref="taxon:9606"
     misc_RNA        1
                     /note="cap site"
```

```
     sig_peptide     67..129
                     /note="pot. signal peptide (aa-21 to -1)"
     CDS             67..363
                     /note="early response precursor polypeptide (aa-21 to
77)"
                     /codon_start=1
                     /db_xref="PID:g33918"
                     /db_xref="SWISS-PROT:P02778"

/translation="MNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRS

LEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKEMSKRSP"
     mat_peptide     130..360
                     /note="mature early response polypeptide (aa 1-77)"
     old_sequence    1138..1141
                     /note="ugaa was uga in [1]"
                     /citation=[1]
     old_sequence    1146..1148
                     /note="caa was ca in [1]"
                     /citation=[1]
     misc_feature    1155..1160
                     /note="pot. polyA signal"
     polyA_site      1172
                     /note="polyA site"
BASE COUNT      384 a    231 c    208 g    349 t
ORIGIN
        1 gagacattcc tcaattgctt agacatattc tgagcctaca gcagaggaac ctccagtctc
       61 agcaccatga atcaaactgc gattctgatt tgctgcctta tctttctgac tctaagtggc
      121 attcaaggag tacctctctc tagaaccgta cgctgtacct gcatcagcat tagtaatcaa
      181 cctgttaatc caaggtcttt agaaaaactt gaaattattc ctgcaagcca attttgtcca
      241 cgtgttgaga tcattgctac aatgaaaaag aagggtgaga agagatgtct gaatccagaa
      301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctcct
      361 taaaaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg
      421 cctctcccat cacttcccta catggagtat atgtcaagcc ataattgttc ttagtttgca
      481 gttacactaa aaggtgacca atgatggtca ccaaatcagc tgctactact cctgtaggaa
      541 ggttaatgtt catcatccta agctattcag taataactct accctggcac tataatgtaa
      601 gctctactga ggtgctatgt tcttagtgga tgttctgacc ctgcttcaaa tatttccctc
      661 acctttccca tcttccaagg gtactaagga atctttctgc tttggggttt atcagaattc
      721 tcagaatctc aaataactaa aaggtatgca atcaaatctg ctttttaaag aatgctcttt
      781 acttcatgga cttccactgc catcctccca aggggcccaa attctttcag tggctaccta
      841 catacaattc caaacacata caggaaggta gaaatatctg aaaatgtatg tgtaagtatt
      901 cttatttaat gaaagactgt acaaagtata agtcttagat gtatatattt cctatattgt
      961 tttcagtgta catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa
     1021 ttttaaaaat acagatagat atatgctctg catgttacat aagataaatg tgctgaatgg
     1081 ttttcaaata aaaatgaggt actctcctgg aaatattaag aaagactatc taaatgttga
     1141 aagatcaaaa ggttaataaa gtaattataa ct
//

LOCUS       SYNRPF4A      225 bp    DNA             SYN       15-JUN-1989
DEFINITION  Human recombinant platelet factor 4 (PF4) gene, complete cds.
ACCESSION   M20901
NID         g209285
KEYWORDS    platelet factor; platelet factor 4.
SOURCE      Synthetic oligonucleotide DNA, clone pIN-III-ompA-2.
  ORGANISM  artificial sequence
            artificial sequence.
REFERENCE   1  (bases 1 to 225)
  AUTHORS   Barone,A.D., Ghrayeb,J., Hammerling,U., Zucker,M.B. and
            Thorbecke,G.J.
  TITLE     The expression in Escherichia coli of recombinant human
platelet
            factor 4, a protein with immunoregulatory activity
  JOURNAL   J. Biol. Chem. 263, 8710-8715 (1988)
  MEDLINE   88243725
FEATURES              Location/Qualifiers
     source           1..225
                      /organism="artificial sequence"
                      /db_xref="taxon:29278"
     CDS              <1..>225
                      /note="recombinant platelet factor 4"
                      /codon_start=2
```

```
                     /transl_table=11
                     /db_xref="PID:g209286"

/translation="ASMEAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQL
                     IATLKDGRKICLDLQAPLYKKIIKKLLESGS"
BASE COUNT       59 a     59 c     51 g     56 t
ORIGIN      HindIII site.
        1 agcttctatg gaagctgaag aagacggtga cctgcagtgc ctgtgcgtta aaactacttc
       61 tcaggttcgt ccgcgtcata tcacttctct ggaagttatc aaagctggtc cgcattgccc
      121 gactgctcag ctgatcgcta ctctcaaaga cggtcgtaaa atctgcctgg acctgcaggc
      181 tccgctgtac aaaaaaatca tcaaaaaact gctggaatct ggatc
//

LOCUS       HUMGRO       1050 bp    mRNA            PRI       11-JUN-1993
DEFINITION  Human gro (growth regulated) gene.
ACCESSION   J03561
NID         g183622
KEYWORDS    gro gene; tumor cell.
SOURCE      Human bladder tumor cell (T24) cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1050)
  AUTHORS   Anisowicz,A., Bardwell,L. and Sager,R.
  TITLE     Constitutive overexpression of a growth-regulated gene in
            transformed Chinese hamster and human cells
  JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 84, 7188-7192 (1987)
  MEDLINE   88041072
COMMENT     Draft entry and computer-readable sequence kindly submitted by
            R.Sager (20-NOV-1987).
FEATURES             Location/Qualifiers
     source          1..1050
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     sig_peptide     54..140
                     /note="signal peptide (put.); putative"
     CDS             54..377
                     /note="gro protein"
                     /codon_start=1
                     /db_xref="PID:g306806"

/translation="MARAALSAAPSNPRLLRVALLLLLLVAAGRRAAGASVATELRCQ

CLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPASPIVKKIIEKMLN
                     SDKSN"
     mat_peptide     141..374
                     /note="gro mature protein (put.); putative"
BASE COUNT      270 a    246 c    239 g    295 t
ORIGIN      52 bp upstream of NcoI site.
        1 ctcgccagct cttccgctcc tctcacagcc gccagacccg cctgctgagc cccatggccc
       61 gcgctgctct ctccgccgcc cccagcaatc cccggctcct gcgagtggca ctgctgctcc
      121 tgctcctggt agccgctggc cggcgcgcag caggagcgtc cgtggccact gaactgcgct
      181 gccagtgctt gcagaccctg cagggaattc accccaagaa catccaaagt gtgaacgtga
      241 agtcccccgg accccactgc gcccaaaccg aagtcatagc cacactcaag aatgggcgga
      301 aagcttgcct caatcctgca tcccccatag ttaagaaaat catcgaaaag atgctgaaca
      361 gtgacaaatc caactgacca gaagggagga ggaagctcac tggtggctgt tcctgaagga
      421 ggccctgccc ttataggaac agaagaggaa agagagacac agctgcagag gccacctgga
      481 ttgtgcctaa tgtgtttgag catcgcttag gagaagtctt ctatttattt atttattcat
      541 tagttttgaa gattctatgt taatatttta ggtgtaaaat aattaagggt atgattaact
      601 ctacctgcac actgtcctat tatattcatt ctttttgaaa tgtcaacccc aagttagttc
      661 aatctggatt catatttaat ttgaaggtag aatgttttca aatgttctcc agtcattatg
      721 ttaatatttc tgaggagcct gcaacatgcc agccactgtg atagaggctg gcggatccaa
      781 gcaaatggcc aatgagatca ttgtgaaggc aggggaatgt atgtgcacat ctgttttgta
      841 actgtttaga tgaatgtcag ttgttattta ttgaaatgat ttcacagtgt gtggtcaaca
      901 tttctcatgt tgaaacttta agaactaaaa tgttctaaat atcccttgga cattttatgt
      961 ctttcttgta aggcatactg ccttgtttaa tggtagtttt acagtgtttc tggcttagaa
     1021 caaaggggct taattattga tgttttcgga
//

LOCUS       HUMGROB5     1110 bp    mRNA            PRI       07-MAR-1995
DEFINITION  Human cytokine (GRO-beta) mRNA, complete cds.
```

```
ACCESSION   M36820
NID         g183628
KEYWORDS    cytokine.
SOURCE      Human lymphocyte, cDNA to mRNA, clone GRO-beta.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1110)
  AUTHORS   Haskill,S., Peace,A., Morris,J., Sporn,S.A., Anisowicz,A.,
            Lee,S.W., Smith,T., Martin,G., Ralph,P. and Sager,R.
  TITLE     Identification of three related human GRO genes encoding
cytokine
            functions
  JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
  MEDLINE   91017578
COMMENT     Draft entry and computer-readable sequence for [Proc. Natl.
Acad.
            Sci. U.S.A. (1990) In press] kindly submitted
            by S.Haskill, 20-JUL-1990.
FEATURES             Location/Qualifiers
     source          1..1110
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="GRO-beta"
                     /tissue_type="monocyte and lymphocyte"
     gene            75..398
                     /gene="GRO-beta"
     CDS             75..398
                     /gene="GRO-beta"
                     /codon_start=1
                     /product="cytokine gro-beta"
                     /db_xref="PID:g183629"

/translation="MARATLSAAPSNPRLLRVALLLLLLVAASRRAAGAPLATELRCQ

CLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKACLNPASPMVKKIIEKMLK
                     NGKSN"
BASE COUNT       300 a    247 c    247 g    316 t
ORIGIN
        1 gacagagccc gggccacgga gctccttgcc agctctcctc ctcgcacagc cgctcgaacc
       61 gcctgctgag ccccatggcc cgcgccacgc tctccgccgc ccccagcaat ccccggctcc
      121 tgcgggtggc gctgctgctc ctgctcctgg tggccgccag ccggcgcgca gcaggagcgc
      181 ccctggccac tgaactgcgc tgccagtgct tgcagaccct gcagggaatt cacctcaaga
      241 acatccaaag tgtgaaggtg aagtcccccg gaccccactg cgcccaaacc gaagtcatag
      301 ccacactcaa gaatgggcag aaagcttgtc tcaaccccgc atcgcccatg gttaagaaaa
      361 tcatcgaaaa gatgctgaaa aatggcaaat ccaactgacc agaaggaagg aggaagctta
      421 ttggtggctg ttcctgaagg aggccctgcc ttacaggaac agaagaggaa agagagacac
      481 agctgcagag gccacctggc ttgcgcctaa tgtgtttgag catacttagg agaagtcttc
      541 tatttattta tttatttatt tatttgtttg ttttagaaga ttctatgtta atatttttatg
      601 tgtaaaataa ggttatgatt gaatctactt gcacactctc ccattatatt tattgtttat
      661 tttaggtcaa acccaagtta gttcaatcct gattcatatt taatttgaag atagaaggtt
      721 tgcagatatt ctctagtcat ttgttaatat ttcttcgtga tgacatatca catgtcagcc
      781 actgtgatag aggctgagga atccaagaaa atggccagta agatcaatgt gacggcaggg
      841 aaatgtatgt gtgtctattt tgtaactgta aagatgaatg tcagttgtta tttattgaaa
      901 tgatttcaca gtgtgtggtc aacatttctc atgttgaagc tttaagaact aaaatgttct
      961 aaatatccct tggcatttta tgtctttctt gtaagatact gccttgttta atgttaatta
     1021 tgcagtgttt ccctctgtgt tagagcagag aggtttcgat atttattgat gttttcacaa
     1081 agaacaggaa aataaaatat ttaaaaatat
//

LOCUS       HUMGROG5     1064 bp    mRNA            PRI       07-MAR-1995
DEFINITION  Human cytokine (GRO-gamma) mRNA, complete cds.
ACCESSION   M36821                                                      /
NID         g183632
KEYWORDS    cytokine.
SOURCE      Human lymphocyte, cDNA to mRNA, clone GRO-gamma.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1064)
  AUTHORS   Haskill,S., Peace,A., Morris,J., Sporn,S.A., Anisowicz,A.,
```

```
            Lee,S.W., Smith,T., Martin,G., Ralph,P. and Sager,R.
  TITLE       Identification of three related human GRO genes encoding
cytokine
            functions
  JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
  MEDLINE   91017578
COMMENT       Draft entry and computer-readable sequence for [Proc. Natl.
Acad.
            Sci. U.S.A. (1990) In press] kindly submitted
            by S.Haskill, 20-JUL-1990.
FEATURES             Location/Qualifiers
     source          1..1064
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="GRO-gamma"
                     /tissue_type="lymphocyte and monocyte"
     gene            78..398
                     /gene="GRO-gamma"
     CDS             78..398
                     /gene="GRO-gamma"
                     /codon_start=1
                     /product="cytokine GRO-gamma"
                     /db_xref="PID:g183633"

/translation="MAHATLSAAPSNPRLLRVALLLLLLVGSRRAAGASVVTELRCQC

LQTLQGIHLKNIQSVNVRSPGPHCAQTEVIATLKNGKKACLNPASPMVQKIIEKILNK
                     GSTN"
BASE COUNT      281 a    237 c    239 g    305 t      2 others
ORIGIN
        1 cacagccggg tcgcaggcac ctccccngcc agctctcccg cattctgcac agcttcccga
       61 cgcgtctgct gagccccatg gcccacgcca cgctctccgc cgcccccagc aatccccggc
      121 tcctgcgggt ggcgctgctg ctccctgctcc tggtgggcag ccggcgcgca gcaggagcgt
      181 ccgtggtcac tgaactgcgc tgccagtgct tgcagacact gcagggaatt cacctcaaga
      241 acatccaaag tgtgaatgta aggtcccccg gaccccactg cgcccaaacc gaagtcatag
      301 ccacactcaa gaatgggaag aaagcttgtc tcaaccccgc atcccccatg gttcagaaaa
      361 tcatcgaaaa gatactgaac aaggggagca ccaactgaca ggagagaagt aagaagctta
      421 tcagcgtatc attgacactt cctgcagggt ggtccctgcc cttaccagag ctgaaaatga
      481 aaaagagaac agcagctttc tagggacagc tggaaaggga cttaatgtgt ttgactattt
      541 cttacgaggg ttctacttat ttatgtattt atttttgaaa gcttgtattt taatatttta
      601 catgctgtta tttaaagatg tgagtgtgtt tcatcaaaca tagctcagtc ctgattattt
      661 aattggaata tgatgggttt taaatgtgtc attaaactaa tatttagtgg gagaccataa
      721 tgtgtcagcc accttgataa atgacagggt ggggaactgg agggtngggg gattgaaatg
      781 caagcaatta gtggatcact gttagggtaa gggaatgtat gtacacatct atttttata
      841 ctttttttt taaaaaagaa tgtcagttgt tatttattca aattatctca cattatgtgt
      901 tcaacatttt tatgctgaag tttcccttag acattttatg tcttgcttgt agggcataat
      961 gccttgttta atgtccattc tgcagcgttt ctctttccct tggaaaagag aatttatcat
     1021 tactgttaca tttgtacaaa tgacatgata ataaaagttt tatg
//

LOCUS       HUMCTAP3      673 bp    mRNA            PRI       06-MAR-1995
DEFINITION  Human connective tissue activation peptide III mRNA, complete
cds.
ACCESSION   M54995 M38441
NID         g181175
KEYWORDS       connective tissue activating peptide-III; platelet basic
protein;
            thromboglobulin.
SOURCE      Human platelet, cDNA to mRNA, clone lambda-c[1,2].
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 673)
  AUTHORS   Wenger,R.H., Wicki,A.N., Walz,A., Kieffer,N. and Clemetson,K.J.
  TITLE     Cloning of cDNA coding for connective tissue activating peptide
III
            from a human platelet-derived lambda gt11 expression library
  JOURNAL   Blood 73 (6), 1498-1503 (1989)
  MEDLINE   89229374
FEATURES             Location/Qualifiers
     source          1..673
```

```
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /tissue_type="platelet"
                     /clone="lambda-c1"
                     /cell_type="platelet"
                     /tissue_type="blood"
                     /tissue_lib="lambda-gt11"
                     /map="4p13-q21"
     gene            67..453
                     /gene="PPBP"
     sig_peptide     67..168
                     /gene="PPBP"
                     /note="G00-127-391"
     CDS             67..453
                     /gene="PPBP"
                     /codon_start=1
                     /db_xref="GDB:G00-127-391"
                     /product="connective tissue activating peptide III"
                     /db_xref="PID:g181176"

/translation="MSLRLDTTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRN

LAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGR
                     KICLDPDAPRIKKIVQKKLAGDESAD"
     mat_peptide     196..450
                     /gene="PPBP"
                     /note="G00-127-391"
                     /product="connective tissue activating peptide III"
     mat_peptide     208..450
                     /gene="PPBP"
                     /note="G00-127-391"
                     /product="beta-thromboglobulin"
     polyA_site      673
                     /gene="PPBP"
                     /note="G00-127-391"
BASE COUNT      202 a    149 c    139 g    183 t
ORIGIN
        1 gggcaactca ccctcactca gaggtcttct ggttctggaa acaactctag ctcagccttc
       61 tccaccatga gcctcagact tgataccacc ccttcctgta acagtgcgag accacttcat
      121 gccttgcagg tgctgctgct tctgtcattg ctgctgactg ctctggcttc ctccaccaaa
      181 ggacaaacta agagaaactt ggcgaaaggc aaagaggaaa gtctagacag tgacttgtat
      241 gctgaactcc gctgcatgtg tataaagaca acctctggaa ttcatcccaa aaacatccaa
      301 agtttggaag tgatcgggaa aggaacccat tgcaaccaag tcgaagtgat agccacactg
      361 aaggatggga ggaaaatctg cctggaccca gatgctccca gaatcaagaa aattgtacag
      421 aaaaaattgg caggtgatga atctgctgat taatttgttc tgtttctgcc aaacttcttt
      481 aactcccagg aagggtagaa ttttgaaacc ttgattttct agagttctca tttattcagg
      541 atacctattc ttactgtatt aaaatttgga tatgtgtttc attctgtctc aaaaatcaca
      601 ttttattctg agaaggttgg ttaaaagatg gcagaaagaa gatgaaaata aataagcctg
      661 gtttcaaccc tct
//

LOCUS       HUMENA78A    2177 bp    DNA             PRI       31-JAN-1996
DEFINITION  Homo sapiens neutrophil-activating peptide 78 (ENA-78) gene,
            complete cds.
ACCESSION   L37036 Z46254
NID         g607030
KEYWORDS    ENA-78 gene; homologue; neutrophil-activating factor;
            neutrophil-activating peptide 78.
SOURCE      Homo sapiens DNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 2177)
  AUTHORS   Walz,A., Burgener,R., Car,B., Baggiolini,M., Kunkel,S.L. and
            Strieter,R.M.
  TITLE     Structure and neutrophil-activating properties of a novel
            inflammatory peptide (ENA-78) with homology to interleukin 8
  JOURNAL   J. Exp. Med. 174 (6), 1355-1362 (1991)
  MEDLINE   92078844
REFERENCE   2  (bases 1 to 2177)
  AUTHORS   Walz,A.
```

```
  TITLE     Direct Submission
  JOURNAL    Submitted (14-OCT-1994) A. Walz, University of Bern, Theodor
Kocher
            Institute, Freiestr. 1, Bern, Switzerand 3012
REFERENCE   3  (bases 1 to 2177)
  AUTHORS   Corbett,M.S., Schmitt,I., Riess,O. and Walz,A.
  TITLE     Characterization of the gene for human neutrophil-activating
            peptide 78 (ENA-78)
  JOURNAL   Biochem. Biophys. Res. Commun. 205 (1), 612-617 (1994)
  MEDLINE   95091791
FEATURES             Location/Qualifiers
     source          1..2177
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /cell_type="lymphoblastoid cells"
                     /clone="4H2, 178C11, 106C1"
                     /chromosome="4"
                     /clone_lib="Chromosome 4 cosmid library of Riess et
al."
     gene            539..1747
                     /gene="ENA-78"
     CAAT_signal     539..547
                     /gene="ENA-78"
     TATA_signal     675..681
                     /gene="ENA-78"
     exon            <803..911
                     /gene="ENA-78"
                     /number=1
     CDS             join(803..911,1046..1178,1289..1372,1729..1747)
                     /gene="ENA-78"
                     /note="homologue to interleukin-8"
                     /codon_start=1
                     /product="neutrophil-activating peptide 78"
                     /db_xref="PID:g607031"

/translation="MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVL

RELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNGKEICLDPEAPFLKKV
                     IQKILDGGNKEN"
     intron          912..1045
                     /gene="ENA-78"
                     /number=1
     exon            1046..1178
                     /gene="ENA-78"
                     /number=2
     intron          1179..1288
                     /gene="ENA-78"
                     /number=2
     exon            1289..1372
                     /gene="ENA-78"
                     /number=3
     intron          1373..1728
                     /gene="ENA-78"
                     /number=3
     exon            1729..>1747
                     /gene="ENA-78"
                     /number=4
BASE COUNT      539 a    512 c    496 g    630 t
ORIGIN
        1 gaattctcag taagcggact taccaaagta ggtgatctgt aggggagtta acaaaattca
       61 gtggtccttt caggccactg acttcaagtg gcaagagaca agggtctctt gttatcatgt
      121 tatcttggct tccaaagctg gttgaagtcc agagattcat aaagtcattc aagaaaccta
      181 gaatgacctg cctgcaagaa gacaggaagg actttcagtt tatagcaatt caaacatgaa
      241 taacatttcc tgattaatag taataataat tagaaaggat tgactttcag aaatttttct
      301 caaatcaagg ctcctgttac tttggttcca ccttttctct ctagaaggag aggaggagca
      361 tctcccagat gctgcgtgct ccagaaaagc cggcatccct agcccgctct ggcacaggcc
      421 atgaggcgct gctgaatcct gctgaatagc tactcccttc tagctggagc cacagctccc
      481 tccaccgcgg aacagggtta caacgtccct ctcggtagag gtgcacgcag ctcctcctgg
      541 ccaccctccc caccagttcc cattgtctgg ccccctccc ccaacctctt ctttccacac
      601 tgccccatga gttcagggaa tttccccagc atcccaaagc ttgagtttcc tgtcagtggg
      661 gagagatgag tgtagataaa aggagtgcag aaggaacgag gaagccacag tgctccggat
```

```
     721 cctccaatct tcgctcctcc aatctccgct cctccaccca gttcaggaac ccgcgaccgc
     781 tcgcagcgct ctcttgacca ctatgagcct cctgtccagc cgcgcggccc gtgtccccgg
     841 tccttcgagc tccttgtgcg cgctgttggt gctgctgctg ctgctgacgc agccagggcc
     901 catcgccagc ggtgagagcg catggcgcgc gggacgcact cgcactcggg cacagaggtg
     961 catcccagcc tctgcggggt cgctgcgttc cagggaactc tcccagcaac ctgccctata
    1021 aagggtgtct ctcttttcttc cccagctggt cctgccgctg ctgtgttgag agagctgcgt
    1081 tgcgtttgtt tacagaccac gcaaggagtt catcccaaaa tgatcagtaa tctgcaagtg
    1141 ttcgccatag gcccacagtg ctccaaggtg gaagtggtgt aagttctgtg ctgctgtgtc
    1201 cgctgtgacc ttggcaagag agaaatcccg cagcctgggt cttcaacctt ggtatctcat
    1261 gagtgtatct tctttttctt tccttcagag cctccctgaa gaacgggaag gaaatttgtc
    1321 ttgatccaga agccccttt ctaaagaaag tcatccagaa aattttggac gggtacttgt
    1381 cactttgatc tttgtggttt ctaaatctga tctagggaga ccatagactt cacaaggtct
    1441 ttattctctg tacgatttaa gtaacacttt tcatgtttag aattaaaagg ttgttgaatt
    1501 gggaaagttt ttctggattg tcctgggaaa atataccaat cttacatgta attacttgag
    1561 caattacaca cagcttgtca ctaagttatg ttttttgttt acccattgct tttattgatt
    1621 tttgtattct ccttttttac caaacatcat aaacgctgag ttttgacaag ggtggagtag
    1681 aaaggagtgt gaaaaatggt taaactaata taacattttt ctcaacagtg gaaacaagga
    1741 aaactgatta agagaaatga gcacgcatgg aaaagtttcc cagtcttcag cagagaagtt
    1801 ttctggaggt ctctgaaccc agggaagaca agaaggaaag attttgttgt tgtttgttta
    1861 tttgtttttc cagtagttag ctttcttcct ggattcctca ctttgaagag tgtgaggaaa
    1921 acctatgttt gccgcttaag ctttcagctc agctaatgaa gtgtttagca tagtacctct
    1981 gctatttgct gttattttat ctgctatgct attgaagttt tggcaattga ctatagtgtg
    2041 agccaggaat cactggctgt taatctttca aagtgtcttg aattgtaggt gactattata
    2101 tttccaagaa atattcctta agatattaac tgagaaggct gtggatttaa tgtggaaatg
    2161 atgtttcata agaattc
//

LOCUS       HSGCP2          254 bp    RNA             PRI       04-MAR-1997
DEFINITION  H.sapiens mRNA for granulocyte chemotactic protein.
ACCESSION   Y08770
NID         g1769436
KEYWORDS    cell surface receptor; CXC chemokine; GCP-2 gene; granulocyte
            chemotactic protein.
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 254)
  AUTHORS     Froyen,G.,  Proost,P.,  Ronsse,I.,  Mitera,T.,  Haelens,A.,
Wuyts,A.,
            Opdenakker,G., Van Damme,J. and Billiau,A.
  TITLE      Cloning, bacterial expression and biological characterization
of
            recombinant human granulocyte chemotactic protein-2 and
            differential expression of granulocyte chemotactic protein-2
and
            epithelial cell-derived neutrophil activating peptide-78 mRNAs
  JOURNAL   Eur. J. Biochem. 243 (3), 762-769 (1997)
  MEDLINE   97210779
REFERENCE   2  (bases 1 to 254)
  AUTHORS   Froyen,G.F.V.
  TITLE     Direct Submission
  JOURNAL     Submitted  (10-OCT-1996)  G.F.V.  Froyen,  Rega  Institute,
University
            of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
FEATURES             Location/Qualifiers
     source          1..254
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /haplotype="diploid"
                     /tissue_type="embryonic"
                     /rearranged
                     /cell_type="fibroblast"
                     /cell_line="E6SM (embryonic strain - skin and muscle)"
     gene            1..254
                     /gene="GCP-2"
     exon            <1..131
                     /gene="GCP-2"
                     /number=2
     CDS             <1..234
                     /gene="GCP-2"
```

```
                     /codon_start=1
                     /product="granulocyte chemotactic protein"
                     /db_xref="PID:e283124"
                     /db_xref="PID:g1769437"

/translation="GPVSAVLTELRCTCLRVTLRVNPKTIGKLQVFPAGPQCSKVEVV
                     ASLKNGKQVCLDPEAPFLKKVIQKILDSGNKKN"
     exon            132..215
                     /gene="GCP-2"
                     /number=3
     exon            216..254
                     /gene="GCP-2"
                     /number=4
     3'UTR           235..254
                     /gene="GCP-2"
BASE COUNT       66 a     64 c     70 g     54 t
ORIGIN
        1 ggtcctgtct ctgctgtgct cacggagctg cgttgcactt gtttacgcgt tacgctgaga
       61 gtaaacccca aaacgattgg taaactgcag gtgttccccg caggcccgca gtgctccaag
      121 gtggaagtgg tagcctccct gaagaacggg aagcaagttt gtctggaccc ggaagccccc
      181 tttctaaaga aagtcatcca gaaaattttg gacagtggaa acaagaaaaa ctgagtaaca
      241 gtcgacgcgg ccgc
//

LOCUS       D63789       5669 bp    DNA             PRI       27-DEC-1996
DEFINITION  Human DNA for SCM-1beta precursor, complete cds.
ACCESSION   D63789
NID         g1754608
KEYWORDS    SCM-1beta; SCM-1beta precursor.
SOURCE      Homo sapiens placenta DNA, clone:hg44.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;   Mammalia;   Eutheria;   Primates;   Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (sites)
  AUTHORS   Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
  TITLE     Molecular cloning of a novel C or gamma type chemokine, SCM-1
  JOURNAL   FEBS Lett. 360 (2), 155-159 (1995)
  MEDLINE   95180438
REFERENCE   2  (sites)
  AUTHORS   Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
Yaoi,T.
            and Yoshie,O.
  TITLE     Structure and expression of two highly related genes encoding
            SCM-1/human lymphotactin
  JOURNAL   FEBS Lett. 395 (1), 82-88 (1996)
  MEDLINE   97002294
REFERENCE   3  (bases 1 to 5669)
  AUTHORS   Yoshida,T.
  JOURNAL   Unpublished (1995)
REFERENCE   4  (bases 1 to 5669)
  AUTHORS   Yoshida,T.
  TITLE     Direct Submission
  JOURNAL   Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya
            Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima,
            Settsu, Osaka 566, Japan (E-
mail:teyoshid@fl.lab.shionogi.co.jp,
            Tel:06-382-2612, Fax:06-382-2598)
FEATURES             Location/Qualifiers
     source          1..5669
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="1"
                     /clone="hg44"
                     /map="1q23"
                     /tissue_type="placenta"
     TATA_signal     2154..2158
     exon            2197..2278
```

```
                     /number=1
     prim_transcript 2197..5349
     gene            2218..5230
                     /gene="SCM-1beta"
     CDS             join(2218..2278,4075..4189,5062..5230)
                     /gene="SCM-1beta"
                     /codon_start=1
                     /product="SCM-1beta precursor"
                     /db_xref="PID:d1010504"
                     /db_xref="PID:g1754609"

/translation="MRLLILALLGICSLTAYIVEGVGSEVSHRRTCVSLTTQRLPVSR

IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMDRKSNTRNNMIQTKPTGT
                     QQSTNTAVTLTG"
     intron          2279..4074
                     /gene="SCM-1beta"
                     /number=1
     exon            4075..4189
                     /gene="SCM-1beta"
                     /number=2
     mat_peptide     join(4077..4189,5062..5227)
                     /gene="SCM-1beta"
     intron          4190..5061
                     /gene="SCM-1beta"
                     /number=2
     exon            5062..5349
                     /number=3
BASE COUNT      1702 a    1058 c    1248 g    1661 t
ORIGIN
        1 ggatccagga ggataacaag ggaatctcct actctcaaag agtctgccat ctagtgggag
       61 acgcaggaat gtaattgagt aggagaacac aatgagattc gttgcagaac agccatgaga
      121 acagaacaaa gttctaagag agcataaagg ggtggcacaa cttaatttta tcaaaaaaat
      181 tcaggaaaac ttatacagag aggaggagtt tacaagtaac tatgtaggga gctgtcatgg
      241 gtattccagt taaaggaaac atgtgaggag cataaaagag gctggcccat tgggttggct
      301 gcacatgtat gtgtttgtta aggtttggga gtgtgtgagt gaatggtgga aggtgagtct
      361 gaaaggaaag cagtactaga tcttgagcat tcttatatat cacaatgaaa gatttgaaat
      421 acatcctgta ggcattggaa gttagcaaaa gaggttctca gtagggaaat ggcatgatta
      481 gattgaggct ttacagtgat taccctggca aagctgcaga gaacagactg agaggaggcc
      541 ctggtctggg taaccagtta gtccactgta atttgcctaa catttgagca gtgtggggag
      601 aaaggaggac acatctcaaa ggactaccta gaaggtatac ttagtccagt ttggttgaga
      661 atgacatgta ggtggatagc aatgagtcta agatgatccc tatatatcag tatttggaaa
      721 ttagatggaa gagaacacat tgctccatgc taaggactaa tatgaggaga agcagtttga
      781 atagaagatg tgtccagtgt tcaaggagtg attgtgcagt aaggtagaga tcattaaaga
      841 gccagtttga agtttagaat gaagtctggg tgaaaaatca aatgcgatta gtgggaagtc
      901 tcttagaggt taacctatac tttttatgaa aacataggaa tttattttca tattccctaa
      961 tagcaaagga cctttaacta cacatatatt taataaatac attttataga tacctatgta
     1021 aaataaagaa caaccaccac acaacaaact cagtggcaga aaagttccag tgcaatcagt
     1081 atatttaaat tctactgggg gtattgcaaa tcaaatttac attttgggag actatatggc
     1141 aatatataat aagagctata aagatgatca tatcattttt cccagtaatc ctactcctgg
     1201 ttattaaagg gaagtaattc agtgtatatt aatgaaatcg accttatagt tctgatcttt
     1261 ataataagtt ataagaaaat ggtttaactt gtatgtgtat atatttactc gaagtagaaa
     1321 tatgaaggct aaaaaaatgg gaagatattt aaattggtgt taaaacagca tttaaaatta
     1381 ccacaattat gagaacacat gtatgccaat gcagattcac tggaaaaata ttgaaaatga
     1441 aaactgtcag atggtaagat tataatttta tttctttttt aatttgaaat aaattggtaa
     1501 cagcacagct tttcaaaagc ttctataaat gtgtatgtta agttgtaata aagcaaacac
     1561 atgcatgtaa gacatgctta aacagttatt taattgtttc ttgggtacct ggggagatgg
     1621 ggtgaagaaa ggggggtgac ttgaatgaag gtggaggaga aaaatgagaa ccaagaaagc
     1681 aaaggatcga gaagctcagt gtggcagcag cctctcttcc cctcctgaga gagtcaaagg
     1741 gtggcatcag ggactcatga tccatggttg tggaagcctc atgtcacact ggatgtcaca
     1801 tgaggtggga tggaacacag tgaccacccc acctcatttc ctttacagct tccgtggggg
     1861 ccatggcagt gaacagcctt caggcatgtc tacggtggaa gatctgaatt caggctggtg
     1921 gcaggagaca acacaaccac gtttttcttt atgcatgcat ttggtttaat tgacacatta
     1981 ccacagaca aaggggtaaa ggccacaagg cgataggtta gtatgaacag ggaaaggac
     2041 attttttttt tttaagaaaa ataaaagcat cagtattgca aagactttcc atgatcctat
     2101 acccacctcg aaagccccct ctcaccacag gaagtgcact gaccattgga ggcataaaag
     2161 agatcctcaa agagcccgat cctcactctc cctgcacagc tcagcgggac ctcagccatg
     2221 agacttctca tcctggccct ccttggcatc tgctctctca ctgcatacat tgtggaaggt
     2281 aagtggagaa gctgtctgtg agataaagaa tagggaggca aggcaggtgg gcacacattt
     2341 tgggtttgac tcgggttttg actggactaa actgctgtct ccaggggagc cttaaacttc
     2401 ccatgtgcaa gaaaggaatg atgattttga ctgtagaggg cttcgtaaac ttccaaaaca
```

```
     2461 gggagaattt gattagtatc tgggctccta cttttcctaa ttgggtaatt tcaggtaaat
     2521 tccttaacca ctcagggcct gtgcttattt atgtataaac tgaatagaat aagagacatg
     2581 atcacctgag attaagatta aataaatatt atggtttatt taataacatc agatttcctt
     2641 acaagcagta atttttgat taatgttagc tatggattag aggtgatgat tataaatgca
     2701 tttgtaggtt ttgcccattt aatatatagt ttgataaatt atcaaaatct tagagagttc
     2761 agttacaata tggggatgca ccagaggatg tatgttctgg agcaaatcaa tgttttcaat
     2821 acaaaacctg tgtgaaggcg acagtagtgc ttgctgtgga ctggatgtcc cagtcttgcc
     2881 ttccttcccc ttgataatgc aataagggac ccccatttta ggacgcagga caggcagaaa
     2941 gataaccagc ttgatggggt ccacaccatg tgcaatcact accagctgag acttcttgtt
     3001 ttccagcaag gtggtgatga tgttaacccc tgctcaaaga acaggtgatt tcctagtggg
     3061 gacaacccct ttgctagcag ctttcttctc agcctgggcc aacagtctct gcttcttctc
     3121 ttgctttgtc tctggtcagt acttgtggat cagcttaagt ggctgagtag ctgtttgggg
     3181 gtctaaggct tgggtgaact ggttaatggc agaaggcatt ttcagctgct tatagaggat
     3241 agctctttgc agctggaacc agatatagcg gggccatttc acaaagcagt ggaggtctct
     3301 tttgggctgg atgtcctgtc caatgcctgc ctaagaaaac tcttaggcct tttctcacac
     3361 agcggtttca tcactttctt agcctcctgc ttcctcacga cggcagggac tgggccacct
     3421 tcttttcttt ggccttcttt cttttcagca tcttaggcag ctgacagaga gggaaatttg
     3481 accatttaaa aaggggaaca cctttattta ctcagtcaaa agcatgcttc cttccctcac
     3541 tgaatgttgc cttgcctaga gtactcttca cgcattactc tgtcatctca cttatggtac
     3601 tgtaacatgt tgcactattt gaaatgatct tttctgtttg cctgtctgct gcctggctcc
     3661 ctcatgagaa gatatgctct atgaaaacag ggataatgtc tgtcttaata aaacatgtgg
     3721 gacacaacag gcaccattgt ataaatgaat gaatgcgtgt cactggggca tttgctagcc
     3781 gtcccaaatg tctaagtgaa aatatacaca gagacgggat aacatcttgt tattttctct
     3841 cagcatgaaa ttcctgaaac aattctgttg attgagtttt taaattagtc aaatatttac
     3901 taagaatctg tgacgggcaa gagattcggg atgcctatca gtcctctctt cccccaaaaa
     3961 gcaaatggcc ttatattctc acaacattct cagagtaatt taacagacga ttgttcctgt
     4021 gatctgggta attgctttat ttttaattgt ctgttgtttt tttttcctca tcaggtgtag
     4081 ggagtgaagt ctcacatagg aggacctgtg tgagcctcac tacccagcga ctgccagtta
     4141 gcagaatcaa gacctacacc atcacggaag gctccttgag agcagtaatg tgagtctgcc
     4201 tcctcagaag ttgggctggg tgggtaccta gaggtataga aatacactct atagaaatgc
     4261 tgccatcctc aggaaaagta ggtcagcata gaggaacacc tcaacttaac caaaaacctc
     4321 tttagttttc cttatcaacc atgtctttct gcagcccaac cgaatagcga ttattgcaga
     4381 aattgggctg ccaaagaaag aatagaagtc ctcctctatt tgtcttagtg gaagagtctg
     4441 ttgaatactg tgcacagctc tgagatctgg gtttagagat ggctggctca tgtcagggtt
     4501 tccctgcaag cctcactgga gttgggggat cttagggttg agttaggcag agtcccatac
     4561 tttatcagtt gccatatttc aagaaaatga gtcaatgcac aacctacatg gtccctttct
     4621 tctaccagaa tctcattttt agaagtaata actcttccca atacatattg caagctttgc
     4681 tctaaagaat gaaaatgtaa aaatcacctt tttaaaaaaa ataagatgag tattttcaaa
     4741 tttgaaaagg aagaggttat ataataatgg aactagatgg cctcaaatgt ctttttgtta
     4801 caacatttgg tgacatggat gagaaaagga gcctgtgaat tatggtgaac aaaggggctg
     4861 gatactactt gcagatattt ctcctttatg ttaaaataga tggcagaaga agggtgctca
     4921 tttatgatct catggctctg aaagactatt tcttgcagta atttctgcac aagatctctt
     4981 catgtctgcc ctgatcttaa ctcctgaccc tgaggctttg agaacgtggc taacttcatc
     5041 tgtcttttcc ttgcgttaca gttttattac caaacgtggc ctaaaagtct gtgctgatcc
     5101 acaagccacg tgggtgagag acgtggtcag gagcatggac aggaaatcca acaccagaaa
     5161 taacatgatc cagaccaagc caacaggaac ccagcaatcg accaatacag ctgtgaccct
     5221 gactggctag tagtctctgg caccctgtcc gtctccagcc agccagctca tttcacttta
     5281 caccctcatg gactgagatt atactcacct tttatgaaag cactgcatga ataaaattat
     5341 tcctttgtat ttttactttt aaatgtcttc tgtattcact tatatgttct aattaataaa
     5401 ttatttatta ttaagaatag ttccctagtc tattcattat atttagggaa aggtagtgta
     5461 tcattgttgt ttgatttctg accttgtacc tctctttgat ggtaaccata atggaagaga
     5521 ttctggctag tgtctatcag aggtgaaagc tatatcgatc actcttagag tccagcttgt
     5581 aatggttctt tacacatcag tcacaagtta cagctgtgac aatggcaaca atttgagatc
     5641 tatttcaact tgtctctata atagaattc
//

LOCUS       D63790       5660 bp    DNA             PRI       27-DEC-1996
DEFINITION  Human DNA for SCM-1alpha precursor, complete cds.
ACCESSION   D63790
NID         g1754610
KEYWORDS    SCM-1alpha precursor; SCM-1 alpha.
SOURCE      Homo sapiens placenta DNA, clone:hg40.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata;    Mammalia;    Eutheria;    Primates;    Catarrhini;
Hominidae;
            Homo.
REFERENCE   1  (sites)
  AUTHORS   Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
  TITLE     Molecular cloning of a novel C or gamma type chemokine, SCM-1
  JOURNAL   FEBS Lett. 360 (2), 155-159 (1995)
```

```
  MEDLINE   95180438
REFERENCE   2  (sites)
  AUTHORS     Yoshida,T.,  Imai,T.,  Takagi,S.,  Nishimura,M.,  Ishikawa,I.,
Yaoi,T.
            and Yoshie,O.
  TITLE     Structure and expression of two highly related genes encoding
            SCM-1/human lymphotactin
  JOURNAL   FEBS Lett. 395 (1), 82-88 (1996)
  MEDLINE   97002294
REFERENCE   3  (bases 1 to 5660)
  AUTHORS   Yoshida,T.
  JOURNAL   Unpublished (1995)
REFERENCE   4  (bases 1 to 5660)
  AUTHORS   Yoshida,T.
  TITLE     Direct Submission
  JOURNAL     Submitted  (07-AUG-1995)  to  the  DDBJ/EMBL/GenBank databases.
Tetsuya
            Yoshida,  Shionogi  Institute  for  Medical  Science;  2-5-1,
Mishima,
            Setsu,          Osaka          566,          Japan          (E-
mail:teyoshid@fl.lab.shionogi.co.jp,
            Tel:06-382-2612, Fax:06-382-2598)
FEATURES             Location/Qualifiers
     source          1..5660
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="1"
                     /clone="hg40"
                     /map="1q23"
                     /tissue_type="placenta"
     TATA_signal     640..644
     exon            683..764
                     /number=1
     prim_transcript 683..5340
     CDS             join(704..764,4064..4178,5053..5221)
                     /codon_start=1
                     /product="SCM-1alpha precursor"
                     /db_xref="PID:d1010505"
                     /db_xref="PID:g1754611"

/translation="MRLLILALLGICSLTAYIVEGVGSEVSDKRTCVSLTTQRLPVSR

IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMDRKSNTRNNMIQTKPTGT
                     QQSTNTAVTLTG"
     intron          765..4063
                     /number=1
     exon            4064..4178
                     /number=2
     mat_peptide     join(4066..4178,5053..5218)
                     /note="SCM-1alpha mature peptide"
     intron          4179..5052
                     /number=2
     exon            5053..5340
                     /number=3
BASE COUNT     1623 a   1139 c   1175 g   1723 t
ORIGIN
        1 aagcttctat aaatgtgtat gttaagttgt aataaagcaa acacatgcat gtagacatgc
       61 ttaaacagtt atttaattgt ttcttgggta cctggggaga tggggtgaag aaaggggggt
      121 gacttgaatg aaggtggagg agaaaaatga gaaccaagaa agcaaaggat cgagaagctc
      181 agtgtggcag cagctctctt cccctcctga gagagtcaaa gggtggcatc agggactcat
      241 gatccatggt tgtggaagcc tcatgtcaca ctggatgtca catgaggtgg gatggaacac
      301 agtgaccacc ccacctcatt tcctttacag cttccgtggt gggccatggc agtgaacacc
      361 ttcaggcatg tctacggcgg aatatctgaa ttcaggctgg tggcaggaga caacacaacc
      421 acgttttctt ttatgcatgc atttggttta attgacacat taaccacaga caaaggggta
      481 aaggccacaa ggcgttaggt tagtatgaac agggaaaagg gacttttttt ttttttttta
      541 agaaaaataa aagcatcagt attgcaaaga ctttccatga tcctacaccc acctcgaaag
      601 ccccctctca ccacaggaag tgcactgacc actggaggca taaaagaggt cctcaaagag
      661 cccgatcctc actctccttg cacagctcag caggacctca gccatgagac ttctcatcct
      721 ggccctcctt ggcatctgct ctctcactgc atacattgtg gaaggtaagt ggagaagctg
      781 tctgtgagat aaagaacagg gaggcaaggc aggtgggcac acattttggg tttgactcag
      841 gttatgactg gactaatctg ctttccccag gggagcctta aacttcccat gtgcaagaaa
```

```
 901 ggaatgatga ttttgactgt agagggcttc gtaaacttcc aaaacaggga gaatttgatt
 961 agtatctggg ctcctacttt tcctaattgg gtaatttcag gtaaattcct taaccactca
1021 gggcctgtgc ttatttatgt ataactgaat agtataacag acttgatcac ctgagattaa
1081 gattaaataa atattatggt ttatttaata acatcagatt tccttacaag cagtaatttt
1141 ttgattaatg ttagctatgg attagaggtg atgattataa atgcatttgt aggttttgcc
1201 catttaatat atagtttgat aaattatcaa aatcttagag agttcagtta cgatgtgggg
1261 atgcaccatt ggatgtatgt tctggagtaa atcaatgttt tcaatacaaa actaagcccc
1321 aaatgactgg aagttcaaac cttcatgtcc agaaaatcaa tattaccttc aagtacgtgg
1381 gggactctgt tagtaatgcc atgactatta ctatttatga gaaatttttct gtttttgtaa
1441 gagaacatac aataataact actaccaaat agatcagcac cttatacaca gttcaataaa
1501 cctgcaagac acatccaggt aagattcaga tataccgagc ccttacctga gcattcagta
1561 ggtatttctt aaggattgat ttttcctatg actggaggtg aatctgtcga cttatttgtg
1621 ttctagttgg taggcttatt acttagacta tgatattata acttaataat gggtccccaa
1681 ggggttccat gaataaaggt ggctaagtct ggaagtcctt gaaattatgg ataaaacaaa
1741 aaaatactga tgaaacaaaa gagtttgatt actacattag gccacatgtt gctacctggc
1801 tggcattttg ctgagacaat gggcatacca tttgagggag actcagatct gagtagggga
1861 aaggagctct ataagtccca ctggtgctta gcttcttaca tacaaaaatg agggaaaacg
1921 gtctctgctt tgactcaatt ttgcaacctg agtgaaggtg atattttaaa aaataacaca
1981 gacactcaaa cattgctgac aataaggaaa aggctttgtg gtttcaagca taacaggatt
2041 ccctgagtct taggagtcca cttcagatac ttcacagaga gaaatattgt ttcttaaata
2101 tgagagaaac agagaaaaaa cccagatttt tcctctttca ttggctacag aaacaattca
2161 ccactaaaaa taaattggca aaggtagagg atagcaatgt gcagactggc attgagagtg
2221 aagaaatgat gaagaaaagc acacaatgaa cactctttgt ttagtccctt gctttaaaaa
2281 atgccttctg atattagcaa cactacagac caatgttggc cattatcagt ggttacttta
2341 gatgcttttt agctgcctat ttccctggga agcaaagacc agtgtctaca gctaaggaga
2401 aaatcagcac ttagaaactt ggattagatt tcacccaacc cttaacagta ttaattctcc
2461 caagttattt ttcctcatgc aatgtttttt tgattctcta cacttaatag tttaattcct
2521 ttgggccatt actattgggg atgcatattt aagggctgac ttccttttat atatatctta
2581 ccttttacca tttattaatt ttttggagag tttttattat ttttatgtac agaaaactca
2641 acagtgtaca tttaacccag tttagtggca agttcctctg cctttgctat ttccagcttg
2701 gcattgtgag ccacagattt tggactcggg acattgcaga tctcatcata tccgtcattg
2761 taatttgtcc tgatagcttc caccagctta gccaaagctc ctttgtcttc ctggttaact
2821 tgtgtgaagg ccacagtggt gcttcctgtg gactggatgt cccagtcttg ccttcttacc
2881 ccttgataat gcattaaggg acccccccatt ttaggacaca ggacagacag aaagttaacc
2941 agcttgatgg ggtccacacc atgtgcaata ccagctgagc cttcttcttt tccagcaagg
3001 tggtgatagt gttaacccct gctcaaagaa caggtgattt cctagtgggg acaacccctt
3061 tgctagcagc tttcttctca gcctgggcca acagtctctg cttcttctct tgctttgtct
3121 ctggtcagta cttgtggatc agcttaagtg gctgagtagc tgtttggggg tctaaggctt
3181 gggtgaactg gttaatggca gaaggcactt tcagctgctt atagaggata gctctttgca
3241 gctggaacca gatatagcgg ggccatttca caaagcagcg gaggtccctt ttgggctgga
3301 tgtcctgtcc aatgcctgcc taagaaaact cttaggcctt ttctcacaca gcggtttcat
3361 cactttctta gcctcctgct tcctcacgac ggcagggtct ggggccactt tccttccttt
3421 ggccatcttt cctttcagca tcttaggcag ctgacagaga gagacatttg accatttaaa
3481 aaggagaaca cctttattta gtctgtcaaa agcatgcttc cttccctcac tgaatgttgc
3541 cttgcctaga gtactcttca cgcattactc tgtcttctca ctatggtact gtaacatgtt
3601 gcactatttg aaatgatctt ttctgtttgc ctgtctgctg cctggctcct tcatgagaga
3661 gatatgctct atgaaaacag gagtaatgtc tgcttagtaa aacatgtggg acacaacagg
3721 caccattgta taaatgaatg aatgcgtgtc actggggcat ttgctagccg tcccaaatgt
3781 ctaagtgaaa atatacacag agacgggata acatcttgtt attttctctc agcatgaaat
3841 tcctgaaaca attctgttga ttgagttttt aaattagtca aatatttact aagaatctgt
3901 gacgggcaag agattcggga tgcctatcag tcctctcttc ccccaaaaag caaatggcct
3961 taaattctca caacattctc agagtaattt aacagatgat tgttcctgtg atctggataa
4021 ttgctttatt tttaattgtc tgttgttttt ttttcctcac caggtgtagg gagtgaagtc
4081 tcagataaga ggacctgtgt gagcctcact acccagcgac tgccggttag cagaatcaag
4141 acctacacca tcacggaagg ctccttgaga gcagtaatgt gagtctgcct cctcagaagt
4201 tgtgctgggt gggtatctag aagtatagaa atacactctg tagaaatgct gccgtcctca
4261 ggaaaagtag gtcagcatag aggaacacct caacttaacc aaaaacctct ttagttttcc
4321 ttatcaatca tgtcttttctg cagcccaacc gaatagcgat tattgcagaa attgggctgc
4381 caaagaaaga atagaagtcc tcctctattt agcttagtgg aagagtctgt tgaatactgt
4441 gcacagctct gagacctggg tttagagatg actggcccat gtcagggttt ccctgcaagc
4501 ctcactggag ttgggggatc ttagggttga gtcaggcaga gtcccatact tttatcagtt
4561 gccatatttc aagaaaatga gtcaatgcac aacctacatg gtcccttctt ctaccagaat
4621 ctcatttttta gaagttaata actcttctca acatgtaatt gcaagcttta ctctaaaaaa
4681 tgaaaaatgta aaaatcactt tttatttaaa aaataagatg aatattttta aatttgaaaa
4741 ggaagaggtt atgtaataat ggaactagtt ggcctcaaag tctttttgtt acaacatttg
4801 gtgacatgga tgagaaaagg accctgtgaa ttattgtgaa caaaggggct ggatactact
4861 tgcagatatt actcctttat gttaaaatag atggcagaag aagggtactc atttatgatc
4921 tcatggctct gaaagactat ttcttgcagt aatttctgca caagatctct tcatgtctgc
4981 cctgatctta actcctgacc ctgaggcttt gagaatgtgg ctaacttcgt ctgtcttttc
5041 cttgcgttac agttttatta ccaaacgtgg cctaaaagtc tgtgctgatc cacaagccac
5101 atgggtgaga gacgtggtca ggagcatgga caggaaatcc aacaccagaa ataacatgat
```

```
     5161 ccagaccaag ccaacaggaa cccagcaatc gaccaataca gctgtgactc tgactggcta
     5221 gtagtctctg gcaccctgtc cgtctccagc cagccagctc atttcacttt acacgctcat
     5281 ggactgagtt tatactcacc ttttatgaaa gcactgcatg aataaaatta ttcctttgta
     5341 tttttacttt taaatgtctt ctgtattcac ttatatgttc taattaataa attatttatt
     5401 attaagaata gttccctagt ctattcatta tatttaggga aaggtagtgt atcattgttg
     5461 tttgatttct gaccttgtac ctctctttga tggtaaccat aatggaagag attctggcta
     5521 gtgtctatca gaggtgaaag ctatatcaat ctctcttaga gtccagcttg taatggttct
     5581 ttacacatca gtcacaagtt acagctgtga caatggcaac aatttgagat gtatttcaac
     5641 ttgtctctat aatagaattc
//

LOCUS       HSU91835     1635 bp    mRNA            PRI       21-MAR-1997
DEFINITION  Human CX3C chemokine precursor, mRNA, alternatively spliced,
            complete cds.
ACCESSION   U91835
NID         g1899258
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1635)
  AUTHORS   Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
  TITLE     A new class of membrane-bound chemokine with a CX3C motif
  JOURNAL   Nature 385 (6617), 640-644 (1997)
  MEDLINE   97177111
REFERENCE   2  (bases 1 to 1635)
  AUTHORS   Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
  TITLE     Direct Submission
  JOURNAL   Submitted (03-MAR-1997) Molecular Biology, DNAX Research
Institute,
            901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES             Location/Qualifiers
     source          1..1635
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     CDS             80..1273
                     /note="membrane-tethered chemokine module"
                     /codon_start=1
                     /product="CX3C chemokine precursor"
                     /db_xref="PID:g1899259"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIP

VALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGT

FEKQIGEVKPRTTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG

VTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA

PSTQDPSTQASTASSPAPEENAPSEGQRVWGQGQSPRPENSLEREEMGPVPAHTDAFQ

DWGPGSMAHVSVVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDA

QAATRRQAVGLLAFLGLLFCLGVAMFTYQSLQGCPRKMAGEMAEGLRYIPRSCGSNSY
                     VLVPV"
     sig_peptide     80..151
     mat_peptide     152..1270
                     /product="CX3C chemokine"
     misc_feature    152..379
                     /note="encodes chemokine module"
     misc_feature    380..1102
                     /note="encodes glycosylation stalk"
     misc_feature    1103..1159
                     /note="encodes transmembrane helix"
     misc_feature    1160..1270
                     /note="encodes intracellular domain"
     3'UTR           1274..1635
                     /note="alternatively spliced; long transcript can be
```

found
in GenBank Accession Number U84487"
BASE COUNT 338 a 544 c 464 g 289 t
ORIGIN

```
        1 ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgcctggcc cccgccggga
       61 ctcttgccca ccctcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
      121 cttctgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
      181 cacgtgcagc aagatgacat caaagatacc tgtagctttg ctcatccact atcaacagaa
      241 ccaggcatca tgcggcaaac gcgcaatcat cttggagacg agacagcaca ggctgttctg
      301 tgccgacccg aaggagcaat gggtcaagga cgcgatgcag catctggacc gccaggctgc
      361 tgccctaact cgaaatggcg gcaccttcga gaagcagatc ggcgaggtga agcccaggac
      421 caccctgcc gccgggggaa tggacgagtc tgtggtcctg gagcccgaag ccacaggcga
      481 aagcagtagc ctggagccga ctccttcttc ccaggaagca cagagggccc tggggacctc
      541 cccagagctg ccgacgggcg tgactggttc ctcagggacc aggctccccc cgacgccaaa
      601 ggctcaggat ggagggcctg tgggcacgga gcttttccga gtgcctcccg tctccactgc
      661 cgccacgtgg cagagttctg ctccccacca acctgggccc agcctctggg ctgaggcaaa
      721 gacctctgag gccccgtcca cccaggaccc ctccacccag gcctccactg cgtcctcccc
      781 agccccagag gagaatgctc cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
      841 caggccagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
      901 cttccaggac tgggggcctg gcagcatggc ccacgtctct gtggtccctg tctcctcaga
      961 agggacccca agcagggagc cagtggcttc aggcagctgg acccctaagg ctgaggaacc
     1021 catccatgcc accatggacc cccagaggct gggcgtcctt atcactcctg tccctgacgc
     1081 ccaggctgcc acccggaggc aggcggtggg gctgctggcc ttccttggcc tcctcttctg
     1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgccctcgaa agatggcagg
     1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
     1261 ggtgcccgtg tgaactcctc tggcctgtgt ctagttgttt gattcagaca gctgcctggg
     1321 atccctcatc ctcataccca cccccaccca agggcctggc ctgagctggg atgattggag
     1381 gggggaggtg ggatcctcca ggtgcacaag ctccaagctc ccaggcattc cccaggaggc
     1441 cagccttgac cattctccac cttccaggga cagagggggt ggcctcccaa ctcaccccag
     1501 ccccaaaact ctcctctgct gctggctggt tagaggttcc ctttgacgcc atcccagccc
     1561 caatgaacaa ttatttatta aatgcccagc cccttctgaa aaaaaaaaaa aaaaaaaaaa
     1621 aaaaaaaaaa aaaaa
//
```

```
LOCUS       HSU84487     3310 bp    mRNA            PRI       15-MAR-1997
DEFINITION  Human CX3C chemokine precursor, mRNA, alternatively spliced,
            complete cds.
ACCESSION   U84487
NID         g1888522
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 3310)
  AUTHORS   Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
  TITLE     A new class of membrane-bound chemokine with a CX3C motif
  JOURNAL   Nature 385 (6617), 640-644 (1997)
  MEDLINE   97177111
REFERENCE   2  (bases 1 to 3310)
  AUTHORS   Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
  TITLE     Direct Submission
  JOURNAL   Submitted (07-JAN-1997) Molecular Biology, DNAX Research
Institute,
            901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES             Location/Qualifiers
     source          1..3310
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
     CDS             80..1273
                     /note="membrane-tethered chemokine module"
                     /codon_start=1
                     /product="CX3C chemokine precursor"
                     /db_xref="PID:g1888523"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIP

VALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGT
```

FEKQIGEVKPRTTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG

VTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA

PSTQDPSTQASTASSPAPEENAPSEGQRVWGQGQSPRPENSLEREEMGPVPAHTDAFQ

DWGPGSMAHVSVVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDA

QAATRRQAVGLLAFLGLLFCLGVAMFTYQSLQGCPRKMAGEMAEGLRYIPRSCGSNSY
VLVPV"
sig_peptide 80..151
mat_peptide 152..1270
/product="CX3C chemokine"
misc_feature 152..379
/note="encodes chemokine module"
misc_feature 380..1102
/note="encodes glycosylation stalk"
misc_feature 1103..1159
/note="encodes transmembrane helix"
misc_feature 1160..1270
/note="encodes intracellular domain"
3'UTR 1274..3310
/note="alternatively spliced; short transcript
deposited
as GenBank Accession Number U91835"
BASE COUNT 659 a 1051 c 916 g 682 t 2 others
ORIGIN

```
   1 ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgcctggcc cccgccggga
  61 ctcttgccca ccctcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
 121 cttctgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
 181 cacgtgcagc aagatgacat caaagatacc tgtagctttg ctcatccact atcaacagaa
 241 ccaggcatca tgcggcaaac gcgcaatcat cttggagacg agacagcaca ggctgttctg
 301 tgccgacccg aaggagcaat gggtcaagga cgcgatgcag catctggacc gccaggctgc
 361 tgccctaact cgaaatggcg gcaccttcga gaagcagatc ggcgaggtga agcccaggac
 421 caccctgcc gccgggggaa tggacgagtc tgtggtcctg gagcccgaag ccacaggcga
 481 aagcagtagc ctggagccga ctccttcttc ccaggaagca cagagggccc tggggacctc
 541 cccagagctg ccgacgggcg tgactggttc ctcagggacc aggctccccc cgacgccaaa
 601 ggctcaggat ggagggcctg tgggcacgga gcttttccga gtgcctcccg tctccactgc
 661 cgccacgtgg cagagttctg ctccccacca acctgggccc agcctctggg ctgaggcaaa
 721 gacctctgag gccccgtcca cccaggaccc ctccacccag gcctccactg cgtcctcccc
 781 agccccagag gagaatgctc cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
 841 caggccagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
 901 cttccaggac tgggggcctg gcagcatggc ccacgtctct gtggtccctg tctcctcaga
 961 agggaccccc agcagggagc cagtggcttc aggcagctgg acccctaagg ctgaggaacc
1021 catccatgcc accatggacc cccagaggct gggcgtcctt atcactcctg tccctgacgc
1081 ccaggctgcc acccggaggc aggcggtggg gctgctggcc ttccttggcc tcctcttctg
1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgccctcgaa agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
1261 ggtgcccgtg tgaactcctc tggcctgtgt ctagttgttt gattcagaca gctgcctggg
1321 atccctcatc ctcataccca cccccaccca agggcctggc ctgagctggg atgattggag
1381 gggggaggtg ggatcctcca ggtgcacaag ctccaagctc ccaggcattc cccaggaggc
1441 cagccttgac cattctccac cttccaggga cagaggggggt ggcctcccaa ctcaccccag
1501 ccccaaaact ctcctctgct gctggctggt tagaggttcc ctttgacgcc atcccagccc
1561 caatgaacaa ttatttatta aatgcccagc cccttctgac ccatgctgcc ctgtgagtac
1621 tacagtcctc ccatctcaca catgagcatc aggccaggcc ctctgcccac tccctgcaac
1681 ctgattgtgt ctcttggtcc tgctgcagtt gccagtcacc ccggccacct gcggtgctat
1741 ctcccccagc cccatcctct gtacagagcc cacgccccca ctggtgacat gtcttttctt
1801 gcatgaggct agtgtggtgt ttcctgggca ctgcttccag tgaggctctg cccttggtta
1861 ggsattgtgg gaaggggaga taagggtatc tggtgacttt cctctttggt ctacactgtg
1921 ctgagtctga aggctgggtt ctgatcctag ttccaccatc aagccaccaa catactccca
1981 tctgtgaaag gaaagaggga ggtaaggaat acctgtcccc ctgacaacac tcattgacct
2041 gaggcccttc tctccagccc ctggatgcag cctcacagtc cttaccagca gagcacctta
2101 gacagtccct gccaatggac taacttgtct ttggaccctg aggcccagag ggcctgcarg
2161 ggagtgagtt gatagcacag accctgcccc gtgggccccc aaatggaaat gggcagagca
2221 gagaccatcc ctgaaggccc cgcccaggct tagtcactga gacagcccgg gctctgcttc
2281 ccatcacccg ctaagaggga gggagggctc cagacacatg tccaagaagc ccaggaaagg
2341 ctccaggagc agccacattc ctgatgcttc ttcagagact cctgcaggca gccaggccac
2401 aagacccttg tggtcccacc ccacacacgc cagattcttt cctgaggctg ggctcccttc
2461 ccacctctct cactccttga aaacactgtt ctctgccctc caagaccttc tccttcacct
2521 ttgtccccac cgcagacagg accaggggat ttccatgatg ttttccatga gtcccctgtt
2581 tgtttctgaa agggacgcta cccgggaagg gggctgggac atgggaaagg ggaagttgta
```

```
     2641 ggcataaagt caggggttcc ctttttggc tgctgaaggc tcgagcatgc ctggatgggg
     2701 ctgcaccggc tggcctggcc cctcagggtc cctggtggca gctcacctct cccttggatt
     2761 gtccccgacc cttgccgtct acctgagggg cctcttatgg gctgggttct acccaggtgc
     2821 taggaacact ccttcacaga tgggtgcttg gaggaaggaa acccagctct ggtccataga
     2881 gagcaaaacg ctgtgctgcc ctgcccaccc tggcctctgc actcccctgc tgggtgtggc
     2941 gcagcatatt caggaagctc agggccctgg ctcaggtggg gtcactctgg cagctcagag
     3001 agggtgggag tgggtccaat gcactttgtt ctggctcttc caggctggga gagcctttca
     3061 ggggtgggac accctgtgat ggggccctgc ctcctttgtg aggaagccgc tggggccagt
     3121 tggtcccccc tccatggact ttgttagttt ctccaagcag gacatggaca aggatgatct
     3181 aggaagactt tggaaagagt aggaagactt tggaaagact tttccaaccc tcatcaccaa
     3241 cgtctgtgcc attttgtatt ttactaataa aatttaaaag tcttgtgaaa aaaaaaaaaa
     3301 aaaaaaaaaa
//

LOCUS       HSU91746     1430 bp    mRNA            PRI       12-MAR-1998
DEFINITION  Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION   U91746
NID         g2581780
KEYWORDS    .
SOURCE      human.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 1430)
  AUTHORS   Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
  TITLE     Identification of a novel human CC chemokine upregulated by IL-
10
  JOURNAL   Blood (1998) In press
REFERENCE   2  (bases 1 to 1430)
  AUTHORS   Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
  TITLE     Direct Submission
  JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901
            California Ave, Palo Alto, CA 94304, USA
FEATURES             Location/Qualifiers
     source          1..1430
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /chromosome="17"
     gene            1..1430
                     /gene="HCC-4"
     CDS             1..363
                     /gene="HCC-4"
                     /note="CC or beta chemokine family member"
                     /codon_start=1
                     /product="IL-10-inducible chemokine"
                     /db_xref="PID:g2581781"

/translation="MKVSEAALSLLVLILIITSASRSQPKVPEWVNTPSTCCLKYYEK

VLPRRLVVGYRKALNCHLPAIIFVTKRNREVCTNPNDDWVQEYIKDPNLPLLPTRNLS
                     TVKIITAKNGQPQLLNSQ"
BASE COUNT      401 a    351 c    293 g    385 t
ORIGIN
        1 atgaaggtct ccgaggctgc cctgtctctc cttgtcctca tccttatcat tacttcggct
       61 tctcgcagcc agccaaaagt tcctgagtgg gtgaacaccc catccacctg ctgcctgaag
      121 tattatgaga aagtgttgcc aaggagacta gtggtgggat acagaaaggc cctcaactgt
      181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
      241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgctgcc taccaggaac
      301 ttgtccacgg ttaaaattat tacagcaaag aatggtcaac cccagctcct caactcccag
      361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
      421 caggggaagc cttattaggc tgaaactagc cagtcacatt gagagaagca gaacaatgat
      481 caaaataaag gagaagtatt tcgaatattt tctcaatctt aggaggaaat accaaagtta
      541 agggacgtgg gcagaggtac gctcttttat ttttatattt atatttttat ttttttgaga
      601 taggtcttac tctgtcaccc aggctggagt gcagtggtgt gatcttggct cacttgatct
      661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccacccca gcctcccgag
      721 tagctgggac tacaggcttg cgccaccaca cctggctaat ttttgtattt ttggtagaga
      781 cgggattcta ccatgttgcc caggctggtc tcaaactcgt gtgcccaagc aatccacctg
      841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgcac
      901 tcttaataca cagaaaaata tatttcacat ccttctcctg ctctctttca attcctcact
```

```
 961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tcctgtccat
1081 ctttatggat ttttctggat ctatattttc ttcaattatt ctttcatttt ataatgcaac
1141 tttttcatag gaagtccgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aacccaagca tgcaataaat aaaactccct tatttgacaa
//
```

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.
US CL :Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,141, 867 A (IVANOFF et al.) 25 August 1992, see entire document.	22-32, 45-55
A	ENG et al. The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo. J. Exp. Med. May 1995, Vol.181, pages 1893-1898, see entire document.	1-21, 33-44
A	ORANGE et al. Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids. J. Exp. Med. March 1995, Vol.181, pages 901-914, see entire document.	1-21, 33-44

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

*	Special categories of cited documents	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 25 MARCH 1999	Date of mailing of the international search report 15 APR 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer PREMA MERTZ Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WU et al. Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System. The Journal of Biological Chemistry. 05 April 1987, Vol.252, No. 10, pages 4429-4432, see entire document.	22-32, 45-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

C07K 14/47, 14/52; C12N 15/12, 15/19, 15/63; A61K 38/16, 38/19, 48/00

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAN ONLINE, MEDLINE, CAPLUS
search terms: chemokine, vaccination, immunogenic, antigen, HIV, efficacy, macrophage-derived chemokine, stromal cell-derived factor, monocyte chemotactic protein, composition, administration

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-21, 33-44, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto.
Group II, claims 22-32, 45-55, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering nucleic acid sequences encoding one or more antigens and nucleic acid sequences encoding one or more chemokines.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product and method, a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto. Further pursuant to 37
C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.